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Abstract  
Background: Variation in birth size has been linked to increased risk of a number of 
disorders later in life, including cardiovascular and metabolic disorders. However, 
less is known about other parameters of birth size, beyond birth weight, on later 
health.  Moreover, the impact of the biological markers of stress, i.e. glucocorticoids, 
on various parameters of birth size remains understudied as well as their impact on 
later metabolic outcomes.   
Aims and objectives:  The aim of this study was to examine the influence of the 
HPA axis on birth size (birth weight, ponderal index, birth length, head 
circumference) and subsequent metabolic health in adolescence.  The main 
predictor being exposure to glucocorticoids either administered clinically or inferred 
as a result of maternal social stress. The genetic environment interplay of birth 
weight lowering alleles near LEKR and CCNL1 and in ADCY5 was also examined.  
Methods: Data came from the Northern Finland Birth Cohort (NFBC1986), and the 
National Finnish Medical Birth Registry (MBR) 2006-2010. Glucocorticoid treatment 
(sGC) to mature foetal lung in threatened preterm birth, social stress measures, and 
birth outcomes were obtained from medical records and via maternal report (in 
NFBC1986) during pregnancy. Data on NFBC1986 children at 16 years included 
anthropometry, blood pressure, blood sample for DNA, and metabolic outcomes.  
Results: The systematic literature review showed a dearth of information on the 
association of sGC on birth size, with the larger studies reporting smaller birth size in 
infants exposed to sGC.  The NFBC1986 cohort showed only 17% (n=58) preterm 
infants had received sGC due to threatened preterm birth, with an association with 
smaller birth length of -0.18cm(95%CI -0.26, -0.10), but a larger birth weight of 
116g(95%CI 98.9, 133.1) and head circumference of 0.75cm(95%CI 0.7, 0.81). In 
contrast, in the MBR (5090 exposed subjects) sGC treatment was consistently 
associated with lower birth weight of -207g(95%CI -220, -195), birth length of -
1.26cm(95%CI -1.31, -1.20), head circumference of -0.94cm(95%CI -0.98, -0.90), 
and ponderal index of -0.91 (95%CI-1.02, -0.81). Maternal social stress during 
pregnancy and risk allele near LEKR and CCNL1 each was associated with smaller 
birth size. The association with stress was magnified with lower birth weight of -
118g(95%CI -156, -79), birth length of -0.30cm(95%CI -0.46, -0.14), head 
circumference of -0.23cm(-0.35, -0.11), and ponderal index of -0.47(95%CI -0.67, -
0.26) in the presence of risk allele. No robust association was found between 
maternal social stress during pregnancy and metabolic syndrome at 16 years. There 
was an association with more adverse lipid profile in particular with apolipoprotein 
B/A ratio (1.92% increase, 95%CI 0.34, 3.52, by maternal exposure to social stress).  
Conclusion: Stress and exposure to sGC during pregnancy in addition to genetic 
risk are related to smaller birth size. In the NFBC1986 there was no evidence of 
longer term impact of in utero stress exposure on metabolic syndrome in 
adolescence, though there was a poorer lipid profile noted. To better understand the 
degree to which the HPA axis plays in foetal programming, maternal and foetal 
cortisol levels during pregnancy would be beneficial.   
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1 Aims, objectives and scope of this thesis   
  
Babies born to mothers given synthetic glucocorticoids (sGC) to stimulate foetal lung 
maturation in threatened preterm birth have a lower risk of morbidity and mortality 
from respiratory distress syndrome, and other causes associated with prematurity. 
The importance of sGC in neonatology is undeniable. However, animal and some 
smaller human studies have indicated possible adverse effects that have received 
less attention, in particular the association of sGC on birth size. Birth size has been 
linked with increased risk of developing disease later in life, e.g. cardiovascular 
disease (CVD) and type 2 Diabetes (T2D), indicating birth size as an important 
outcome in predicting future health.  The aim of this thesis was to examine whether 
exposure to sGC during pregnancy was associated with birth size of the neonate. 
Glucocorticoids (GC) are also produced naturally by the human body in the form of 
cortisol, a stress hormone needed in maintaining homeostasis during stress via the 
hypothalamic pituitary adrenal axis (HPA); where stress results in an increase GC 
production. Therefore if GCs lead to a reduced foetal growth, as animal studies 
indicate, we can hypothesise that cortisol production may be a link between stress 
during pregnancy and potentially smaller birth size. Psychosocial stress during 
pregnancy has indeed previously been linked to smaller birth size of the neonate. 
However, defining psychosocial stress during pregnancy is a difficult measure.  This 
thesis examines the association of psychosocial stress using operationalized 
composites of psychosocial stress variable (maternal young age, maternal low 
education and maternal single status) on birth size. As indicated by recent studies, 
size at birth depends on multiple factors, including genetic variability, where specific 
birth weight lowering polymorphisms have been identified.  This thesis explores also 
the interplay of psychosocial stress and genetic variance in the population on birth 
size.  Although previous studies show that foetal stress associates with size at birth 
and that stress factors, mostly measured in adults, are strongly associated with CVD 
risk there were no studies as far as I knew examining directly the association of 
between maternal stress during pregnancy and offspring metabolic health in 
adolescence. While there is compelling evidence that lower birth weight is 
associating with higher CVD disease risk all these data gave me a novel and good 
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scientific basis to study the potential impact of maternal psychosocial stress on 
metabolic health in adolescence.   
The overall primary aim of this work was therefore to explore the associations of 
sGC and psychosocial stress during pregnancy on birth anthropometric outcomes of 
the neonate (birth weight, head circumference, birth length and ponderal index). The 
secondary aims were to examine the genetic interplay with psychosocial stress and 
their joint impact on foetal growth as well as whether maternal psychosocial stress 
during pregnancy may have longer term impact on offspring’s metabolic health. The 
studies included pregnant mothers and their infants followed up at 16 years of age in 
the Northern Finland birth cohort 1986 (NFBC1986), and all pregnant mothers and 
their infants born between 2006-2010 in data extracted from the Finish medical birth 
registry (MBR). The concept behind these studies relates to The Developmental 
Origins of Health and Disease (DOHaD), aiming to  ‘bring new insights into the 
pathogenesis of disease’, with focus on the in utero period in human life and to get 
potentially further insight to inform clinical practice. It is not birth size itself that is 
thought to be causal in the development of disease later in life but multiple factors 
and their interplay.  However, in spite of intensive research, still our understanding of 
mechanisms how foetal development links with later life diseases and disorders is 
fragmented. One suggested metabolic pathway through which birth size is 
associated with development of disease later in life maybe through the HPA axis. A 
study examining the role of GCs (a main effect hormones) would give further insight 
as to whether mechanisms through HPA-axis can be considered as one of the 
pathways through which birth size associates with disease later in life. As reported in 
animal and small human studies the sGC given during pregnancy not only have 
beneficial but potential detrimental effects on the offspring. However, large scale 
human studies are lacking.  
The specific research objectives of this thesis were: 
Study I: 
Objective: To carry out a systematic literature review, taking study quality into 
account, to determine the impact of sGC during pregnancy on birth size.   
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Study II: 
Objective: To perform the largest study to date on exposure to sGC on birth 
size using data from entire annual birth cohorts of Finland.  
 
Study III: 
Objective: To study the impact of social stress experienced by the mother 
during pregnancy at individual (social adversity) and neighbourhood 
(neighbourhood social disparity) levels on birth size.  Further, to evaluate 
whether there was an additive impact of birth weight-lowering alleles near 
LEKR and CCNL1 and in ADCY5 together with social stress on birth size.   
Study IV: 
Objective: To study exposure to maternal social stress on offspring metabolic 
outcomes at the age of 16 years.   
The main predictor in these analyses was exposure to GC, either 
administered clinically in cases of threatened preterm birth or inferred as a 
result of maternal social stress. 
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2 Introduction 
 
This chapter gives an overview of how the concept of Developmental Origins of 
Health and Disease approach (DOHaD) was evolved, and a background on the 
potential foetal programming to be examined in this thesis. It also introduces the 
different environmental factors that may affect foetal growth and potentially foetal 
programming of later life diseases and disorders. The aim of this chapter is to 
summarise the background of the work presented in this thesis. 
 
2.1 Developmental origins of health and disease 
 
In 2004, the international society for Developmental Origins of Health and Disease 
(DOHaD) was formed, and the idea of the foetal origins of disease hypothesis was 
expanded. The purpose was to ‘recognize the broader scope of developmental cues, 
extending from the oocyte to the infant and beyond and the concept that the early life 
environment has widespread consequences for later health’(3).  The foetal origins of 
disease hypothesis indicated that adverse in utero events leading to reduced foetal 
growth and small birth size (birth weight, birth length, head circumference, and 
ponderal index), may cause permanent structural and physiology changes(4;5). 
These permanent changes in the foetus consequently result in an increased risk of 
developing diseases later in life such as; CVD, T2D and their intermediate risk 
factors (e.g. high blood pressure, high serum cholesterol and plasma fibrinogen 
concentrations), and mental health related conditions such as affective and cognitive 
disorders (1;4-19) among others. Subsequent studies examining the foetal origins of 
disease hypothesis would further indicate that environmental influences occurring as 
early as pre-conception were also associated with foetal outcome; a recently 
published study reported an association between maternal pre-gestational BMI and 
birth weight of the child (20). As further research was conducted to explore the foetal 
origins hypothesis, an increasing number of previously unknown variables were 
reported to be associated with health outcomes across the life course. However, a 
complete explanation for the associations with the development of disease later in 
life or the mechanism underlying these associations are still lacking.   
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Historically, the concept of early life factors impacting on disease later in life is not a 
new concept, the ancient Greeks already considered the foetal period important for 
later health. In modern day medicine, in the latter half of twentieth century, difference 
in prevalence of CVD was noted in ecological studies revisiting the possibility of 
other yet unexplored factors associated with disease later in life (21;22). A large 
international study for Monitoring trends and determinants in CVD diseases 
(MONICA), showed that only 25% of variance with CVD was linked with known risk 
factors, which left a large proportion unexplained of yet unknown risk factors(23). 
The current concept of foetal origins of disease as we understand it today, was 
pushed forward and popularised by Barker et al in 1986(24) . Barker et al’s initial 
concept was tried to understand and explain the causes of ischaemic heart disease 
(IHD), which expanded views beyond adult lifestyle, such as diet, exercise, and 
smoking. In their earlier studies, Barker et al used geographical data from Britain, 
and compared mortality rates for IHD from 1968-78 with infant mortality registered 
since. They reported a correlation between areas in Britain with high rates of IHD, 
with past high rates of early infant mortality. In addition, the research was expanded 
to examine the correlation between stroke, bronchitis, stomach cancer, rheumatic 
heart disease and lung cancer, with neonatal, postnatal and other causes of infant 
mortality, to try and understand a possible congenital link. Barker et al had used 
results from the Wolf et al study to interpret their findings; In 1947, Wolf et al did a 
detailed analysis of infant mortality in the county boroughs of Britain between 1928 
and 1938, and reported more than 80% of neonatal deaths (<28 days old) were 
registered as congenital, whereas the most common causes of post neonatal (>28 
days old) deaths’ registered were bronchitis and pneumonia (25). Barker et al 
therefore noted in their studies, that areal congenital death had the highest 
correlation with IHD and stroke in their ecological study. Infant deaths from bronchitis 
and pneumonia showed the highest correlation with adult mortality from bronchitis. 
At the time of publication, the authors inferred that the deaths from bronchitis, 
stomach cancer and chronic rheumatic heart disease were closely related to infant 
mortality, both which rose and then declined at similar rates; and therefore with post 
natal environment, such as socioeconomic status (SES). Both adult mortality from 
IHD, stroke, bronchitis, stomach cancer and chronic rheumatic heart disease were 
 
 
19 
linked with low SES, as was high infant mortality. However, though IHD was reported 
to have the highest correlation with infant mortality (both neonatal and post-
neonatal), IHD continued to rise after the turn of the twentieth century when infant 
mortality rates were falling as overall SES improved, which introduced a paradox. 
The authors could not explain this paradox in their findings with dietary intake, 
psychosocial stress or smoking alone, as the geographic variance in these variables 
differed from IHD and infant mortality. Barker et al used another previously published 
report by Rose in 1964 to explain this discrepancy; Rose noted that families which 
reported higher rates of infant mortality and stillbirths of siblings also had higher 
rates  of coronary heart disease (26). This gave further weight to the idea of that 
congenital or in utero events may explain the missing risk factor for IHD. Finally 
Barker et al used unpublished data from the 1930’s on maternity hospitals in Preston 
(UK), to link poor maternal nutrition and birth weight with development of disease 
later in life. In Preston, high neonatal and maternal mortality was reported compared 
to those in London, and it was in this data that it was also noted the average mean 
birth weight of babies was 289 g lower than those born in London. The Barker et al 
study on ‘infant mortality, childhood nutrition, and ischaemic heart disease in 
England and Wales’(24) was, however, received by the scientific community with 
scepticism. It nonetheless paved the way for extensive further research.  
Numerous studies later, Barker et al eventually went on to publish in 1992 the 
hypothesis of foetal origins of coronary heart disease, which states; ‘foetal under 
nutrition in middle to late gestation, which leads to disproportionate foetal growth, 
programmes later coronary heart disease’ (1). They used the previously introduced 
idea by Widdowson and McCane, of ‘critical’ periods in development and ‘catch up 
growth’, to explain how birth weight was associated with the development of disease 
later in life (27). Critical periods of growth were defined as ‘time of rapid cell division’ 
during development, and varied between different tissues. Deprivations of oxygen 
and nutrition during the critical period of tissue growth, results in reduced rate of cell 
division and disproportionate growth. Though later able to catch up in cell volume, 
cell division would no longer take place outside these ‘critical’ periods. The idea was, 
that, this change or ‘programme’ of the body would translate into pathology (i.e. 
persistent changes in blood pressure, insulin responses to glucose, and 
metabolic/endocrine/immune parameters), as shown previously in animal studies at 
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the time.  In their study, Barker et al went on to explain that low birth weight rather 
than premature birth showed a trend with an increased risk of developing 
hypertension and non-insulin dependent diabetes. Those questioning the hypothesis 
commented that foetuses exposed to adverse in utero environment were also likely 
to be exposed to adverse environments later in life. The authors argued that 
controlling for confounders of lifestyle, such as smoking, though adding to the 
intrauterine effects, did not remove the association between birth weight and CVD 
later in life. Barker et al went on further and showed an association between low 
ponderal index or thinness (birth weight/lenght3) to ‘insulin resistance syndrome’ (i.e. 
impaired glucose tolerance, raised blood pressure, and disturbed lipid metabolism in 
adult life) (28). Ponderal index, when there is reduction in weight, but preserved 
length, it is an indication of poor weight gain of the baby during pregnancy.  
Other factors and pathways were also being reported which tried to explain the 
association of birth size with the development of disease later in life; Irrespective of 
birth weight, rise in placental size was also shown to be associated with increased 
blood pressure (29). Raised foetal placental pressure to maintain placental perfusion 
in adverse foetal environments, which persisted after birth, was a suggested 
pathway that linked birth size to higher blood pressure later in life. Barker et al 
realised that the association of birth size on the development of disease later in life 
was complex, and possibly involving multiple variables, particularly under nutrition 
which they explored further in future studies. Using under nutrition as the starting 
point of their hypothesis, Barker et al developed a framework of ideas (Figure 1) , a 
working hypothesis at the time about the potential role of poor nutrition in utero in the 
CVD development; highlighting the presence of many unknown factors or pathways 
in the link between in utero environment and the development of disease later in life.  
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Figure 1. Baker et al framework of ideas in the foetal origins hypothesis linking 
foetal undernutrition with later disease(1) 
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Though under nutrition was a key factor explaining the foetal origins of disease 
hypothesis, or DOHaD as it is now known, it did not explain the biology behind the 
association between of in utero environment and development of disease later in life.    
This led to further questions as for example to the definition of under-nutrition; the 
effect of different nutrients on foetal development; and what role genetics and other 
yet unknown factors play. Also important is to understand the role that metabolic 
pathways may play, and finally it does not explain why some people develop disease 
while others do not. The term foetal programming was then popularised to explain 
the missing link between the foetal period and the development of disease later in 
life. The foetal origins of health and disease did eventually catch the attention of the 
scientific community, and studies examining the association between low birth 
weight and coronary heart disease were replicated among populations of Europe, 
North America and India.  
Thirty years after Barker et al first popularised the foetal origins hypothesis, 
premature morbidity, disability and mortality resulting from non-communicable 
diseases (e.g. CVD and T2D), are still an increasing public health concern on a 
global scale (30). Being born small for gestational age (SGA), even if at term, carries 
an immediate risk of increased neonatal morbidity and mortality and consequently a 
significant increase risk of hospitalisation of the infant (31;32). This has significant 
financial implications for a health system. Hospital costs for preterm/low birth weight 
infants were estimated at $5.8billion in 2001 in the USA alone (33).  
The importance of tending to the health of women of reproductive age will have a 
profound impact of the wellbeing of their offspring and parallels the WHO 2005 report 
’make every mother and child count’. Because current strategies in public health 
depend heavily on prevention in the control of non-communicable disease, studies 
on DOHaD are predominantly aimed at identifying and modifying factors associated 
with foetal programming and which are responsible for increased risk of developing 
disease later in life. Adult degenerative diseases are associated with different 
patterns of growth, with the same disease possibly originating through more than 
one pathway (34). The development of many non-communicable diseases therefore 
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involves a variety of interactions, including genetics (35-37). Environment or genetics 
on their own play only a partial role in the development of health and disease in 
adulthood; therefore indicating the importance of further exploring the gene-
environment interaction when in the framework of DOHaD (36;37).  
 
2.2 Foetal programming 
 
Barker et al, although the first to give strong epidemiological support through their 
studies on foetal programming in the 1980’s, as a concept, the idea of foetal 
programming was not a new one. It was first introduced into modern scientific 
literature by Dörner in 1974, foetal programming was used to define the phenomena 
whereby evidence indicates that prenatal and postnatal periods of development 
significantly modulate the effects on health in adulthood (38). Dörner concluded that 
increased levels of hormones, metabolites, and neurotransmitters during vital 
periods of foetal development were capable of pre-programming brain development 
which lasted into adulthood. Dörner also proposed an interaction between genetics 
and environmental influences in early foetal development, which determined later 
function in adulthood. Thirty nine years later, there are now a substantial number of 
experimental animal models that support the ‘foetal programming hypothesis’, but 
there are still many unknown factors (36;37;39), the issue being also that 
experimental models may not directly be transferrable into human development. 
Using growth-restricted rats, animal studies have demonstrated the long-term 
outcomes of under-nutrition in the foetal period on the adult offspring. Pregnant rats 
fed on protein restricted diets, one of the most extensively studied examples, gave 
birth to offspring, with smaller birth size and higher blood pressure relative to the 
control rats (40-44).  But the mechanism of how and why maternal nutrition affects 
the health and long term development of the offspring is still not clearly understood. 
Also, how do these results translate to humans is still unclear. Maternal under-
nutrition has therefore received a lot of attention in terms of foetal programming, but 
it is important to note that it is not the only factor involved. 
The mechanism of maternal under-nutrition, as a well-researched factor, is none the 
less a good example for the purpose of explaining the different pathways of foetal 
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programming. Figure 2 is a representation by Tomkins of possible multiple pathways 
through which maternal under-nutrition may affect foetal programming(45). Although 
this figure is complex and hypothetical, it gives a more generalised overview of some 
of the more common pathways considered in the association between maternal 
nutrition and foetal programming, including the HPA axis. 
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Figure 2. Possible foetal adaptive mechanisms to maternal under-nutrition that 
could predispose adult offspring to hypertension, a representation by Tomkins 
(45) 
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In the HPA axis, glucocorticoids in the form of cortisol, is the main effector hormone, 
vital in maintaining homeostasis in periods of stress (detailed description found in the 
next section).  Glucocorticoids are also important during pregnancy, as they play a 
significant role in the tissue maturation of the foetus. Synthetic glucocorticoids 
(Betamethasone and dexamethasone) have a much higher affinity for the 
glucocorticoid receptors in the body and cross the placenta more readily than does 
endogenous GC. Synthetic glucocorticoids are therefore extremely important in 
cases of pregnant mothers with threatened preterm birth, where they are given to 
stimulate foetal lung maturation and facilitated better survival after premature birth. 
Examining babies of mothers exposed to sGC during pregnancy may therefore give 
us better insight into how significant the HPA axis, and with it the GC pathway is, in 
regards to its association on birth size. The GC pathway was therefore chosen for 
this thesis, as it would not only give insight into the association of sGC on birth size 
in regard to foetal programming, but also from the clinical perspective, enabling 
exploration of negative (or positive) effects of sGC on foetal development; 
specifically as now sGCs are widely (in 5-10% of pregnancies, personal 
communication, no accurate data available) used to stimulate foetal lung maturation 
in threatened preterm birth.  There are other numerous suggested pathways involved 
with foetal programming, but are beyond the scope of this thesis.  
The importance of foetal programming is thought to be as a necessary process for 
survival of a species, as part of the evolution, to prepare the foetus for future 
adaptive advantages (46).  However evolution is a slow process and the human 
body may not be ‘ready’ for a rapid environmental change. A good example relates 
to nutrition when foetal adaptation to nutrient restriction leads to an insulin 
resistant/deficiency phenotype. This trait, thought to support survival in hunter-
gatherers whose nutrition was low, represents a risk phenotype of T2D in modern 
day society (46). A complex polygenic disease, T2D often manifests years before 
clinical diagnosis and sometimes in a cluster with other phenotypes such as high 
blood pressure obesity and dyslipidaemia- known as metabolic syndrome (47). 
Equivalent human studies to the animal model, is found in the epidemiological 
studies of the Dutch winter famine (1944), where those children of mothers exposed 
to famine during pregnancy were more likely to have low birth weight, CVD, obesity 
and adverse lipid profiles later in life (48). Metabolic syndrome in adolescence is 
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considered a precursor for CVD and is important when examining the link between 
an exposure and risk of developing disease later in life in an otherwise healthy young 
population. Metabolic syndrome as an outcome will also be examined in this thesis.  
We understand foetal programming as an adaptation process to an adverse 
environment to improve survival of the foetus in the extra uterine life.   However 
there are many ways of defining adverse environment.  The key question is that how 
does the adverse environment impact foetal development and programming. In this 
thesis, one up-to-date aspect of foetal environment and potential pathway related to 
HPA-axis will be examined.  In this thesis, adverse environment is defined as 
intrauterine exposure to sGC and psychosocial stress, and adversity. There are 
three main pathways through which the foetus is thought to respond to an adverse 
environment, which are:  
1) Epigenetic: These are environmentally induced changes in the genetic 
expression of phenotype that occur without directly affecting the underlying DNA 
sequence. Studies show these changes can be trans-generational, for example in 
the Dutch famine, SGA children born during the period of famine had grandchildren 
who were also born with smaller birth size (49). This can be better explained through 
the example of the IGF-1 gene (Figure 3), responsible for the production of the 
insulin growth factor 1 (IGF-1) hormone, which plays an important role in foetal 
growth. The IGF-1 genes are sensitive to epigenetic changes, with low levels of IGF-
1 also linked with insulin resistance (50). Hepatic IGF-1 levels are determined 
partially by nutritional intake, therefore over nutrition in early life may lead to elevated 
IGF-1 gene expression were as under nutrition in early life may lead to reduced IGF-
1 gene expression; reductions in IGF-1 expression would result in reduction in IGF-1 
hormone production as well as increase insulin resistance, and through that growth 
restriction and T2D. Thus explaining not only the association with SGA, but the 
increased risk of T2D of infants born SGA (37).   
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Figure 3. Maternal under nutrition leads to reduced IGF-gene production and 
insulin resistance in the foetus 
 
 
2) Changes in tissue differentiation: In order to protect the foetus from poor in 
utero conditions, such as under-nutrition, foetal programming results in the growth of 
some organs being sacrificed in order to protect more sensitive and vital organs, 
such as lungs and the brain (37). For example, both animal and human studies have 
shown that small birth size is associated with smaller kidneys; kidney size itself is 
directly proportional to nephron count, with lower nephron counts associated with an 
increased risk of hypertension in adulthood (51-53).  
3) Altered homeostatic process: Homeostasis is the body’s way of constantly 
adjusting to changing environments allowing it to adapt and survive. The ‘fight or 
flight’ response in moments of stress is an example of homeostasis. Animal studies 
show that offspring fed a low protein diet experiences changes to the peri-portal and 
peri-venous hepatocytes resulting in altered ratio of phosphenolpyruvate 
carboxykinase to glucokinase-enriched cells in the liver. Phosphenolpyruvate 
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carboxykinase is an important enzyme on the metabolic pathway of 
gluconeogenesis, i.e. the metabolic pathway for the generation of glucose from non-
carbohydrate substrates. This leads to greater hepatic glucose production and 
increased risk of developing T2D (54;55).  
Foetal environment, though a complex term to define, can be summed up as a 
combination of maternal health (e.g. genotype, age, diseases such as gestational 
diabetes or hypertensive disorders) and lifestyle (e.g. nutrition, smoking, alcohol 
consumption, drugs), and function of the utero-placental unit.  Though foetal 
environment is crucial for foetal growth and development, it is not the sole indicator 
for birth size. Genetic factors are thought to play a role in foetal programming as 
demonstrated by correlations between paternal height or weight and birth weight of 
the new-born (56). A recent study shows that the same genetic variant can be linked 
to both lower birth weight and increased risk of T2D, which introduces a mechanism 
linking lower birth weight and increased risk of developing disease in adulthood. 
Foetal genotype seems to have a significant role in predicting birth size; although 
variants identified so far are a few and the proportion of the variance in birth weight 
explained by these genotypes is small. The polymorphisms in the ADCY5 and near 
the CCNL1 and LEKR genes, known to be associated, especially ADCY5, with T2D 
and glycaemic traits, have now also been linked with small birth size (57). A recent 
study in 2013 has reported further variants or replicated previously identified and 
associated them with later life phenotypes (some pleiotropic effects); ADCY5 and 
CDKAL1 with T2D, ADRB1 with adult blood pressure, HMGA2 and LCORL with adult 
height, indicating a link between foetal growth, postnatal growth and metabolism 
(58). The genetic variance even in this large study by Horikoshi et al only shows a 
small proportion of variation in birth size, none the less based on epidemiological 
and twin studies, inheritance is considered to play an important role. Though genetic 
variation may explain some of the association between birth size and disease in 
adulthood, there is still some missing link between genotype and phenotype. Twin 
studies of genetically identical twins have found that the lower birth weight twins 
have higher blood pressure in adulthood; which suggests the presence of other 
predictors beyond genetics to explain the association between birth size and 
diseases in adulthood (46).  
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Though the importance of the in utero environment in foetal development is known, 
the exact molecular mechanism behind it is still unclear. The term foetal 
programming is therefore often used in current literature to define the pathway which 
links the foetal period and any resulting long term consequences in the offspring. 
Epidemiological studies play an important role for understanding the mechanisms 
behind foetal development and also help give clues as to the possible molecular 
mechanisms involved in foetal programming to be taken forward to experimental 
studies.  
It is important to remember that though small birth size has repeatedly been linked to 
increased risk of developing disease in adulthood, it is misleading to make the direct 
inference that small birth size actually causes disease in adulthood. Birth size is a 
proxy for prenatal growth conditions and therefore an important indicator of 
environmental and genomic influences during foetal development that could lead to 
future health problems (59). Understanding the link and interaction between genes 
and environment is important to explain foetal development and consequent birth 
size. Studies on the Northern Finnish Birth Cohort have advanced studies on foetal 
growth, birth weight as well as related to current genetic studies (60). The advantage 
of the Northern Finnish Birth Cohort is its prospective design with detailed repeated 
measures, which make it a unique resource.  This design allows for the study of 
genetic, biological, social/behavioral risk factors in the emergence of disease across 
the life stages. Life stages of human development entail complex biological 
processes interacting with environmental physical and psychosocial factors to 
determine health and function across the life course, the life stages include 
pregnancy, infancy, childhood, adolescence, adulthood and old age. In this thesis we 
touch on three of these seven stages of life, pregnancy, infancy and adolescence.  
2.3 The Hypothalamic pituitary adrenal axis 
 
Survival of an organism depends on its ability to maintain equilibrium in an always-
changing environment, this process is called homeostasis. The HPA axis is key 
component in mammals for maintaining homeostasis. Endogenous GCs are one of 
the main hormones in the HPA pathway and is currently being suggested as possible 
part of the pathway in foetal programming (61). The HPA axis is a vital part of the 
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neuroendocrine system, which maintains homeostasis through negative feedback 
and regulates multiple body processes including, the digestive system, immune 
system, energy storage and expenditure and mood (Figure 4).  
Figure 4. The hypothalamic pituitary adrenal pathway, adapted from ‘An 
introduction to neuroendocrinology’ by R. E. Brown 
 
 
The pituitary gland, also known as the master gland, together with the hypothalamus 
and adrenal glands, form the peripheral limb of the stress system, the HPA axis. The 
human body responds to external stress stimuli in two ways, 1) neuromuscular 
response e.g. jumping out of the way of a speeding car and 2) a neuroendocrine 
response via the HPA axis. In the neuroendocrine response, stimulation of higher 
centres of the brain through chemical changes results in the release of specific 
neurotransmitters, which in turn stimulate the release of selective hormones from the 
hypothalamus. These hormones released by the hypothalamus act by stimulating 
specific target cells in peripheral organs i.e. adrenal gland, heart, liver, skeletal 
muscle, and adipose tissue to maintain homeostasis under stress (Figure 4). The 
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principal hypothalamic regulator of the HPA axis is the corticotrophin releasing 
hormone (CRH), which stimulates the release of ACTH from the anterior pituitary as 
well as acting as a neuro-modulator in the brain itself. ACTH in turn stimulates the 
secretion of GC hormones (cortisol in humans) from the adrenal cortex, the final 
effectors of the HPA axis.  Excess GC, we know from animal studies, can cause a 
reduction in growth of the foetus. 
The HPA axis is not a static system that comes into play during situations of stress, 
but is a vital component in maintaining both basal body as well as stress-related 
homeostasis. In healthy individuals, CRH is actively secreted into the circulation in a 
circadian, pulsatile flow at two to three secretary episodes per hour (62). In addition 
to stress, alterations in light and feeding cycle influence the diurnal levels of CRH 
release. In the in utero period, the foetal adrenocortical system is responsible for 
maintaining homoeostasis and organ maturation in preparation for extra uterine life. 
In the foetus, ACTH secretion and the embryonic adrenal cortex are identifiable as 
early as the 8th week of gestation (63;64).  
Glucocorticoids, the final effectors of the HPA axis, act by binding with their cytosolic 
GC receptors (GR). These GC receptors (GR) are ubiquitously distributed, with high 
expressions in the amygdale, hippocampus and paraventricular nucleus of the 
hypothalamus in the brain. Glucocorticoid receptors therefore play a major role as 
modulators of the HPA axis. Synthetic glucocorticoids have a 25-fold higher affinity 
to GR than naturally occurring GC (65). Foetal GR in the hippocampus have been 
detected as early as the 24th week of gestation and possibly are present at even 
early stages of development (66).   Previous animal studies indicate sensitivity of the 
foetal HPA axis to early life factors, including exposure to GC (67). As the 
hippocampal GR and mineralocorticoids receptors (MR) are the primary level of 
programming of the HPA axis in the prenatal period, any alteration in these would 
affect foetal HPA axis programming (68). The placenta acts as a natural barrier to 
maternal cortisol, breaking it down to its inactive product, cortisone, through the 
enzyme 11β-hydroxysteroid dehydrogenase. Synthetic glucocorticoids have lesser 
affinity for this enzyme, with betamethasone and dexamethasone crossing the 
placenta at 3:1 and 2:1, respectively (maternal to foetal levels) (69-71). Therefore 
with higher concentrations of sGC crossing the placenta to the foetus, the negative 
effects this drug may cause become an issue.  
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The binding of GC to their cytosolic GR results in the translocation of active GR into 
the nucleus. Through interaction as homodimers (i.e. combination of two identical 
molecules) with specific GC responsive elements within the DNA, the GR up 
regulates gene transcription of appropriate hormone specific protein production e.g. 
anti-inflammatory proteins. This mechanism of action is known as transactivation. 
The active receptor-glucocorticoid complex also has a transrepression mechanism of 
action by inhibiting other transcription factors, e.g. positive regulators of growth of the 
immune system and other cells. Transrepression of the NF-қB, an important 
regulator of numerous cytokine genes (where cytokines are signalling molecules) 
through active GR, results in the immunosuppressive action of GC (72-74). 
Glucocorticoids also act as key regulators of the HPA axis through a negative 
feedback action on extra-hypothalamic regulatory centres, resulting in termination of 
the stress response. Prolonged activation of the HPA axis results in growth 
restriction through the inhibitory actions of activated GR. 
In their systematic review, Tegethoff et al (75) examined the association of exposure 
to sGC on the foetal, neonatal, and infant HPA axis and concluded the following: in 
utero exposure to sGC  reduces HPA activity in basal conditions as well as after pain 
related stress. They found marked effects with increased sGC exposure with 
variation between GC exposure and HPA axis assessment. However, the long-term 
effects of in utero sGC exposure beyond the first month of life remained unclear. 
Animal studies, which examined the effect of sGC on circulating GC and the HPA 
axis, given in the last week of pregnancy, reported a significant blunted HPA axis, 
with lower levels of ACTH and corticosterone. In addition, lower birth weight was 
noted after in utero exposure during the final week of pregnancy of the offspring rats 
to dexamethasone (a sGC) (76). In addition, growth of the offspring was reduced till 
weaning. It was suggested that dexamethasone inhibits placental glucose transport, 
which may explain the resulting reduction in birth weight.   
Current studies suggest that both endogenous GCs and maternal nutrition are key 
targets in understanding some of the mechanism of reduced foetal growth. Previous 
animal studies have reported an independent association with both under-nutrition, 
and sGC exposure with smaller birth size in the offspring (77;78). Animal studies 
have shown that malnutrition in the foetal period results in a stress response of 
increased GC secretion, with this increased GC foetal exposure resulting in foetal 
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growth restriction as well as development of higher blood pressure in the offspring 
(78). The increase in blood pressure can however, be eliminated by blocking 
maternal GC synthesis, supporting the hypothesis that the GC pathway is related to 
a possible mechanism in foetal programming (44;79-82). Experimental studies on 
rats report a reduction in placental weight in pregnant rats fed on low protein diet 
(83). This reduction in placental size did not affect foetal size until late gestation, 
when rats on low protein diets gave birth to lower birth weight offspring. There was 
no difference in GC levels between rats except in late gestation, when there was an 
increased level of GC in rats fed low protein diet. Rats with adrenal glands removed, 
a vital organ for the production GC, also showed increased levels of GC in late 
gestation, suggesting a premature activation of the foetal HPA axis and GC 
production (83). Epigenetic factors thought to be involved in foetal programming 
involve changes in GC receptor gene (84). However, the GC receptors are also 
highly species specific, therefore, how this would translate to human studies is 
unclear. Also, how this information can be used to explain human foetal 
programming is also unclear.  
Cortisol, a naturally occurring GC is the effecter hormone in the HPA axis and acts 
directly through ubiquitously distributed GR on target tissue. Cortisol in humans is 
secreted in a diurnal pattern, which peaks early in the morning and progressively 
declines over the day. Research on the cortisol awakening response (CAR) has 
shown a link between blunted CAR and conditions such as stress disorders, chronic 
fatigue syndrome and sleep disorders (85;86). Chronically elevated cortisol levels 
have also been linked to multiple adverse conditions, which include cognitive 
decline, immunosuppression and insulin resistance (87-90). The autonomic nervous 
system (epinephrine and norepinephrine hormones) also form part of the stress 
response, which is activated in acute states, is also being considered to play an 
important role in development of disease later in life, but its role in foetal 
programming is less understood (91).  
During pregnancy, the mother’s HPA axis is profoundly altered, resulting in a rise in 
cortisol levels. Data suggests that the neonatal HPA axis is not isolated from 
maternal stress, but responds similarly to maternal HPA axis activity, indicating some 
crossover of cortisol into the foetus (92;93). Although the foetus is protected during 
pregnancy through the action of the placental 11 β-hydroxysteroid dehydrogenase2 
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enzyme (11βHSD2) which converts maternal GC to its inactive form, 33-40% of the 
variance in foetal cortisol is still linked to that of maternal levels (94).  Maternal 
anxiety has also shown to have a negative link with 11βHSD2, indicating a link with 
maternal stress and HPA axis in association with smaller birth size (95). Cushing’s 
syndrome, a condition of hypercortisolemia, most commonly resulting from pituitary 
driven adrenal hyperplasia, is a rare condition during pregnancy. It forms a natural 
experiment for infants born exposed to increased maternal levels of cortisol. In the 
few cases (n=58) that have been reported, there was a high level of both maternal 
and infant morbidity and mortality, with two thirds of the infants born prematurely. 
Birth weight to gestational age was not regularly reported in all cases, but the 
average of difference 26.6% in birth weight, which was considered underestimation 
of true birth weight difference (96).   
In the foetus both animal and neonatal post-mortem studies, the HPA axis is 
suggested to function already in early pregnancy with GR identified as early as the 
24th gestational week, and adrenocorticotropic hormone, an important regulatory 
hormone of the HPA axis, identified as early as the 8th gestational week (63;65;66). 
In the foetus, GC is also a vital component for normal foetal growth and for initializing 
terminal maturation of organs. A systematic review of animal studies examining the 
association of in utero exposure to sGC on birth outcomes reported a reduction in 
foetal growth and disturbance in nervous system and brain development (77). This 
suggests that though important for foetal development, excess levels of GC may 
affect foetal programming. 
Using data on sGC (betamethasone and dexamethasone) given during pregnancy 
may be a way to understand the link between excess GC exposure and birth size in 
humans.   Synthetic glucocorticoids are recommended in threatened preterm birth for 
stimulating foetal lung maturation. Unlike endogenous GC, of which 67% of maternal 
GC is made inert by 11β HSD2 enzyme, sGC are less sensitive to the activities of 
the placental 11β HSD2 enzyme. Only 2% dexamethasone and 7% betamethasone 
are made inert by 11β HSD2, with a 3-fold lower concentration of betamethasone 
reported in the plasma of the cord blood compared to maternal blood concentrations 
(75).  
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The ability of 11β HSD2 to make sGC crossing the placenta inert is, however, also 
decreased by late gestation.  Of the sGC, betamethasone has a plasma half life of 
6.5 to 9h, and dexamethasone of 4 to 4.6h, and has long acting activity ranging 
between 36-54h, only 60-75% bind to protein (with unbound sGC being the active 
form), as well as a 25-fold higher affinity to the glucocorticoid receptors than naturally 
occurring glucocorticoid. Protein binding capacity has been shown to be higher in the 
human foetus, as well as having a prolonged half life of sGC.  In contrast, cortisol 
has a plasma half life of 1.5 h, a biological activity of 8-12h, and a protein binding 
capacity of 95% (75). Mineralcorticoid receptors also have a high affinity for GC, but 
they are only present in later stages of development in rodents (97). Synthetic 
Glucocorticoids actions prenatally are GR specific, unlike prenatal stress which 
involves both MR and GR as well as catecholamine release.  
In animal models, prenatal social stress, excess sGC or inhibition of 11βHSD2 
enzyme reduces birth weight and results in altered glucose metabolism (98;99), 
hypertension (81), increased HPA axis reactivity, and increased anxiety related 
behaviours (100;101). While research evidence on sGC is available, there is a 
dearth of available data on foetal cortisol measures, and little is known about the 
impact of other stress mediators such as catecholamine’s, adrenaline and 
noradrenalin on the foetus. On the human side, routine longitudinal epidemiological 
studies are important when there is a gap in knowledge of the association of GC on 
foetal growth, and gathering information on cortisol is difficult (at larger scale). 
Therefore, where direct measures of foetal cortisol are not available, prenatal stress, 
as well as exposure to sGC may help to shed further light on foetal programming. 
Based on current evidence, we can summarise that the pathways through which 
stress mediated through the HPA axis translates to disease later in life is still 
unclear.   
 
2.4 Social stress and pregnancy 
 
We can define social stress as either low social class, experiencing from social 
adversity or neighbourhood social disparity. Low social class or experiencing social 
adversity is associated with increased morbidity and mortality from almost every 
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disease condition (102-104). Chronic stress due to increased exposure to stressful 
events as well as fewer social and material resources is widely considered to be the 
biological link between social stress and risk of morbidity and mortality.  
The HPA axis is one of the main biological regulators of stress, with cortisol as the 
main effecter hormone. The body reacts to conditions of stress through the HPA axis 
and by secreting increased levels of cortisol. It can be thought that the HPA axis 
response to stress, mirrors that of the individuals, with acute response generally 
adaptive, but prolonged response can result in deleterious effects; for example, there 
is long standing evidence that early exposure to stress in childhood, results in 
sensitisation of receptors in the brain, and in disease such as depression, 
hypermania, or mania (105). Pharmacological levels of GC have a potent anti-
inflammatory reaction, prolonged exposure at higher doses result in metabolic 
derangements, which include increased visceral fat accumulation, dyslipidaemia, 
non esterified fatty acids, and an impaired glucose and insulin tolerance (106). 
Excess GC in periods of stress also results in increased protein degradation, with 
generation of amino acids as precursor for glucose synthesis in the liver. Glucose 
uptake in muscle is reduced through the inhibition of translocation of glucose 
transporter-4. Eventually resulting in insulin resistance, hypertriglyceridemia, and 
hepatic steatosis.  Though the levels of GC continue to be regulated through the 
HPA axis, however uptake depends on GC receptors, affinity of receptors, and 
alterations in GC metabolism and clearance.  
Nonetheless, the biological pathways and mechanisms through which social stress 
translates into biological risk of disease remains a debate (107). In a recent literature 
review by Dowd et al (85) the authors try to extrapolate whether there is a relation 
between cortisol levels and low social class. However, no firm conclusion could be 
drawn due to varying results and methods used in previous studies examining low 
social class and cortisol levels.  
In contrast, animal studies have shown a link between animal hierarchy and cortisol 
levels (108). Social animals living in dominant hierarchies show increased levels of 
basal GC depending on the type of dominance; where dominance rank is achieved 
by repeated physical assertion, better access to resources and where better quality 
of life does occur. However, these animals live an increased stressed existence and 
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show a more active GC system with elevated basal GC levels. In social animals 
where dominant rank is maintained through non-physical intimidation, it is the 
subordinate animals that are exposed to social stressors and increased levels of 
basal GC levels. 
Social adversity may serve as an index of social stress particularly in large 
epidemiological studies or when it is not feasible to measure (maternal) physiological 
stress directly. Although stress and altered levels of cortisol is the hypothesized 
mechanism linking psychosocial stress during pregnancy and poor birth outcomes, 
reported perceived stress does not correlate well with measures of cortisol and this 
may be due to methodological issues.  Nonetheless, studies have indicated a 
negative association between social adversity and birth weight, i.e. the higher end of 
the social adversity seem to result in lower birth weight (109-114). It is known that 
maternal stress during pregnancy resulting from psychiatric sequelae, spousal 
violence or natural disasters have been linked with low birth size of the infant (115-
120). It is also not just the short term outcomes that are linked with maternal stress; 
maternal stress during pregnancy has also been reported to associate with long term 
outcomes on the physiological and cognitive outcomes of the offspring (100;121). 
Using ultrasound between the 27-28 gestational week, an association between 
maternal mood and foetal behaviour has also been shown, indicating a link between 
maternal stress and consequently foetal stress (122). 
However, quantifying maternal stress, outside the realm of natural disasters or 
spousal abuse, as a variable in different populations is difficult. As events considered 
stressful by one culture, may not translate in another. As a summary, the evidence is 
incomprehensive and the question remains un-answered that whether there is a 
definite link between social stress and foetal growth, birth at size as a marker or is 
the potential association between social stress and foetal growth a function of many 
different biological factors? 
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2.5 Metabolic syndrome and other metabolic outcomes in teenage years and the       
association with diseases in adulthood 
 
Small birth size is associated with an increased risk of developing T2D, high blood 
pressure and CVD, dyslipidaemia and obesity, later in life. However, these 
conditions often occur in clusters in the same individual, known as metabolic 
syndrome. Metabolic syndrome is defined as having at least three of five of the 
following conditions; obesity, elevated blood pressure, elevated serum triglycerides, 
low serum high-density lipoprotein (HDL), cholesterol and impaired glucose 
tolerance or insulin resistance (47). Though signs of some of these diseases appear 
later in life, it has now been suggested that their symptoms can appear as early as in 
childhood.  Dyslipidaemia, defined as abnormal blood lipids levels (high levels of low 
density lipids (LDL), intermediate density lipids (IDL), very low density lipids (VLDL), 
and low levels of HDL), and is a major risk factor for developing atherosclerosis, 
leading to CVD disease; atherosclerosis has already been shown to start developing 
in early childhood before symptoms occur, therefore making it imperative to identify 
those at risk (123-125). Dyslipidaemia is therefore a good link between adverse 
foetal development and CVD disease later in life.   
Metabolic disease is not a result of a single factor but a complex interaction of 
multiple factors, including physiological, genetic, behavioural, and environment. For 
example, the risk of developing metabolic syndrome in small birth size infants is 
increased in postnatal environments such as low physical activity and/or increased 
energy intake (126).  Adverse foetal environment has also been shown to induce 
structural and functional abnormalities in the pancreatic islet cells, resulting in 
irreversible changes in insulin sensitivity (127). Studies have shown a link between 
birth size and lower insulin sensitivity, which is reported as early as in the pre-
pubertal period and is an important link in developing T2D later in life (128). It is 
therefore important that early identification of children at risk of developing metabolic 
syndrome occurs, before disease actually develops. Understanding the key 
environmental factors in the prenatal period which associate in particular with 
metabolic syndrome will also help further understanding of pathways of foetal 
programming.  
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Other metabolic predictors, such as blood apolipoprotein B, apolipoprotein A and 
apoB/apoA-I are linked to CVD disease in adulthood and are considered in some 
studies as better predictors than total/HDL cortisol ratio, for coronary heart diseases 
assessment (129;130). The Triglyceride/HDL cholesterol ratio which is elevated in 
insulin resistant patients, is also considered a better predictor of coronary heart 
disease in adults than the LDL, VLDL and IDL alone (131).  The IDL fraction in LDL 
is attributed to the risk that has in the past linked high LDL levels to atherosclerosis 
(132). Lipids have a wide variety of function in the body for example, cell membranes 
as phospholipids and are also a major source of energy. Lipids are either derived 
from dietary fats or synthesized by the body itself (133). It is stored as triglycerols in 
the adipose tissues, with serum lipids and its derivatives transported between areas 
of synthesis in the liver and intestine to peripheral tissues for utilization and storage. 
This is done through transport in a macromolecule complex of lipid and protein called 
lipoproteins. Significant components of the lipoprotein particles are apolipoproteins, 
accumulation of which considered an important predictor of CVD (134). Figure 5 
shows a summary of the metabolism of the lipoprotein pathway. When cholesterol is 
absorbed from the intestine it forms chylomicron particles which are metabolized in 
the circulation and liver. Apolipoprotein B-100 synthesized in the liver is present in 
LDL, IDL and VLDL particles.  Apolipoprotein B is an essential lipoprotein required 
for the binding and uptake of LDL particle to receptors to all cells. The concentration 
of apolipoprotein B has been shown to be correlated with non-HDL cholesterol levels 
and thus indicates the levels of potential atherogenic lipoproteins. Expressions of 
levels of apolipoprotein A, on the other hand, are determined by the levels of HDL, 
i.e. Apolipoprotein A is considered therefore protective against CVD risk. In addition 
apolipoprotein A is an important cofactor for lecithin cholesterol acyl transferase, 
which is important in removing excess cholesterol from tissue and binding it with 
HDL. However further studies in this field are still needed.  
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Figure 5. Summary of lipoprotein metabolism pathway adapted from Walduis 
and Junger(134), Apo: apolipoprotein’ CEPTP, cholesteryl ester transfer 
protein; HL, hepatic lipase; IDL, intermediate-density lipoprotein; LCAT, 
lecithin cholesterol acyl transferase; LL, lipoprotein lipase; VLDL, very low-
density lipoprotein  
 
Examining these metabolic outcomes in adolescence, will help to identify how certain 
exposures during pregnancy, which are independent of birth size themselves, also 
link to disease in adulthood. 
 
2.6 Hypothesis for this thesis 
 
This thesis consists of four studies in which the following hypotheses were tested:  
 
Hypothesis 1: Because sGC administered during pregnancy results in 
premature organ maturation and reduced foetal growth in animal studies, we 
expected sGC to also have a similar impact on birth size in humans 
documented in the research literature.   
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Hypothesis 2: Women exposed to sGC during pregnancy prescribed in cases 
of threatened preterm delivery are likely to have infants of smaller birth size 
than unexposed counterparts.  
Hypothesis 3: Because both social stress, at individual and neighbourhood 
levels, and specific genetic factors have each been associated with smaller 
birth size, it is expected that exposure to both risks will magnify the 
association.  
Hypothesis 4: Given that social adversity in childhood has been associated 
with development of metabolic syndrome later in life, we hypothesized that 
prenatal exposure to social adversity would be associated with metabolic 
outcomes in adolescence.  In addition, if the social adversity during pregnancy 
is associated with smaller size at birth, then it will also be associated with 
more adverse metabolic status in adolescence. 
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3 Literature review 
 
The aim of this chapter is to summarise the available published literature related to 
the work presented in this thesis; it details a systematic literature review on the 
association of sGC on birth size, now published in a peer reviewed journal. It also 
summarises in separate sections the published literature available examining the 
association of social adversity, birth size and the genetic interplay, social adversity 
during pregnancy and the association on metabolic outcomes in adolescence.  
 
3.1 Glucocorticoids during pregnancy and the association with size at birth, a 
systematic literature review 
 
The first part of this thesis was done to conduct a systematic literature review, which 
explored the literature available that examined the association of sGC on birth size. 
In this section the systematic review published by this author, supervisors and 
collaborators is summarised (Paediatric and Perinatal Epidemiology, 2010). This 
work was conducted as a part of the background of this thesis.  
 
3.1.1 Introduction for systematic literature review 
 
Graham Liggins changed the face of neonatology when in 1969 he showed that 
foetal lung maturation was stimulated in pregnant ewes exposed to sGC, resulting in 
improved survival of the preterm born offspring (135). He confirmed his animal 
studies findings in a controlled trial of mothers who had threatened premature 
delivery before the 37th gestational week (136). In human studies, 3.2% of the 
preterm infants exposed in utero to sGC, presented with respiratory distress 
syndrome (RSD) born at the 32nd gestational week, compared to 15.0% in those who 
were not exposed (136). Following this, sGC were recommended in threatened 
preterm birth for foetal lung maturation; nevertheless, it was not until the early 1990s, 
before it was accepted as routine therapy in threatened preterm birth. Over the last 
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20 years, sGC have now become the most important form of treatment for 
acceleration of foetal lung maturation in threatened and elective preterm births, with 
dexamethasone and betamethasone as the recommended sGCs. In addition to the 
reductions in the risk of developing RDS, sGC also contribute to the reduction of 
overall mortality and morbidity from other complications of prematurity (e.g. 
intraventricular haemorrhage, necrotizing enterocolitis). Their importance in 
neonatology can thus no longer be doubted (137;138).  
 Given that sGC, have proven to be invaluable in reducing risk of neonatal morbidity 
and mortality due to preterm birth, it is now widely accepted that their benefits 
outweigh any possible risks; as such adverse consequences of treatment with sGC 
for foetal lung maturation have received much less attention. Animal studies, often 
using relatively high doses, show that exposure to sGC in utero leads to a reduction 
in cell proliferation, premature cell differentiation and organ maturation (139;140) and 
those mimicking clinical doses show similar results (141-146). Insulin resistance has 
also been linked with antenatal betamethasone treatment in a 30 year follow up 
randomised control trial  (147).   
Studies examining the association of sGC with, for example, birth size and its link 
consequently with increased risk of developing disease in adulthood are few. Further 
research is needed to address this gap in knowledge that may help in understanding 
of the true consequence of excess sGC exposure and its link with foetal 
programming. Should any link be noted, this may help give support to the HPA axis 
pathway as one of the suggested pathways for foetal programming. 
  
3.1.2 Methods for systematic literature review 
 
3.1.2 (i) Search strategy (study I) 
 
The literature search was performed, searching for studies dating from 1978 to 
January 2013 using Medline, EMBASE, PubMed, Cochrane, Google scholar and 
Institute of Life Science search engines. Because sGC were first introduced as 
treatment for lung maturation during the 1970s, the sparse studies available before 
 
 
45 
1978 were characteristically small, consequently underpowered and were thus not 
included. The following search keywords were used alone or in combination: birth 
weight, head circumference, birth length, ponderal index, corticosteroid (i.e. 
glucocorticoids, dexamethasone and betamethasone), pregnancy and RDS. 
Respiratory distress syndrome was included in order to capture all potential studies 
reporting anthropometric measures. This yielded 1,101 publications (Figure 6). Each 
paper available in full text was first screened by performing a word search for birth 
weight/ head circumference/ birth length/ ponderal index. Abstracts for papers 
unavailable in full text online were screened, and those reporting analysis of the 
relation between intrauterine exposure to sGC and birth measures were ordered and 
examined fully. Reference lists of selected papers were also examined and 
potentially relevant papers were ordered.   
 
Figure 6. Method of reviewing and selecting articles. Inclusion criteria: (1), 
English language, (2) human studies, (3) adjustment for gestational age, (4) 
used dexamethasone or betamethasone 
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3.1.2 (ii) Study inclusion criteria 
 
Of all the quantitative and qualitative studies examining the possible effect of sGC 
taken internally on birth size, publications that were reviewed included those (1) 
written in English, (2) based on human subjects, (3) adjusted for gestational age, and 
(4) used dexamethasone or betamethasone. We collected systematically the 
following information: type of study, participants, source of measurements, year of 
birth, dose of sGC, length of treatment, sample size, confounding factors, study 
design, birth size, and regression and probability estimates. 
 
3.1.2 (iii) Study quality assessment  
 
The general quality of each publication was assessed using the criteria for 
observational study designed by Tooth et al (148) (designated here as T scores).  
This checklist was designed to enable examination of study quality and comparability 
across studies (Table 3). Maximum score achievable was 33. However, as these are 
general criteria, an additional checklist was created to assess specifics relevant to 
studies examining birth size. This checklist focused on Design, Analytic strategies, 
and Confounders (DAC; Table 2). The design elements received one point each for: 
sufficient statistical power (based on Cohen and Cohen (2), the sample size required 
is n=788 for an 80% power of detecting an effect size of Cohen’s d=0.20, 
representing a difference of 100g in birth weight and assuming SD=500g, α= 0.05 
[two tailed hypothesis]), examined control versus exposed groups, and used a 
prospective design. One point was given for each of the following features: 
multivariable analysis rather than univariate, separate analysis of preterm versus 
term births, and singletons versus multiples. One point was given per included 
confounder, thus there was essentially no maximum DAC score as this depended on 
the number of confounders included. Higher scores indicated better study quality. 
After completion of analysis, scores were cross checked by a second individual. 
[Original papers were also reviewed by senior specialists: Professor Anna-Liisa 
Hartikainen, Professor Alina Rodriguez and Professor Marjo-Riitta Jarvelin]. 
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3.1.3 Summary of results of the systematic literature review 
 
The systematic literature review to examine the current available literature, which 
has been updated for the purpose of this thesis to include an up to date review of 
studies examining the association of sGC exposure during pregnancy and its 
association with birth size is as follows: 
Though animal studies have suggested an association with small birth size, over the 
last 40 years, only 19 human studies (149-167) have been published to date which 
examine the association of in utero exposure to sGC on the outcome birth size (birth 
weight, birth length, head circumference and ponderal index) (168). Examining all 
measures of birth size as an outcome is important as birth weight, length, head 
circumference and ponderal index have all been linked to adverse outcomes in 
childhood and later life. Glucocorticoids are important for normal brain development; 
however animal studies indicate that higher levels of GC are associated with 
deleterious outcomes regarding the brain. Excess GC was associated with reduced 
optic nerve myelination and as well as that of the corpus callosum of foetal sheep 
which persisted into adulthood (144). Vital for normal vision, the optic nerve 
transmits impulses from the retina to the brain; The corpus callosum is the 
connective pathway between the two hemispheres of the brain (169;170). Any 
damage to the optic nerve would affect sight and that to the corpus callosum would 
affect normal neurological development. In rats, lower brain weight was seen in rats 
treated with GC, designed to mimic those of clinical settings which persisted for 3 
weeks postnatal (171).  A brain weight reduction of 10% was seen in term lambs 
born to ewes given single dose of betamethasone (0.5mg/kg) (172). Birth weight is 
most commonly used in studies as a measurement of foetal growth and 
development. Change in length at birth was reported as proportional to birth weight, 
also resulting in decreased length with increased GC usage as shown in animal 
study (173). 
 Of the 19 articles that examined the association of in utero sGC exposure on birth 
size, not all looked at the association with all measures of birth size. All examined 
birth weight (149-167), however, only eleven included head circumference 
(149;152;153;155;157;160;162;163;165-167), six birth length (152;155;160;165-167) 
and one ponderal index (165). Altogether, the 19 studies, represented a study 
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population which ranged in sample size from 152 - 14,338 and with year of birth from 
1988 to 2006. Study designs differed, and consisted of three randomized control 
trials (152;160;165), three prospective observational (155;166;167), and thirteen 
retrospective (149-151;153;154;156-159;161-164). Type and sGC courses also 
differed between studies; eleven studies (149;150;152-155;158;159;161;162;166) 
compared multiple courses of sGC, eight (151;152;156;160;163-167) compared 
exposed versus non-exposed and one (157) examined the effects of complete 
versus incomplete course of sGC. Gestational age at birth varied from the 25th to the 
40th gestational week (GW), with only eight studies examining infants born after 34 
GW (152;158;159;162;163;165-167). The mean birth weights and head 
circumference ranged from 1086g to 3412g and 25.5 cm to 34.5cm, respectively. In 
total, approximately 128g reduction in birth weight was reported in these studies 
(averaging their combined results). 
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Table 1. Glucocorticoid treatment due to threatened preterm birth: Summary of results from systematic review according 
to study design 
 
n total 
range of 
sample size  
 n studies examining 
birth weight              
(range and [average] 
reductions in grams) 
 n studies examining 
head circumference 
(range and [average] 
reductions in cm) 
 n studies examining 
birth length           
(range and 
[average] 
reductions in cm) 
 n studies 
examining 
ponderal index 
 Yes   No  Yes  No  Yes   No  Yes   No 
Retrospective 13(149-
151;153;154;1
56-159;161-
164) 
152-14,338  7(150;151;15
6;158;159;16
3;164)                  
(-12 to -332 
[-134])* 
6(149;1
53;154;
157;161
;162) 
 2(153;163)           
(-0.31)* 
3(149;150
;154;157;
162) 
 0 0  0 0 
    BMZ=(-63 to 
-332 [-227]) 
DEX=(-12 to-
161[-89]) 
BMZ 
&DEX=(-39 
to-80[-59]) 
          
Prospective 1(155) 477  1(155)                    
(-122 to -150           
[-136]) 
0  1(155)               
(-1.02) 
0  1(155) (-
0.8) 
0  0 0 
Randomized 
control trial 
3(152;160;165
) 
591-1,853  2(160;165)            
(-113)* 
1(152)  1(160)                
(-0.6) 
2(152;165
) 
 1(160) (-
0.9) 
2(152;
165) 
 0 1(165) 
               
Total average reduction   -128g   -0.64cm   -0.85cm   NA  
*all studies did not report the measure of reduction in size, BMZ=betamethasone, DEX= dexamethasone. 
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Due to methodological differences between the studies, no combined analysis of the 
result such as a meta-analysis, weighted mean or even forest plot describing the 
means, was possible. Some studies presented results graphically rather than 
providing exact birth weights and others only stated whether or not differences were 
statistically significant without reporting estimates (149;154;164). In order to examine 
the general quality of the studies, the criteria for observational study designed by 
Tooth et al (T score) was used. Due to the lack of structured reporting requirements 
for observational longitudinal studies, Tooth et al developed a checklist to test the 
problems with the validity of published papers. They based their checklist criteria on 
recruitment, data collection, biases, study population and generalizability. However, 
as these are general criteria, we created more specific additional checklist, in 
particular, to examine the ability to report an association between sGC during 
pregnancy and birth size. A separate checklist  was designed to focus on study  
design, analytic strategies, and confounders (DAC score), which is specifically 
relevant to studies that examine birth size (Figure 7) (168). Details of the important 
caveats complicating interpretation and the drawing of a firm conclusion from the 
systematic literature review are as follows: 
Figure 7. The Tooth et al and DAC scoring systems     
The Tooth et al checklist was designed to enable examination of study quality and 
comparability across studies (Maximum score 33). See appendix 
 The DAC score:  
3. Design elements received one point each for:  
a. Sufficient statistical power (based on Cohen and Cohen(2), the 
sample size required is n=788 for an 80% power of detecting an 
effect size of Cohen’s d=0.20, representing a difference of 100g in 
birth weight and assuming SD=500g, α= 0.05 [two tailed 
hypothesis]) 
b. Examined control versus exposed groups 
c. Used a prospective design. 
4. One point was given for each of the following features: 
a. Multivariable analysis rather than univariate 
b. Separate analysis of preterm versus term births 
singletons versus multiples 
c. One point was given per included confounder 
 There was essentially no maximum DAC score as this depended on the number 
of confounders included. Higher scores indicated better study quality.  
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Studies were generally of low quality; The DAC score (Table 2) for studies which 
reported on birth weight ranged from 2 to 22, with a low mean of 7.5; Six 
(151;155;159;160;163;167) of the eleven studies that scored above average 
reported a reduction in birth weight with three of these (155;159;163) having the 
highest quality rankings. The DAC score for studies examining head circumference 
ranged between 2 and 22, where half (155;160;163;166;167) of the studies that 
scored above average (again a low mean of 8.5) also reporting a reduction in head 
circumference. DAC scores for studies examining birth length were comparatively 
lower and varied between 2 and 11 (mean 7.5). The study (155) with the highest 
score reported a reduction in birth length. 
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Table 2. Design, Confounders and Analysis (DAC) checklist 
Study                         Design and sample (max 5points): 
 Sample size >788=1 
 Case-control (exposed vs. 
unexposed)=2 or case study (single 
vs. multiple course)=1 
 Retrospective=0, prospective=1, 
randomized trial =2 
Number of 
confounders 
Analysis (max 3points) 
 Multivariate analysis=1 
 Preterm and term infants 
separately considered=1 
 Separate analysis of 
singletons and multiple 
births=1 
Sub total 
Pratt et al, 1999(161)   0 
1 
0 
1 1 
1 
0 
4 
Elimian et al, 2000(154)   0 
1 
0 
1 0 
0 
0 
2 
Shelton et al, 2001(162) 
 
0 
1 
0 
6 1 
0 
1 
9 
Dirnberger et al, 2001(153)   0 
1 
0 
1 0 
0 
1 
3 
Thorp et al, 2001(164)   1 
1 
0 
3 1 
1 
0 
7 
Thorp et al, 2002(163)  
 
1 
1 
1 
18 1 
0 
0 
22 
Haas et al, 2004(156) 
 
1 
2 
0 
1 0 
0 
0 
4 
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Table 2. Design, Confounders and Analysis (DAC) checklist (cont.) 
Study                         Design and sample (max 5points): 
 Sample size >788=1 
 Case-control (exposed vs. unexposed)=2 
or case study (single vs. multiple 
course)=1 
 Retrospective=0, prospective=1, 
randomized trial =2 
Number of 
confounders 
Analysis (max 3points) 
 Multivariate analysis=1 
 Preterm and term infants 
separately considered=1 
 Separate analysis of 
singletons and multiple 
births=1 
Sub total 
Kumar et al, 2005(157) 0 
1 
0 
5 1 
0 
0 
7 
Lam et al, 2001(158) 0 
1 
0 
1 
 
0 
0 
1 
3 
Bloom et al, 2001
(151)
 
 
1 
2 
0 
4 1 
1 
1 
10 
Murphy et al, 2002(159) 
 
1 
1 
0 
7 
 
1 
1 
1 
12 
Banks et al, 1999(150) 
 
0 
1 
0 
2 1 
0 
1 
5 
Abbassi et al, 2000(149) 
 
0 
1 
0 
2 1 
1 
1 
6 
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Table 2. Design, Confounders and Analysis (DAC) checklist (cont.) 
Study                         Design and sample (max 5points): 
 Sample size >788=1 
 Case-control (exposed vs. 
unexposed)=2 or case study (single 
vs. multiple course)=1 
 Retrospective=0, prospective=1, 
randomized trial =2 
Number of 
confounders 
Analysis (max 3points) 
 Multivariate analysis=1 
 Preterm and term infants 
separately considered=1 
 Separate analysis of 
singletons and multiple 
births=1 
Sub total 
French et al, 1999(155) 
 
0 
2 
1 
7 1 
1 
0 
11 
Wapner et al, 2004(165) 
 
0 
1 
2 
1 
 
0 
1 
1 
6 
Crowther et al, 2006(152) 1 
1 
2 
3 1 
0 
0 
8 
Murphy et al, 2008(160) 1 
2 
2 
3 1 
0 
0 
9 
Davis et al, 2009 0 
2 
1 
2 
1 
1 
0 
7 
Norberg et al, 2011 0 
1 
0 
6 1 
0 
0 
8 
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T scores (Table 3) averaged between 15 -22, with a mean of 18.6. The study (150) 
achieving the highest T score reported an inverse relation with birth weight, but no 
effect on head circumference. Studies examining birth length had T scores of 15-20, 
with four reporting a reduction in birth weight (155;160;166;167). 
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Table 3. Checklist for general study quality based on criteria developed by Tooth et al(148)* 
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Study rational:                     
Objectives and hypothesis stated 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
                     
Population recruitment:                     
Target population defined 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
Sampling frame defined 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
Study population defined 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
Defined study setting/geographic location 1 0 1 0 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 15 
Dates of the study are stated or implicit 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 17 
                     
Biases:                     
Eligibility criteria stated 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 18 
Issues of “selection in” to the study 
mentioned 
0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 1 8 
Number of participants justified 0 1 1 0 1 0 1 0 0 0 0 1 0 0 1 1 1 0 0 8 
Numbers meeting and not meeting the 
eligibility criteria stated 
0 0 1 1 0 1 1 1 1 0 0 1 1 0 0 0 0 1 1 10 
For those not eligible, the reasons for it are 
stated 
1 0 1 1 0 0 0 0 1 0 0 1 0 0 0 1 1 1 1 9 
The number of people who did/did not 
consent to participate stated 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 
The reasons that people refused to consent 
are stated 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Consenters were compared with non 
consenters 
0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 3 
The number of participants at the 
beginning of the study was stated 
1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 18 
Measurements:                     
Methods of data collection were stated 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
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Table 3. Checklist for general study quality based on criteria developed by Tooth et al(148)*.(cont.) 
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0
0
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0
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2
0
1
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l 
The reliability of measurement 
methods were mentioned 
0 0 0 0 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 4 
The validity of measurement 
methods were mentioned 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
                     
Data analysis:                     
Confounders were mentioned 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
The number of participants at each 
stage were specified 
1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 0 0 0 15 
Reasons for loss to follow-up were 
quantified 
1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 4 
The missingess of the data items at 
each wave were mentioned 
1 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 3 
The type of analyses conducted 
was stated 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
 “longitudinal” analysis methods 
was stated† 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Absolute effect sizes was reported 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 0 16 
Relative effect sizes was reported 0 1 0 0 0 0 0 1 1 0 0 0 0 0 1 0 0 1 1 6 
Loss to follow-up was taken into 
account in the analysis 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Confounders were accounted for in 
the analysis 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
Missing data was accounted for in 
the analysis 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 
 
 
58 
 
 
 
Table 3. Checklist for general study quality based on criteria developed by Tooth et al(148)*.(cont.) 
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Generalizability:                     
The impact of biases was assessed 
qualitatively 
1 1 1 1 0 1 1 1 1 0 1 1 1 1 1 0 0 0 0 13 
The impact of biases was estimated 
quantitatively 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Authors related results back to a target 
population 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
There was a discussion of 
generalizability 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19 
                     
Total 20 19 21 19 19 19 20 17 17 15 17 22 19 15 20 21 19 18 18  
* A score was given when the set criteria were clearly met (maximum score=33).  
† Because no study assessed growth beyond birth this criteria was not applicable. 
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The great variability in dosing regimens for sGC across studies complicated direct 
comparison and evaluation between studies (Table 4). Betamethasone was 
administered either at 12mg (149;150;154;156;157;159-165) or 11.4mg (152;155) 
twice, 24 hours apart. Dexamethasone was given in either four 6mg (149;150) or 
5mg (151) doses, 12 hours apart, or as two 10mg doses every 12 hours (158). 
Depending on local practices, courses were administered either only once or 
repeated weekly until the 34th gestational week, delivery or discharge. This shows 
that even though sGCs have been used over the last 30 years, there was a lack of 
uniform guidelines. In Finland for example, national guidelines were introduced for 
the first time in 2011.  
Table 4. Number of reviewed articles by glucocorticoid type and dose  
 2x12mg            
24hrs apart 
2x11.4mg 
24hrs apart 
4x6mg     
12hrs apart 
2x10mg   
12hrs 
apart 
4x5mg     
12hrs 
apart 
Betamethasone 11(149;150;154;156;
157;159-165) 
2(152;155) 0 0 0 
Dexamethasone 0 0 2(149;150) 1(158) 1(151) 
 
As we know, different sGC’s cross the placenta at different rates, and have different 
bioactivity and half lives; therefore trying to compare or combine results from 
different sGCs may not reflect their true associations. Betamethasone for example, 
was used in fourteen of the nineteen reviewed studies, but was associated with 
reduced birth weight in only eight studies. The three studies (149-151) that used 
dexamethasone all reported an association with reduced birth weight. Two studies 
did not differentiate between dexamethasone and betamethasone, and of these, only 
one reported a reduction in birth weight (Table 5).  
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, 
birth length and ponderal index 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Retrospective          
Betamethasone:         
Pratt et al, 1999(161)  2x12mg 24h 
apart 
Range= 2-11 
courses 
Mean=3.2 
courses 
Median=2 
courses 
Case study 
ntotal=409  
nSD=273 
nMD=136 
 
Meriter Hospital 1992-
1996 
GA <32week: 
BWs=1216 (395) 
BWm=1301 (386) 
32-34 week: 
BWs=1991 (333) 
BWm=1976 (427) 
>34 week 
BWs=2907 (608) 
BWm=2749 (563) 
NS(Estimates not 
reported) 
No significant reduction 
in BW 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical estimates (P-
values, Odds ratios, 
Regression estimates, 
difference in means, 
IQR) 
Comments of 
association of 
exposure(glucoc
orticoid) with  
outcome 
(BW,HC,BL) 
Elimian et al, 
2000(154) 
 
2x12mg 24h 
apart 
Repeated after 7 
days in multiple 
course group  
Case study 
ntotal=354  
nSD=261     nMD 
=93 
New York 
medical college 
1990-
1997 
GA BWSD=1159 (339) 
BWMD=1252 (321)  
Percentiles: 
BWSD=39.2(23) 
BWme=36.7(25.9)  
HCSD=40.1(30.8) 
HCMD=40.0(31)  
BLSD=40.8(31.1) 
BLMD=39.6(31.9)  
BW                    p=0.013  
(unadjusted)       
Percentiles:         BW                
p=0.38 (unadjusted)      
HC                p=0.90 
(unadjusted)  
 BL  p=0.80 (unadjusted) 
No effect on BW 
percentiles, HC 
percentiles, or BL 
percentiles 
Shelton et al, 
2001(162) 
 
2x12mg 24h 
apart 
Single dose or 
multiple 
(range= 2-7 
courses) 
Case study 
ntotal=152  
nSD=107 
nMD=45 
 
Duke 
University 
Medical Centre  
1991 – 
1995 
GA, sex, race, 
tobacco use, 
alcohol use, illicit 
drug use  
BWSD=1717(707) 
BWMD=1783(647) 
p=0.59 (unadjusted) 
HCSD=28.2(3.6) 
HCMD=29.2(2.9) p=0.15 
(unadjusted) 
BW (mean) exposed/not 
exposed: 1757/ 1752 (p= 
NS) 
HC (mean) exposed/not 
exposed: 28.5 / 29 (p=NS) 
No effect on BW  
or HC 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Dirnberger et al, 
2001(153)  
N/A Single or 
multiple courses 
Case study 
ntotal=206 
Singletons: 27-
29 GW: nSD=42 
nMD=21 
30-31 GW: 
nSD=39 nMD=13 
Multiple:     26-
29 GW: nSD=10 
nMD=12 
30-31 GW: 
nSD=8   nMD=23 
 
 
N/A 1994-
1999 
Stratified by GA 
and multiple/single 
pregnancy 
Singletons:              27-
29 GW: BWSD=1124 
(228) BWMD=1105 (203) 
HCSD=26.5 (1.4) 
HCMD=25.5 (1.6) 
30-31 GW: BWSD=1442 
(406) BWMD=1533 (929) 
HCSD=27.8 (2.3) 
HCMD=28.2 (1.2) 
Multiple:                 27-
29 GW: BWSD=1145 
(258) BWMD=1004 (138) 
HCSD=25.8 (1.4) 
HCMD=25.5 (1.1) 
30-31 GW: BWSD=1525 
(312) BWMD=1430 (299) 
HCSD=28.7 (1.4) 
HCMD=28.3 (2.1) 
Singletons:             
27-29 GW:        BW: 
p=NS         HC: 
p=0.023 (unadjusted)                          
30-31 GW:        BW: 
p=NS         HC: p=NS 
(unadjusted) 
                  Multiple:             
26-29 GW:        BW: 
p=NS         HC: p=NS 
(unadjusted) 
30-31 GW:        BW: 
p=NS         HC: p=NS 
(unadjusted) 
Reduction in HC for 
repeated GC treated 
singletons below the 29 
gestational week  
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 Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Thorp et al, 
2001(164)  
 
2x12mg 24h 
apart 
Weekly till 
delivery or 
discharge or 
33+6 gestational 
week (range 0-
91 days) 
Case control 
ntotal=414 
St Lukes 
hospital, Kansas 
city 
1991-
1994 
All: Preeclampsia, 
multiple gestation, 
maternal smoking 
<34 GA:        GA, 
duration of painful 
labor, pre-
eclampsia 
Excluding patients 
with pre-
eclampsia: GA, 
white race, 
duration of painful 
labor, duration of 
betamethasone, 
multiple gestation, 
maternal smoking 
N/A BW:            p=<0.05 
(estimates not given) 
Duration of GC was 
associated with larger 
BW in the entire 
population, as well as 
the population where 
patients with pre-
eclampsia was excluded, 
no effect on population 
born <34GW 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Thorp et al, 
2002(163)  
2x12mg 24h 
apart 
Weekly till 
delivery or the 
33gestational 
week 
Case control   
BW: n=14,338 
HC: n=13670 
100 NICU 
across the USA 
1997-
2000 
GA, Abrubtio, 
alcohol use, 
bleeding, brethine, 
chorioamnionitis, 
diabetes, illicit 
drug use, 
indomethacin, 
magnesium use, 
male sex, multiple 
gestation, 
nifedipine use, 
non-white race, 
poor prenatal care, 
preeclampsia, 
premature rupture 
of membrane, 
premature labor, 
smoking 
BW= 1671 (574) 
HC=2.89 (0.33) 
BW=-63g± 5.7 
(95%CI -74.1,-
51.9,p<0.001)         
HC=-0.31cm±0.04 
(95%CI -0.38,-0.24, 
p<0.001)    
After adjusting for 
BW in addition to 
other variables: 
HC=-0.12cm ± 0.03 
(95%CI -0.18, -0.06, 
p<0.001) 
A reduction of 3.8% in 
mean BW as well as a 
reduction in HC  
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Haas et al, 
2004(156) 
 
12mg 12hrs 
apart 
12mg 24hrs 
apart 
1 course Case control 
ntotal=909 
Naval medical 
centre         San 
Diego 
1996-
2000 
Stratified by 
gestational age 
30-31GW:            BWc= 
1843 BW12=1531.2 
BW24=1511   
32-33 GW : BWc=2179 
BW24=1979.7  
30-31GW:        
p=0.025 (for BW12 vs. 
BW24)  
 p=0.014 ( for BW24 
vs. BWc)                         
32-33 GW:     p=0.03 
(unadjusted) 
A reduction in BW was 
seen in all three groups 
in the strata of 30-
31gestational week, and 
between those with 
course 24hrs apart and 
those not exposed in the 
32-33 gestational week 
Kumar et al, 
2005(157)  
2x12mg 24h 
apart 
Range = 2-8 
courses    Mean 
= <2 courses 
<2course: 
n=241   
2courses :     n= 
37         2.5-
3courses: n=26          
3.5-4courses: 
n=10   5courses:    
n=3               7-
8course:  n=2 
Case study 
ntotal=319  
nSD=241 
nMD=78 
N/A N/A GA, multiple 
births, 
chorioamnioitis, 
neonatal morbidity 
and postnatal 
steroid use 
BWSD =1086 (284) 
BWMD =1111 (248)  
P=0.5 (unadjusted) 
Below the 10 
percentile at 
discharge: 
BW: OR 1.83 
(95%CI 1.03,3.25; 
p=0.04) 
HC: OR,3.25 (95%CI 
1.44,7.3; p=0.015) 
No difference in BW or 
HC. Increased risk of 
having a BW and HC 
bellow the 10th 
percentile at discharge 
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Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocortic
oid) with  outcome 
(BW,HC,BL) 
Davis et al, 
2009 
2x12mg 24h 
apart 
Single dose Case study  
ntotal=105 
nexposed =30 
University of 
California 
 Matched for : GA 
and sex at birth. 
(excluded infants 
where mothers 
smoked, or 
substance abuse) 
BW exposed =2946(549) 
BW controls =3346(524) 
BW PTLcontrols=3259(359) 
 
 
 z-score:                    BW=-
0.5(1.0)   p<0.001 
HC=-0.4(1.0)         p<0.001 
BL=-0.6(1.2)            
p<0.001 
Smaller BW, HC, 
and BL,  on 
exposure to GC 
Norberg et al, 
2011 
3x8mg followed 
by 1x12g 
weekly 
Multiple does: 
2 courses=28 3 
courses=26 ≥4 
courses=40 
Case study 
ntotal=  
n2cousrse=28        
n 3courses=26 
n≥4courses=40 
 
 
Danderyd 
Hospital, 
Sweden 
1983-
1996 
Maternal age, 
height, parity, 
blood pressure 
disease, mjultiple 
pregnancy, 
smoking 
BW  2cousrse =2381   BW  
3courses =2192   BW 
≥4courses =2291 
BL  2cousrse =46.2           
BL  3courses =44.6           
BL  ≥4courses =44.9 
HC  2cousrse =32.5           
HC  3courses =31.8           
HC  ≥4courses =31.9 
BW 2cousrse=-0.21SDscore 
BW 4cousrse=-1.01SDscore 
P=0.04  
BL2cousrse=-0.19SDscore BL 
4cousrse=-1.04SDscore P=0.07 
HC2cousrse=-0.21SDscore HC 
4cousrse=-1.01SDscore P=0.04 
 
Exposure to 4 or 
more courses GC 
resulted in 
reduction in BW 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Dexamethasone         
Lam et al, 2001(158)  2x10mg  12h 
apart 
Range=4-10 
courses 
Repeated every 
7 days until 34 
weeks of 
gestation if risk 
remained high 
2 courses: n=36               
3 courses: n=15            
≥4 courses: 
n=37 
Case study 
ntotal=236  
nSD=148 
nMD=88 
A University 
teaching 
hospital 
1995-
1999 
GA N/A BW ratio of:  single 
course=1.03 
(IQR=0.93-1.12)   
2 courses=1.01 
(IQR= 0.87-1.12)                 
3 courses=0.92 
(IQR=0.87-1.08)        
>4 courses=0.96 
(IQR=0.83-1.03)  
Intergroup difference 
p=0.08 
1-3 courses=1.02 
(IQR=:0.9-1.1)  
>4courses=0.96 
(IQR=0.83-10.3), 
OR=3.02 (95%CI 
1.05-8.63)  
BW is negatively 
correlated with number 
of courses of 
corticosteroids received 
(p=0.02) 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Bloom et al, 
2001(151) 
4x 5mg every 
12 hours 
From 24-34 
gestational 
week at 7 days 
intervals 
partial course:  
n=425             1 
course: n=301           
2-4courses: 
n=235 
Case control 
ntotal=4213  
ne=961 nhc=444 
nmc=2808 
Parkland 
hospital, Texas 
1988-
1998 
GA, Maternal race, 
Gender, parity 
At 24-26 GW:      BW= -
12 
27-29 GW:           BW= -
63 
30-32 GW:           BW= -
161 
33-34GW:           BW=- 
80 
 
 P<0.001 for all 3 
comparison groups 
Reduction in BW 
between exposed and 
historical controls. Also 
between exposed and 
matched controls and 
reference obstetric 
population 
Murphy et al, 
2002(159) 
 
Prophylactic:  2 
doses 24h apart. 
Rescue: 
2x12mg 12 hr 
apart 
Every 2 weeks 
from 24-32 
week or till 
delivery 
Or 
Rescue therapy 
before delivery 
Case study 
ntotal=1038 
Prophylactic: 
n=136 
Rescue:  n=902 
St. Michael’s 
hospital Bristol 
Twins1
990-
1997 
GA, gender, parity, 
infertility, 
smoking, 
chorionicity, twin 
pairing 
N/A >37GW:          BW= -
129    (95%CI -218,-
33; p=0.008) 
Preterm:          BW= -
6.6     (95%CI -87, 
74;p=0.87) 
A reduction in BW for 
those born after the 
37gestational week. No 
reduction in BW in 
preterm’s receiving 
prophylactic treatment 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Betamethasone and dexamethasone:        
Banks et al, 
1999(150) 
2x12mg 24h 
apart  
Or 
 4x6mg 12h 
apart 
Range 1-13 courses 
(mean=1 course) 
1course:       n=410                 
2 courses:     n=158                 
3 courses:      n=77                   
4-5 courses :  n=54                  
6-7 courses:  n=10                  
8-13 courses:  n=1 
Case study 
ntotal=1010 
nSD=710 
nMD=300 
Using data from 
the Multicenter 
North American 
Thyrotropin-
Releasing 
Hormone Trial 
for prevention 
of lung disease 
in a premature 
child 
1992-
1996 
Gestational age, 
multiple gestations 
N/A 
 
≤32GW:           BW= 
-39 (P=0.016)  
 >32 GW:        BW= -
80 (p=0.09) 
Inverse dose 
relationship with BW, 
no effect on HC 
 
70 
 
Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug  (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Abbassi et al, 
2000(149) 
(dexamethasone 
(17%) and 
betamethasone 
(83%)) 
2x12mg 24h 
apart 
Or  
4x6mg 12 h 
apart 
Singletons: range 
2-12 courses  
2-4 courses: 
n=69.4%            5-
12 courses: 
n=30.6% 
 
Case study 
ntotal=713  
Singletons: 
nSD=177 
nMD=192 
Multiple births: 
nSD=163 
nMD=147 
Pennsylvania 
Hospital and 
Winthrop 
University 
Hospital 
1994-
1998 
 GA, fetal number, 
pre-eclampsia 
Singletons: BWSD=1626 
(544) BWMD=1687 (591) 
p=0.67 (unadjusted) 
HCSD=28.4(3.1)  
HCMD=28.1(3.0) 
Multiple births:   Birth 
weights and head 
circumferences were 
similar in exposed and 
unexposed groups 
 
Singletons:         HC: 
β=0.46(SE=0.19)         
p= 0.013 
Singletons 24-
42week:              HC:          
β=0.23cm (SE=0.15)     
p=0.12 
Born within a week of 
GC therapy:            
HC:                β=0.73 
(SE=0.20) p=0.0004 
No effect on BW. A 
trend in the reduction of 
HC 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Prospective:         
Betamethasone:         
French et al, 
1999(155) 
 
2x11.4 mg 
either 12hr or 
24hr apart 
0 course:  n= 311            
1course:   n= 123             
2courses:  n=20 
≥3courses:  n=23 
Case study 
ntotal=477 
Geographic 
cohort in 
western 
Australia 
1990-
1992 
GA (as a quadratic 
function), Gender, 
social class, racial 
origin, maternal 
smoking, parity of 
mother, pregnancy 
complications 
Median(IQR) 
BW0=1435( 905-1810)    
BW1=1345(1010-1735)           
BW2=1517.5(1210-
1660)              
BW≥3=1455(1080-1715)            
p=0.78(unadjusted) 
HC0=28   (25-30)          
HC1=27.5  (25-29)          
HC2=28.5  (26.2-29.5)      
HC≥3=28.1 (26-29.2)              
p=0.55(unadjusted)  
BL0=40.5 (35.5-43) 
BL1=39.5 (36-43)          
BL2=40.5 (37-42.5)         
BL≥3=40.7 (38-42.5) 
p=0.84(unadjusted)  
≥3courses 
BW:                     ß= -
122 (p=0.014), 
HC:                     ß=-
1.02 (p=0.0024)  
BL:                      ß=-
0.8 (p=0.06) 
>14 days since 1st 
course. 
BW=-150 (p=0.0008) 
An increased reduction 
in BW (9%), HC (4%) 
and BL (2%) with 
increased courses of GC 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Randomised control trial:        
Betamethasone:        
Wapner et al, 
2004(165) 
2x12mg Repeated every 7 
days till birth or 
33+6 gestational 
week. After 67 
patients, the 
number of courses 
was limited to 4 
Case control 
ntotal=591 
ne=297  nc=294 
18 centers of the 
NICHD MFMU 
Network 
N/A GA All: 
BWe=2194.3 (762) 
BWc=2289.6 (791.8) 
p=0.09(unadjusted) 
HCe=30.6 (3.1) 
HCc=30.8 (3.3) 
p=0.25(unadjusted) 
BLe=44.2 (4.6) 
BLc=44.7 (5.1) 
p=0.08(unadjusted) 
PIe=24.4 (3.6) PIc=24.5 
(3.5) p=0.88(unadjusted)  
Singletons: 
BWe=2365.1 (773.9) 
BWc=2468.6 (816.8) 
p=0.19(unadjusted) 
 
All (MOMs): 
BWe=0.88 BWc=0.91     
(p=0.01) 
BLe=0.98  BLc=0.99       
(p=0.10)  
Singletons (MOMs): 
BWe=0.91 BWc=0.95 
(p=0.003) 
BLe=0.99    BLc=1.0             
(p=0.01) 
 
A reduction in BW by 
95g (p=0.09), more 
prominent when 
exposed to 4 or more 
courses of GC 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
       HC
e=31.1 (3.1) 
HCc=31.3 (3.3) 
p=0.31(unadjusted  
BLe=45.1 (4.6) 
BLc=45.7 (5.0) 
p=0.12(unadjusted)  
PIe=24.8 (3.7) PIc=24.9 
(3.5) p=0.87(unadjusted) 
Below 10th percentile: 
All:                  BWe=59 
(23.7) BWc=37 (15.3) 
p=0.14(unadjusted)  
Singletons:         
BWe=39 (19.3) BWc=16 
(8.4) 
p=0.002(unadjusted) 
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Table 5. Studies examining the association of in utero exposure to glucocorticoids with birth weight, head circumference, birth length and 
ponderal index (cont.) 
Type of study, 
drug (author, 
year)                        
Dose of GC 
per course 
Number of 
courses  
Sample size 
(n) and 
design 
Source of 
study 
subjects 
Year 
of 
birth 
Adjustment Mean(SD) Birth 
weight(in g)/HC/ 
BL(in cm) 
Statistical 
estimates (P-
values, Odds 
ratios, Regression 
estimates, 
difference in 
means, IQR) 
Comments of 
association of 
exposure(glucocorti
coid) with  outcome 
(BW,HC,BL) 
Crowther et al, 
2006(152) 
11.4mg Weekly till 32 GW 
or birth 
ne=489  nc=493 16 hospitals in 
Australia 
7 hospitals in 
New Zealand 
1998-
2004 
GA, antepartum 
haemorrhage, 
preterm prelabour 
rupture of 
membranes 
BWe=1867  BWc=1877  
HCe=29.6      HCc=29.7 
BLe=42.1           
BLc=42.1 
Z scores: 
BWe=-0.4      BWc=-
0.27    p=0.04 
HCe=-0.3        HCc=-
0.14            p= 0.03  
BLe=-0.53           
BLc=-0.48     p=0.38 
Mean birth weight, 
length and head 
circumference did not 
differ between the 
groups, however the Z-
scores for weight and 
head circumference 
were lower in infants 
receiving GC 
Murphy et al, 
2008(160) 
2 x12mg  24 
hrs apart 
 
Repeated every 14 
days till 33 
gestational week or 
birth 
ne=935  nc=918 80 centers in 20 
countries 
2001-
2006 
GA,  center , 
multiple gestation 
BWe=2216  BWc=2330  
HCe=31.1      BLe=44.5           
BLc=45.4      HCc=31.7 
BW                          
β=-113g           
p=0.0026       
HC                             
β=-0.6           
p=<0.001 
BL                        β=-
0.9                
p=<0.001 
A reduction in birth 
weight, head 
circumference and birth 
length  
BL= birth length; BW= birth weight; GA=Gestational Age; GW= gestational week; HC= head circumference; IQR= Inter quartile range; 
MOMs= Multiples of the gestational age specific, median birth weight; PI=Ponderal index 
c
 =controls;
 e
 =exposed to GC; 
hc
=historical cohort; 
m
=multiple births;
 mc
=matched cohort; 
 MD
=multiple dose; 
s
=Singleton births; 
SD
=single dose; 
12
= 12hrs apart;
24
= 24hrs apart
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In addition there was an inconsistent use of dosage, and length of treatment which 
further complicated determination of foetal exposure. These reported differences in 
birth size may possibly be attributed to the difference in sGC type or dosage (i.e. with 
increasing exposure, greater reduction on birth size).   Wapner et al and Norberg et 
al (165;167) both reported a greater decrease in birth size with exposure to four or 
more courses of sGC, suggesting a dose related association. One of the relatively 
larger studies done by Thorp et al 2002 (163), where data were obtained from 100 
sites across the USA, both sGC dosage and duration of exposure varied broadly 
according to local practice, this complicated interpretation of results.  
In addition, not all studies were designed with the primary aim of examining the 
association of sGC with birth size. Birth weight was examined post hoc, in some 
studies where associations with other medications/hormones were the main aim of 
the studies (150;164). This creates potential confounding effects with the original 
drug/hormone. Of the eight studies (149;153;154;156;159;161;164;165) that were 
not designed to test birth weight and consequently unable to control for confounders 
relevant for birth size, half reported a reduction in birth weight. 
Due to small size it was evident that the power of the studies was not high enough to 
detect statistical significance. For example the smallest study had 152 participants 
(162).This lack of availability of sufficient sample size cohorts may be due to the fact 
that it took 20 years after Liggens first discovered the neonatal importance of sGC, 
for the use of sGC to become a standard therapy. This therefore makes the 
representativeness and consequently the generalizability of these small studies 
debatable. Two more recent randomised control trials (152;160), though having more 
power in their design, examined the effects of multiple versus single doses of sGC 
(Betamethasone) and also showed conflicting results, with Murphy et al only 
reporting a reduction in mean birth size. The largest study, by Thorp et al (2002) had 
the power needed for an association (n=14,338) to be detected, but as mentioned 
previously, was weakened by the variability of dosage and forms of sGC given 
across the different centres.  
There are also a range of important intervening factors (e.g. maternal weight, weight 
gain, smoking, illnesses) that may confound or modify the association with birth size 
of which only a few were taken into account in most of the studies (Table 6). For 
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example, major pregnancy-induced diseases, such as pre-eclampsia, were 
considered only occasionally, where as pre-eclampsia, a condition involving many 
body sysetms during pregnancy resulting in high blood pressure and protein urea, 
can lead to both spontaneous and elective pre-term birth as well as intra uterine 
growth retardation(149;163;164;167). The results therefore could not exclude 
possible associations that may be explained away or appear by confounding factors 
that were not adjusted for.   
Other confounders such as socio-economic status were also not addressed; social 
class was only controlled for in two studies; by French et al (an Australian study). 
This is of particular importance as inequalities in access to prenatal care could be a 
possible confounder of birth size, particularly in the USA where most studies were 
conducted.
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Table 6. Studies on glucorticoid treatment and birth size from 1970 to 2008 and  
confounding factors 
 Number of studies adjusting for 
the factor 
Significance of 
confounders 
Potential confounding factor   
Gender 5(151;155;159;162;163) Previous studies have shown 
male foetuses are more 
vulnerable to intrauterine 
insults (174).  
Ethnicity 4(151;155;162;163) Ethnicity or race is a 
common threat of genetic 
material and a biologically 
distinct group dispersed over 
time and geography (175). 
Multiple gestations 7(150;153;157;159;160;163;164) Preterm labour and low birth 
weights are known 
complications of multiple 
pregnancies (176). 
Maternal smoking 5(155;159;162-164) Cigarette smoking during 
pregnancy, accounts for 
birth weight reductions 
ranging between 90-150g 
(177). 
Parity of mother 3(151;155;159) Nulipara women are more 
likely to give birth to low 
birth weight infants than 
multipara women (178). 
Alcohol consumption 2(162;163) Alcohol consumption has an 
inverse relation with birth 
weight (179) 
Illicit drug use 2(162;163) A difficult confounder to 
control for, as the 
association depends on the 
drug used. A clear 
association between cocaine 
and poor foetal growth has 
been established. But the 
social, psychological factors 
are not always taken into 
account (180). 
Pregnancy complications 1(155) Complications of any kind, 
for example depression, 
have previously been 
associated with adverse 
foetal outcomes (181). 
Pre-eclampsia 3(149;163;164) A condition  involving many 
body sysetms during 
pregnancy resulting in high 
blood pressure and protein 
urea, can lead to both 
spontaneous and elective 
pre-term birth as well as 
intra uterine growth 
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 Number of studies adjusting for 
the factor 
Significance of 
confounders 
Potential confounding factor   
retardation 
(149;163;164;167). 
Placenta abruption 1(163) Separation of the placental 
lining from the uterus, 
known to result in birth 
weight discrepancy, as 
shown in twin study (182). 
Bleeding 2(152;163) Sufficient blood volume and 
iron stores are required for 
foetal growth. Depletion 
resulting in smaller birth 
size of offspring (183). 
Poor prenatal care 1(163) Prenatal care has been used 
as a means to identify 
mothers at risk of delivering 
preterm, or growth-retarded 
infants, and to provide 
medical, nutritional and 
educational interventions 
with intent to reduce the risk 
of low birth weight babies. 
Social class 1(155) Social stress characterized 
by low social class, social 
adversity, or social disparity, 
have been linked to small 
birth size (112;114;184-
186). 
Diabetes 1(163) Condition of high blood 
glucose, which can occur 
during pregnancy, results in 
babies born larger for 
gestational age. 
Neonatal morbidity 1(157) Other conditions, inborn 
errors, that could result in 
the infant being born small 
for gestational age. 
Premature rupture of membranes 2(152;163) Can be an indication of 
underlying infection, 
inflammation, vascular 
disease and often results in 
preterm birth (187). 
Chorioamnionitis 2(157;163) Infection of the foetal 
membranes, usually due to 
bacterial infection. 
Premature labor 1(163) Previous studies suggest that 
birth size is affected already 
in infants born preterm 
(188). 
Chorionicity 1(159) Whether one or two 
placentas in twin pregnancy, 
and can result in discordant 
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 Number of studies adjusting for 
the factor 
Significance of 
confounders 
Potential confounding factor   
growth (189). 
Medications as confounding 
factors 
  
Brethine  1(163) Terbutaline used to treat 
wheeze, as well as to slow 
preterm labour. 
Indomethacin  1(163) Non-steroidal anti-
inflammatory drug used for 
short term treatment of 
preterm labour. 
Magnesium  1(163) Used to slow uterine 
contractions in preterm 
labour, as well as in cases of 
pre-eclampsia. 
Nifedipine 1(163) A calcium channel blocker 
and smooth muscle relaxant, 
used sometimes in preterm 
labour. 
   
 
Preterm labour and low birth weights are also known complications of multiple 
pregnancies (176). Only half of the reviewed papers took multiple pregnancies into 
consideration; two studies, (153;162) excluded twins and only one reported an 
association with smaller birth size (153). One study (159) was conducted only on 
twins and found no reduction in birth size. Six out of ten studies 
(150;159;160;163;163;165;167) adjusted for multiple births and reported an 
association with lower birth weight in singletons, with Thorp et al (2002) being one of 
these studies. Five of the six studies that did not control for multiple pregnancies 
(151;155;156;158;165) reported a reduction in birth weight. Thus, the extent to which 
multiple gestation acts as a confounder or a moderator in the association between 
sGC and reduced birth size remains unresolved.   
Not all studies included individuals that delivered at term. Eight studies, 
(150;151;153-157;163) examined neonates born before the 34th GW; by restricting 
the population to preterm infants (<34GW), information is lost on infants born at term 
and potential long term effect of sGC. Infants born within 24 hours after sGC 
exposure will have the shortest time lag between exposure and birth. Presumably a 
relatively short time lag between exposure and birth makes potential growth 
restriction undetectable. In contrast, infants born at term, with longer time lag 
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between exposure and birth, consequently have more opportunity to grow and a 
potential reduction in birth size may be detectable. In addition, studying infants born 
after the 34th GW or even at term, who are more likely to have been exposed to 
repeated courses of sGC, makes it possible to study a dose-response relation. 
Previous studies have also suggest that birth size is affected already in infants who 
are born preterm which may mask the effects of sGC (188). Therefore, by examining 
pre-term infants only, associations resulting from intrauterine complications leading 
to preterm birth cannot be easily excluded.  
We see that combining and interpreting results of previous studies examining the 
association between prenatal sGC exposure and birth size is riddled with 
complications, making a firm conclusion difficult. Nonetheless, can we conclude 
whether the reductions of birth weight and head circumference that have been 
reported in the studies, are of clinical significance? The average foetal growth in 
normal gestation is 200g/week during the 32-38 GW (190), however, calculations of 
gestational age are also likely to have an error of one week. Therefore, this would 
suggest that a small reduction in birth weight of 63g, as reported in the largest study 
(163) is clinically meaningful.  Cigarette smoking during pregnancy, which is well 
known for its negative association with birth size, accounts for birth weight reductions 
ranging between 90-150g (177). This difference in birth weight is comparable to the 
reduction of 122g on sGC exposure reported by French and colleagues (155) and 
113g reduction in the MACS randomised control trial (160). In studies on smoking, 
these small differences in size have reported to associate with significant increase in 
infant morbidity and mortality, adding further clinical significance to these results 
(177).  
Head circumference provides an indirect measurement of brain growth, with a 
reduction of 1cm equivalent to 11% reduction in brain volume (190-192). Subnormal 
head circumference has been associated with poor developmental and cognitive 
outcomes (193).The studies that examined head circumference reported reductions 
of 0.023 to 1.02cm (cf. normal growth being 13mm/week during the 32-38GW), again 
indicating the clinical importance of these results. 
Ponderal index (an indicator of symmetrical growth) was examined in only one small 
study (165) and was not associated with sGC treatment. 
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Overall, the papers were generally of low quality, with just over half of the studies 
reporting statistically significant reductions in birth weight, seven out of eleven 
reported reductions in head circumference, and four out of six a reduction in birth 
length. In summary, methodological limitations in the studies hindered a firm 
conclusion; however, the more methodologically sound papers suggest that 
exposure to sGC in utero contributes to a reduction in birth size. It is therefore 
evident that more research is needed to address the immediate risks associated with 
prenatal sGC exposure as well as their long-term consequences. 
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3.2 Social stress during pregnancy and the interplay of genetic variance near LEKR 
and CCNL1 on the association with size at birth 
 
Both environment and genetics have been associated with birth size; however, 
studies examining the interaction with regard to birth size are rare.  
 
Various environmental factors including social stress characterized by low social 
class, social adversity, or social disparity, have been linked to small birth size, 
though results are inconsistent (112;114;184-186). This inconsistency again may be 
due to methodological differences across studies concerning measurement of social 
factors, insufficient statistical power, and lack of uniform covariates 
(112;114;184;185). Previous studies have often used income and occupation to 
describe the level of social class; these factors are however difficult to assess in all 
populations, as they are often confounded by access to care in many countries. In 
addition, by using income and occupation, trade in non-monitory income such as 
crops for labour in rural areas are not being assessed (194); this therefore may 
grade individuals as being  worse off than they actually are. Also, maternal 
occupation may change during pregnancy and therefore not reflect the true social 
gradient at which the individual lies. In addition, maternal occupation alone may in 
itself also not reflect the social level of the household in which the mother is not the 
main earner.  
A composite of social adversity would be a better indicator of the individual’s level of 
social stress. Social adversity has been previously operationalised, i.e. defined, as 
the presence of at least one known environmental factor associated with stress at 
the individual level (195-198). These factors in an expectant mother could be; young 
maternal age, an indicator of poor social conditions and behavioural risk factors 
(199); low education, an index of social class (110); and single parenthood, 
associated with low household income and lack of social support (200). All three of 
these indicators of social adversity have each been previously associated with low 
birth weight (199-212) and poor developmental outcomes (198). However, no studies 
have used operationalised social adversity as an indicator of social stress, at an 
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individual level, to study the association with birth size. Social adversity would also 
be easier to evaluate and compare across populations than social economic status 
defined by occupation and income. 
An individual’s response to environmental stimuli changes as they grow, with varying 
consequences and impact; all of which depends on the age, or phase of 
development. As discussed in previous sections, the HPA axis plays a vital role in 
the body’s response to environmental stimuli. The CRH as well as adrenal GC 
hormones assist in the adaptation of the body to the ever-changing environment, 
whether it is through behavioural or metabolic needs.  Glucocorticoid and 
mineralocorticoid receptors are found in neural structures such as the hippocampus, 
prefrontal cortex and amygdala. With their actions of gene expression, the GC’s play 
an important role in reprogramming neural responses, which can result in beneficial 
or detrimental effects. Programming of the brain, and behaviour during the early 
periods of life, therefore influence the body’s ability to respond to environmental 
stimuli later in life.  Using ultrasound between the 27-28 GWs, an association 
between maternal mood and foetal behaviour has been well established (122). 
However, studies have yet to show an increase in foetal cortisol levels due to 
maternal stress. (213). Nonetheless, excess maternal cortisol production is 
postulated as the mechanism underlying the association of maternal stress and 
smaller birth weight (214-217).   
Previous studies examining social stress and birth weight, have often also neglected 
other measures of birth size, i.e. birth length, head circumference and ponderal 
index.  All three are, in addition to birth weight, known important indicators of poor 
development and cognitive outcomes in the infant (218;219), (220-222).  
Both environment and genetic factors play an important role in the DOHaD concept. 
It is therefore important to examine whether genetic variance adds to the association 
between social stress and birth size, something that has previously not been 
examined. Better understanding of the interplay between genetics and environmental 
factors would also strengthen our ability to predict outcomes. A recent large genome 
wide association study (GWAS) identified variants near LEKR and CCNL1 and in the 
ADCY5  associating with birth weight (57). It would therefore help our understanding 
of DOHaD, to examine whether controlling for the low birth weight gene would 
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eliminate, reduce, or even add to the association between social adversity and birth 
size. 
It is not only social stress at an individual level, as defined by social adversity, that is 
important when investigating DOHaD, but also neighbourhood social stress. Poor 
neighbourhood environment has been shown to be associated with lower birth 
weight and also influences morbidity and mortality (223-225). Neighbourhood social 
disparity, i.e. living in areas where neighbourhood financial capacity differs from 
individual SES is also associated with higher all-cause mortality (186). This disparity 
may be explained partly through differences in access to care and amenities 
between neighbourhoods as well as the social stress brought about by 
neighbourhood social disparity. However, the interplay of genetic determinants with 
regard to neighbourhood social disparity and birth size is unknown as it has 
previously not been examined. Previous studies, examining the association between 
neighbourhood social disparity and birth size, have not been able to consider 
important covariates such as smoking, maternal pre-pregnancy BMI, and race, thus 
potentially biasing results (223-225). This underscores the need for further studies to 
extrapolate the true impact of neighbourhood social disparity on birth size.  
 
3.3 Social Stress during pregnancy and the association with metabolic outcomes in 
adolescence  
 
An individual’s response to environmental stimuli changes as he/she grows, with 
varying consequences and impact; all of which depend on the age, or phase of 
development. Exposure to economic disadvantages in childhood and midlife, is 
known to influence the overall mortality later in life, specifically in relation to CVD 
(226). The key issue is to understand how social adversity translates to CVD on a 
molecular level, and how does it do so across several decades of life? CVD disease 
is a leading cause of mortality worldwide (227-229), but still the contribution of very 
early life events, especially prenatal, in disease development, is largely lacking.  
 
There are multiple cross-sectional studies especially in adulthood showing the 
associations between social status and disease risk but longitudinal studies are 
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much fewer with relatively short follow-ups (230).  Evidence suggests that 
atherosclerosis begins in childhood with lipid accumulation in artery intima, forming 
fatty streaks. Some level of aorta fatty streaks have been reported in children as 
early as in the third year of life, with increase after 8 years of age and present as 
atherosclerotic plaques in coronary arteries during adolescence (231-233). This 
shows the importance of identifying possible risk factors that may influence 
atherosclerotic development from early life. Parental social adversity has been 
associated with not only higher levels of hostility, anxiety, and depression in their 
offspring, but also poor physical health outcomes in adulthood including ischemic 
heart disease, cancer, chronic lung disease, skeletal fractures, and liver disease 
(234).  Negative experiences have been suggested as a predictor of diverse 
physiological changes in childhood (235), for example, increased neurobiological 
systems activation related to stress, which include HPA axis, the sympathetic 
nervous system, and others (236). Animal studies examining time of exposure to 
stress, suggest the existence of sensitive periods in which the offspring were more 
vulnerable. Rodents exposed to stress in the first 8 days of life (quality of maternal 
care was varied) resulted in offspring with subsequent long-term alterations in HPA 
response to stress (237). Persistence of the altered HPA axis is a result of down 
regulation of GR expression in the hippocampus, a region of the brain which is 
implicated in GC negative feedback regulation.  This difference in GR expression 
attenuates with time so that when exposure to stress occurs in the second week of 
life results in mild alteration, and no effect is detected when exposure occurs in third 
week of life. This suggests a specific window of vulnerability in the development of 
the offspring (238). Similar rodent studies have reported an association between 
stress and an overly aggressive inflammatory response in the offspring (239). This 
suggests that exposure to maternal stress, in the animal model, is associated with 
changes in the HPA response of the offspring. However, how this explains the 
association between stress and CVD in humans is still unclear. Some research 
suggests that, the direct neuroendocrine effects and indirect effects are mediated by 
adverse health behaviours (240;241). Altered HPA axis function are reported in 
several chronic inflammatory disorders, which suggests a possible mechanisms by 
which psychosocial stress influence risk of CVD (242). Dyslipidaemia is considered 
the link between social adversity and development of CVD disease, where social 
adversity both during childhood and adulthood are associated with poorer adult lipid 
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profiles (243;244). Though adversity in childhood and the later life disease outcome 
has been examined, the work is limited and there is very little research about how 
maternal psychosocial adversity during pregnancy may impact on the risk of 
developing disease later in life. This is important, particularly since it has been 
suggested there are different windows in growth which affect the development of the 
offspring more than others (238). To the best of my knowledge there is no published 
literature examining the association between prenatal exposure to maternal social 
adversity and indices of metabolic syndrome in adolescents.  
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Figure 8. Adverse in utero environment associates with small birth size, linked 
through metabolic syndrome to CVD later in life.  
 
 
 
In DOHaD, the early foetal programming concept is highlighted as an important 
factor in disease development through the life course. Early disadvantage leads to 
later disadvantage and to increasingly compromised ability to respond to new insults 
(Figure 8). Therefore, identification of individuals at risk of developing CVD disease, 
but currently asymptomatic is an important concern for primary prevention.  
 
3.4 Overall summary of the literature review  
 
This section summarises the literature on the studies conducted as part of this 
thesis.  
Dating back to ancient Greece, the foetal period has been considered important in 
context of adult health. This idea was revisited in the 20th century, eventually put 
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forward and popularised by Professor Barker’s group, who launched and further 
advanced the foetal origins of disease hypothesis.  Barker et al’s initial study from 
1989 linking smaller birth size to development of CVD later was replicated in many 
future studies. The importance of the foetal period now being recognised by the 
science community, resulted in the formation in 2004 of DOHaD, where the aims are 
to broaden the scope of the original foetal development hypothesis, spanning from 
pre-conception to infancy and beyond. There have been many pathways postulated 
through which foetal programming may occur, including the HPA axis. The HPA axis 
is vital in maintaining the homeostasis through negative feedback, with GC as the 
main effector hormone. Changes in the HPA axis response resulting in excess GC 
secretion have been linked to reduced foetal growth and development of 
hypertension later in life in animal studies. Human studies to examine the 
association of GC exposure in controlled circumstances during pregnancy on birth 
size and later development would be difficult to conduct on ethical grounds. 
However, in humans, sGC’s are used to stimulate foetal lung maturation in 
threatened preterm birth, giving rise to an ethical way of examining the association 
between GC and birth size. Due to the fact that the usefulness of sGC’s in 
threatened preterm birth cannot be denied, the possible less evident risks associated 
with foetal exposure to sGC, has received very little attention. A systematic literature 
review was conducted as a part of this thesis for the purpose of exploring whether 
sGC’s were associated with reduced size at birth (study I). Due to the difference in 
methods, no meta-analysis was possible. However, although the association results 
varied, it was evident that the larger studies and those with better quality reported an 
association of sGC with smaller birth size. Thus, giving a clue of the link between the 
HPA axis during pregnancy and foetal programming. However, none of the studies 
could be used as a gold standard, leaving doubt and indicating the need for further 
studies. In this thesis, the largest prospective cohort to date examining the 
association of sGC on birth size was used (study IIb).   
In times of stress, the HPA axis maintains homeostasis through the release of 
cortisol. Psychosocial stress during pregnancy has been linked to increased risk of 
morbidity and mortality in the offspring. However, studies examining psychosocial 
stress do not use a single definition that is comparable across different populations. 
In this thesis, psychosocial stress was operationalized as social adversity, defined as 
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having at least one indicator of poor environment during pregnancy, such as young 
maternal age, low education and single marital status; all individually been linked 
with small birth size; and used to examine the association of psychosocial stress at 
an individual level on birth size. In addition, the importance of neighbourhood social 
disparity has as yet received little attention, though it has been shown to increase the 
risk of morbidity and mortality. This thesis will therefore also examine the association 
of neighbourhood social disparity on birth size. Foetal programming is not a 
straightforward association but considered to be multifactorial. Genetic variance is 
also thought to play a significant role in foetal programming. The interplay between 
psychosocial stress and genetics on the outcome on birth size has to date not been 
examined. This thesis will examine; the interplay of genetic variance when examining 
the association of social stress and birth size (study III). Psychosocial stress, both in 
childhood and during adulthood has also been linked with increased risk of CVD later 
in life, however, little has been done to examine the association of psychosocial 
stress and CVD. The risk of developing CVD later in life can be predicted during 
adolescence by the presence of metabolic syndrome and dyslipidaemia. In this 
thesis we examine the association between psychosocial stress during the foetal 
period and metabolic syndrome and dyslipidaemia in adolescent (study IV).  
Priority of research, time constraints and data availability have given some 
restrictions to the scope of this thesis and the generalizability of the results. Firstly 
data on sGC in the NFBC1986 were limited, even after a new detailed and 
meticulous search into the original medical files; restricting simple analysis to case-
control analyses with t-test. Secondly, genetic data was only available for half the 
cohort, restricting the generalizability of the results. 
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4 Materials 
 
In this chapter, the study population and data used for each of the original studies is 
presented.   
 
4.1 Background of the study populations 
 
Studies IIa, III-IV were all based on the Northern Finland Birth Cohort 1986 
(NFBC1986) and study IIb was based on the 
Finnish Medical Birth Registry 2006-2010 (MBR 
2006-2010). Figure 9 shows a map of Finland 
and catchement area of the NFBC studies (blue). 
Study I consisted of a systematic literature review 
of sGC treatment due to threatened preterm birth 
during pregnancy, size at birth and did not use 
any new data.  Launched formally in 1944, 
Finland’s national antenatal maternal health care 
and surveillance system is exemplary. It is made 
up of a network of municipal maternity health 
centres (MHC) where access is available to all 
pregnant women with about 100% attendance. 
According to the national guidelines, expectant mothers are required to visit a MHC 
on a monthly basis from time of conception to the 28th week of pregnancy, after 
which frequency of visit increases to twice monthly. After the 36th week, weekly visits 
are expected (245). With these regular evaluations, standardized forms and careful 
record keeping, there is a reduced risk of recall bias in this population, as register-
based population are being used (i.e. for example in NFBC1986 both personally 
collected and register based data can be used for cheking and retrieving additional 
information). The data in MBR is also based on the information from individual 
maternity cards which include data on each visit to the local maternity centre,  from 
mothers, hospital records and attending midwives and clinicians. In addition, Finland, 
with its extensively available healthcare data, relatively genetically homogenous 
Figure 9. Map of Oulu and 
Lapland regions (blue) of 
Northern Finland 
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population, and having one of the lowest levels of income inequality in the developed 
world, is an ideal study base for genetic and epidemiological studies. Anthropometric 
measures are recorded immediately after birth, according to the uniform procedures 
in the entire country, with birth weight in grams, birth length and head circumference 
in centimetres. Ponderal index is calculated using the standard formula [birth weight 
(kg) / birth length (m3)]. The established antenatal health care system made it 
possible to launch the Northern Finland Birth Cohort programme in mid 1960s, when 
the first one-year mother-child birth cohort, NFBC1966, was established. This was 
followed, twenty years later by NFBC1986, which is used in the present study 
(Figure 10).   
 
 
 
4.2 Data collection in the Finnish Birth Registry 2006-2010 
 
Data was extracted from the Finnish Medical Birth Register (MBR), dated 1st January 
2006 to 31st December 2010. The MBR contains data on all women regardless of 
citizenship who gave birth in Finland and comprised of 289,013 mothers and 
singleton neonates, (still births, twins, and those born <24th GW were excluded from 
the present study). The MBR records data on all new-borns weighing a minimum of 
500g or of >22 GW, and up to age seven days (246). Forms detailing birth data are 
completed and returned to the National Institute of Health and Welfare within 7 days 
after birth. Information includes sGC given during pregnancy to stimulate foetal lung 
maturation. This information as “Yes” or “No” response was provided for all infants, 
but an additional form was filled out for preterm birth only with detailed information 
on sGC type, and number of doses. Though introduced in Finland over 20 years ago, 
national standard recommended dose for sGC therapy was first prescribed in 2011, 
prior to which doses followed international trends and no single defined dose of sGC 
for all births was available in the MBR.  
12gw              birth                 7-8 years               15-16 years 
Figure 10. The NorthernFinland Birth Cohort 1986: main follow-up ages 
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This study was approved by the ethics committee of the University of Oulu in 
accordance with the Declaration of Helsinki, and approved by the Committee 
governing register data use at National Institute of Health and Welfare.  
 
4.3 Data collection in the NFBC1986 cohort 
 
4.3.1 Data on phenotype 
 
The North Finland Birth Cohort study, 1986, (NFBC1986) was originally set up to 
enable the study of the epidemiology of disease, risk factors for pregnancy outcomes 
(perinatal deaths, preterm births and low birth weight children) and school 
achievements later in life. All expectant mothers of the Northern provinces of Oulu 
and Lapland, whose expected date of delivery was between the 1st July 1985 and 
the 30th June 1986, were eligible for the study. The provinces of Lapland and Oulu 
(Figure 9), with 74 localities, are made up of quite a homogenous population of 
630,000 people, with only a very small ethnic minority (Sami population) of circa 
1700 individuals, which is defined by language.  
The expected date of delivery had been calculated using the first day of the last 
menstrual period, which was the established method in use at that time. However, 
84% of the mothers had ultrasound to confirm gestational age. In total there were 
9362 women, which made up 99% of eligible mothers, and 9203 live-born singletons 
in the target area (60;247;248).  
Recruitment and data collection began in the 12th week of pregnancy, when the 
mothers visited for the first time their municipal maternity health centre, and 
continued after birth with further data collections at age 7 (questionnaire to the 
parents), 8 (questionnaire to the teachers) and 16 years (questionnaires to the 
adolescents, parents and clinical examination of the youngsters). Data concerning 
maternal health and social-demographics were collected via medical records, 
examinations/interviews by midwives, and from a self-report questionnaire 
administered to pregnant women at the first visit to maternity health centres at 
approximately 12th GW and returned by 24th GW, if still pregnant (60). The three 
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questionnaires used to collect data were, “questionnaire I for pregnancy”, 
“questionnaire II for pregnancy” and “the follow-up of pregnancy and delivery”. Data 
on birth weight, head circumference, length, gestational week, glycosuria and blood 
pressure during pregnancy, were retrieved from maternity cards (midwives 
transferred the data on study-specific forms), and from questionnaires on the follow-
up of pregnancy and delivery. Questionnaire I and II were used to collect data on 
smoking habits, SES, parity, use of medications during pregnancy and complications 
of pregnancy.  
During the last clinical data collection sweep, the team collected blood samples, 
which were analysed for a wide variety of metabolites representing lipid, glucose, 
kidney and liver function (about 30 serum metabolites by now) (248;249). Information 
on maternal social adversity was available for 9106 mothers and genotypes for 5369 
children (57). 
This study was approved by the ethics committee of the University of Oulu, and the 
Ethics committee of the Northern Ostrobotnia Hospital District, in accordance with 
the Declaration of Helsinki. The study participants and their parents provided the 
written informed consent during the 16 year data collection.  
 
4.3.2 Laboratory analyses, genotyping and genetic risk scores 
 
The blood samples were drawn after overnight fasting (8.00–11.00 am). Samples for 
serum insulin were stored at 20C until analyzed by radioimmunoassay with 
commercial reagents (Pharmacia Diagnostics, Uppsala, Sweden)  within 7 days.  
The other samples were analyzed within 24 hours of sampling in the Oulu University 
Hospital laboratory by using ongoing internal/external quality control. Plasma 
glucose, high density lipoproteincholesterol, low density lipoprotein cholesterol, and 
triglycerides were analyzed by a Cobas Integra 700 automatic analyzer (Roche 
Diagnostics, Basel, Switzerland).  A recently presented  computational approach  
(287)  based on neural network regression models, was applied to estimate VLDL, 
IDL, and apoliporpotein  A-1 (I use here term apolipoprotein A) and apolipoprotein B. 
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Genetic data was extracted from blood samples taken at age 16 years old. The DNA 
extractions, sample quality controls, biobank up-keeping and aliquotting were 
performed at the National Public Health Institute, Biomedicum Helsinki, Finland. The 
rs900400 and rs9883204 single nucleotide polymorphisms (SNPs) near LEKR and 
CCNL1 and in the ADCY5 genes were genotyped (n=5369) by Taqman allelic 
discrimination in Lille, France. No deviation (p≥0.05) from Hardy-Weinberg 
equilibrium was observed (57). Success rate in genotyping was 0.96 for both SNPs. 
For the analyses, genetic variants were categorized into two classes: 0 or at least 1 
risk allele.  
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5 Methods 
 
This section details the methods of extracting, cleaning, and coding the data, as well 
as statistical analysis, including descriptive, linear, and logistic regression analyses 
for studies II-IV. The detailed methods for the systematic literature review on the 
association of sGC on birth size (study I) have already been described in section 3.1, 
under the systematic literature review. 
5.1 Covariates selection and analysis 
 
Variables that could possibly 
predict the outcome variable 
being examined are defined 
as covariates. They can 
either be confounding or 
interact directly with the 
outcome. In the regression 
analyses, variables are 
defined as exposure 
variables, covariates or 
confounders, or outcome 
variables (Figure 11). 
Potential covariates were selected a priori based on previous studies and included 
gestational age, sex, parity, maternal pre-pregnancy BMI, maternal smoking, 
maternal social adversity, gestational diabetes and hypertensive disorder during 
pregnancy.  However, the final selection took also into account the results from 
statistical association analyses (Chi square tests or logistic regression analyses for 
categorical phenotypes;  t-test or linear regression analyses for continuous 
phenotypes).  I  tested also  for collinearity to ensure that there no issues that could 
bias the results (Appendix 1). Gestational age is the single most important 
confounder when examining associations with birth size and social adversity, with 
birth weight increasing with gestational age, and mothers of lower social adversity 
more likely to deliver prematurely. Sex of the infant is also indicated as an important 
Figure 11.  Relations between predictors, 
confounders and outcomes 
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biological indicator of birth size, with differences between male and female offspring 
weight at birth (179). Smoking and alcohol consumption have long been established 
as having an inverse relation with birth weight (179) as well as known to be 
associated with social adversity.  
The methods of defining the selected covariates in the two cohorts are described in 
the following two sections.  
 
5.1.1 MBR (study IIb)  
 
Information on gestational diabetes and hypertensive disorders during pregnancy in 
the MBR was limited to categorized variables for pathological glucose test and 
hospitalization due to hypertension. Maternal pre-pregnancy BMI was calculated 
using the standard formula [kg/m2]. Information on smoking (non-smoker=0; 
smoker=1), alcohol consumption (no alcohol consumed=0; alcohol consumed=1) 
and parity were taken from the self-report questionnaires during pregnancy. 
Operationalised social adversity, as previously discussed, is defined as the presence 
of at least one known environmental factor associated with stress at the individual 
level (195-198). These include; young maternal age (<20 years), an indicator of poor 
social conditions and behavioural risk factors (199); low socio-economic status which 
was defined by occupation (manual labour, student, pensioned or unemployed), as 
education level was unavailable for the majority of mothers; and single parenthood 
(single, divorced or widowed); associated with low household income and lack of 
social support (200). All these three indicators of social adversity have each been 
previously associated with low birth weight (199-212) and poor developmental 
outcomes (198;250). Additional data on pregnancy hypertensive disorder and birth 
malformation were extracted from the available ICD10 codes. 
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5.1.2 NFBC1986 (study IIa, III-IV) 
 
In the NFBC1986 cohort, gestational age was calculated from the date of the last 
menstrual period (in 16%) or ultrasound examination (in 84% of the pregnant 
women). Maternal pre-pregnancy BMI was calculated using standard formula 
[kg/m2]. Information on smoking (non-smoker=0; smoker=1), alcohol consumption 
(no alcohol consumed=0; alcohol consumed=1) and parity were taken from the self-
reported questionnaires during pregnancy.  
Blood pressure (BP) during pregnancy was classified as gestational hypertension 
(BP≥140 systolic and/or 90 diastolic in the absence of proteinuria after the 20th GW), 
pre-eclampsia (BP≥140 systolic and/or 90 diastolic with proteinuria after the 20th 
GW), chronic hypertension (on anti-hypertensive medication due to pre-existing 
hypertensive disorder or blood pressure of ≥140/90 before the 20th GW), 
superimposed pre-eclampsia (chronic hypertension with proteinuria; BP≥140, 
diastolic <90 with proteinuria, or diastolic ≥90 and systolic<140 with proteinuria), 
proteinuria and normotensive. Proteinuria was tested using a urinary dip-stick test 
(≥0.3g/L). Oral glucose tolerance test (OGTT) was used as a method of screening 
mothers for gestational diabetes mellitus according to national guidelines, between 
the 26th and 28th GWs. Screening was indicated in the case of glycosuria, prior 
gestational diabetes mellitus, suspected foetal macrosomia, previous macrosomic 
infant (birth weight >4500g), maternal pre-pregnancy body mass index greater than 
25kg/m2 and age greater than 40 years. OGTT was performed using oral glucose 
load of 75g after overnight fasting; upper ranges were 5.5, 11.0, and 8.0 mmol/L at 
fasting, 1 hour, and 2 hours post glucose load. A single abnormal value in the OGTT 
was considered pathological and a diagnosis of gestational diabetes mellitus made 
(251).  
As in the MBR dataset, the operationalised variable for social adversity was used as 
an environmental factor associated with stress at the individual level(195-198). 
These include; young maternal age (<20 years); low education (<11years), an index 
of social class (110); and single parenthood (single, divorced or widowed). Metabolic 
syndrome was defined according to the International Diabetes Federation (IDF) 
criteria, i.e. having at least three of the following conditions; obesity (Waist 
circumference ≥87.4cm in boys and ≥80cm in girls), elevated blood pressure 
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(≥130mmHg systolic or ≥85mmHg diastolic), elevated serum triglycerides (≥ 
1.7mmol/l), low serum high-density lipoprotein (<1.03mmol/l), and impaired glucose 
tolerance or insulin resistance (glucose ≥5.6mmol/L) (252) (47). 
 
5.2 Exposure 
 
This section describes how the different exposure variables, not already in the 
covariate sections, where defined.  
 
5.2.1 Synthetic glucocorticoids (study II) 
 
Prior to commencing this thesis, a pilot study was done as part of my MSc thesis, to 
create a shortlist of variables to indicate whether mothers were likely to have 
received sGC for threatened preterm birth in the NFBC1986 cohort. This was done, 
as the initial descriptive analysis showed only 8 women exposed to sGC for 
threatened preterm birth in the NFBC1986, which was not reflective of the  
information on use of sGC at the time. This is likely due to the fact that the 
questionnaire filled out did not specifically ask for information on sGC. The variables 
used to do a new data sweep were re-checked by Professor Anna-Liisa Hartikainen, 
an obstetrician and gynaecologist who was well versed with the clinical practices at 
the time. A pilot study was first run to collect data from one of the main district 
hospitals, where hospital records were reviewed for those mothers who fit our 
criterion, i.e. likelihood to have required sGC for threatened pre-term birth. After 
success of the pilot, a full-scale data collection took place in all local hospital from 
records of all mothers from the NFBC1986 cohort who fit the criterion for possibly 
requiring sGC for threatened preterm birth. After final sweep, 58 mothers were found 
to have received sGC for threatened preterm birth in the NFBC1986 cohort. In both 
datasets, MBR and NFBC1986, the infants exposed prenatally to sGC were coded 
as 1 and those not exposed as 0.   
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5.2.2 Social stress (study III-IV) 
 
As previously described, social stress was operationalised as young maternal age 
(<20 years), low education (<11years), and single parenthood (single, divorced or 
widowed). Social stress at the individual level consisted of the sum of these three 
stressors, thus scores ranged between 0 and 3. Young maternal age was defined as 
being <20 years at time of delivery and coded as 1, otherwise as 0 (199). Low 
education was coded as 1 when maternal education was <11 years or 0 if higher 
(110). Unmarried maternal marital status was coded as 1 if single, divorced or 
widowed and 0 if married or cohabiting with the expectant father (200). 
Social stress at the neighbourhood level, i.e. neighbourhood social disparity, was 
defined as a discrepancy between the family SES and the neighbourhood financial 
estimate. A disparity score was created by comparing family SES (highest maternal 
or paternal occupation) with neighbourhood financial estimate. Maternal and paternal 
occupation were categorized as 1=professional, 2=upper white collar, 3=lower white 
collar, 4=unskilled worker, 5=farmer/farmer’s wife owning >8 hectares of land, 
6=farmer/farmer’s wife owning <8 hectares of land. 
Neighbourhood financial estimate was based on financial capacity category (FCC) of 
the neighbourhood for the 1982-92 classification by the National Finnish KOUTA 
database and rated from one (deprived) to six (affluent) (60;253).  FCC takes into 
account factors such as density and age distribution in the population, income, 
expenditure on social and health care, education, net total expenditure, capital 
liabilities and industry (253). Neighbourhood social disparity was coded as 1 when 
participants lived in a deprived environment with a low FCC score relative to their 
own SES. Disparity was coded as 0 when participants lived in an environment 
matching with their individual SES (i.e. the neighbourhood had a high FCC score and 
individual had high SES or reversed, low FCC and low SES). 
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5.3 Descriptive analysis (studies II-IV) 
 
For each study II-IV, a descriptive analysis of the data was done to search for 
discrepancies and possible errors in the data. Frequencies and percentages were 
calculated for maternal and infant demographic and anthropometric measures, and 
compared. SAS procedure in version 9.2 (SAS Institute Inc. 2010) was used to 
perform the analysis. Continuous variables were examined using graphical tools for 
distributions of normality and linearity; in SAS the procedure was used to display 
both graphical and theoretical distributions of the continuous variable in question. 
Where data were not normally distributed, as for the metabolic outcomes, they were 
log transformed, as in the case of IDL, VDL, Apo lipoprotein A, Apo lipoprotein B, 
and triglycerides. Multi-collinearity of the different variables were examined using the 
Pearson correlation for continuous and Spearman correlations for categorical data.   
The Chi Square test statistic was used to test for the unadjusted associations 
between exposure (sGC, social adversity, neighbourhood social disparity) and 
categorized birth outcomes and maternal factors.  
After initial analysis of data there was insufficient information available in the 
NFBC1986 with regards to the sGC, with only 58 mothers having received sGC for 
threatened preterm birth, the MBR was therefore used as the main study for this 
analysis. There were two distinct data sets used for the purpose of this thesis, 
NFBC1986 for studies IIa, III-IV  and MBR for study IIb. The following two sections 
describe how the different variables for analyses were extracted and assessed. First, 
I started with literature on the variables and associations, and then secondly carried 
on with statistical analyses of the nature of the relationship between exposure, 
outcome  and potential confounding variables (i.e. if the variable  may confound the 
association between the exposure of interest and outcome).  The final selection of 
confounding variables (or otherwise contributing factors) was based on the existing 
literature, our experiences and the results from statistical analyses. I used 
multivariable regression to analyse independent associations between the exposure 
and the outcome taking into account potential confounding variables.  All analyses 
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excluded both diabetics and participants where non-fasting glucose data were 
unavailable. 
 
5.4 Paired t-test  
 
Due to small sample size in prenatal exposure to sGC (n=58) in NFBC1986, each 
exposed participant’s medical record was examined manually (Appendix 2). 
Following this procedure a matched analysis was conducted comparing infants 
exposed, to those not exposed to sGC, matched for sex, gestational age, and 
maternal smoking using a paired t-test (proc ttest). For each exposed child all 
possible unexposed children from the NFBC1986 data were used as a reference 
population (matched individually). This was done to extrapolate the difference in birth 
size, between infants exposed versus unexposed, to sGC during pregnancy in the 
NFBC1986 cohort.  
 
5.5 Multivariable linear and logistic regression analyses (studies II-IV) 
 
Multivariable linear regression analyses were run to examine: 1) the association of 
sGC on birth size in the MBR, 2) the interplay of genetics and social adversity on 
birth size in the NFBC1986, and 3) the association of social adversity on metabolic 
outcomes at age 16 years in the NFBC1986.  Logistic regression analyses were 
used to analyse the association between social adversity and metabolic syndrome 
adjusted for potential confounders or contributing factors as well as for sCG 
exposure, hospitalizations, discharges  and deaths.    
In these studies, the differences in means were evaluated using the actual birth size 
measures (birth weight in grams, head circumference in cm, birth length in cm, and 
ponderal index kg/m3). The general linear model (proc glm), in SAS, is used to 
analyse any linear association between exposures and continues outcome variables 
(254). The general linear model was used to examine the association between 
prenatal exposure (sGC in MBR or social stress in the NFBC1986) and the 
association with outcome (birth size or metabolic outcomes). First step was a 
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univariate analysis examining the association between exposure and outcome. To 
extrapolate the extent of influence each confounder was having on the final outcome 
measure, a stepwise analysis was run where each covariate was removed and then 
re-inserted into the final model (Appendix 3, Appendix 4, Appendix 5, Appendix 6, 
Appendix 7). The final adjusted linear regression analysis controlled for selected 
confounders i.e. gestational age, parity, maternal pre-pregnancy BMI, maternal 
smoking, maternal social adversity (in the sGC analysis), pathological glucose test 
and hospitalisation due to hypertension. In order to classify as a confounder, the 
variable should be associated with the outcome and the exposure variable, but not 
lie on the causal pathway. A chi-square tests or logistic multivariable regression 
analyses when appropriate were performed to examine the association between 
possible confounders and the exposure (for categorical variables).  Overall, the 
analyses were performed for males and females together (adjusted for sex) as well 
as separately by sex. In study IIb in the MBR dataset, the linear regression analysis 
was repeated using term births only, which excluded preterm birth as it is considered 
as a condition in itself. In the MBR analysis, examining the association between sGC 
and birth size, we examined variables, which were previously shown to associate 
with birth size (hospitalization due to threatened preterm birth including bleeding and 
other causes, mode of delivery, neonatal intubation, intensive care unit treatment, 
exchange transfusion, phototherapy, antibiotic therapy, and birth malformations), 
however, they did not substantially change the associations (Appendix 8).    
 
5.6 Analysis examining the additive effect of foetal genetic variance and maternal 
social stress during pregnancy on the association with birth size (study III) 
 
This analysis was done to examine the additive association of genetic variance and 
maternal social stress during pregnancy, on birth size.  
The rs900400 and rs9883204 SNPs near LEKR and CCNL1 and in the ADCY5 were 
chosen as their variation  has previously been shown in a GWAS study to be 
associated with lower birth weight (57). The General Linear Model was used when 
examining the additive effect of social stress and carrying at least one birth weight 
lowering risk allele.  This was done by comparing the reference group, who had 
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neither social stress nor risk allele (coded as 0), with the following groups, who 
either: 1) carried at least one risk allele only, or 2) experienced social stress only, or 
3) had both social stress and at least one risk allele. The P-value for trend across the 
exposure categories was also calculated.  
In order to examine the generalizability of the results a comparison of the 
associations between social adversity and birth outcomes in the subset with genetic 
information  and the whole dataset was conducted.   
Tests were two tailed and the level of significance set at 0.05. Correction for multiple 
testing was not used due to a priori set hypotheses, and analytical strategies. 
Version 9.1 of the SAS system for windows (SAS Institute Inc., Cary, NC) for 
statistical analyses was used. 
 
5.7 Handling of missing data 
 
As all infants born between 2004-2010 were registered in the MBR, including 
information on sGC given for threatened preterm birth used in Study IIb, there were 
no missing data for use of sGC for threatened preterm birth, also no missing data for 
measures of birth size. Taking all confounders into account, after multivariable 
analysis, there were13,600 individuals with missing data for any of the covariates. 
The decision was made not to impute the data and therefore complete case 
analyses were used to run the multivariable analysis in SAS.  In the NFBC1986 for 
study IIa, due to only a small proportion of women receiving sGC for threatened 
preterm birth (attributed to either it not being given or data not found in our renewed 
search of the data); a multivariate analysis was not conducted due low statistical 
power.  Instead, the analyses were therefore computed on matched exposure-
unexposure sets, with a paired t-test to compare the difference in means.  The 
matching was employed to take into account confounding and increase the statistical 
power of a small exposure sample. As sGC in threatened preterm birth was only 
given in the hospital setting, we assume those not hospitalised were highly unlikely 
to have received sGC for threatened pre-term birth; this, however, may lead to 
misclassification  and decrease generalizability of the study.  
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In Study III, the data on genetic variance in the population was restricted to 5369 out 
of the population of 9135. To examine whether this subset (n=5369) of NFBC1986 
data, where genetic data were available was representative of the whole population 
(n=9135); the association of social adversity on birth size was examined in both the 
whole population and on the subset separately. The results were comparable with 
overlapping confidence intervals, which indicated the subset is a sufficient 
representation of the whole cohort population.  In Study IV, information on metabolic 
outcome was missing for a proportion of the adolescent population, however, the 
remaining population held sufficient power for the analysis. A complete case analysis 
was therefore used in the multiple regression analysis.  
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6 Results  
 
In this section the main results from studies II-IV are presented. The results and 
outcomes from study I (systematic literature review) are presented in the literature 
review.     
 
6.1 Association of sGC and birth size in NFBC1986 (study IIa) 
 
In theNFBC1986, of the 349 pregnant women who delivered preterm, only 58 (17%) 
in threatened preterm birth received sGC (dexamethasone n=50, betamethasone 
n=4) for foetal lung maturation. This was much less than expected and led to further 
investigations in the later and much larger cohort, the MBR. Of those infants 
exposed in utero to sGC, 48.3% were born preterm. In the NFBC1986, overall in 
preterm births, there was no difference in the univariable analysis for maternal 
characteristics of smoking, alcohol consumption, pre-pregnancy BMI and social 
adversity between those exposed in utero to sGC and those unexposed. 
In the paired analysis of exposed  and unexposed, matched on sex, gestational age 
and maternal smoking, sGC exposure was associated with shorter length at birth -
0.18cm (95%CI -0.26, -0.10)  while birth weight 116g (95%CI 98.9, 133.1), head 
circumference 0.75cm (95%CI  0.70, 0.81) and ponderal index of 0.12 (95%CI 0.11, 
0.13) were higher in exposed (Table 7). 
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Table 7. The association between prenatal glucocorticoid exposure and birth 
size (mean difference), matched on gestational age, sex and maternal smoking 
using the whole NFBC1986 sample (exposed:unexposed,  1:5000).  Statistical 
significance tested using paired t-test. 
 n Mean 95%CI mean t-value p-value 
      
      
Birth weight 5239 116 98.90, 133.1 13.31 <0.0001 
      
Birth length 5201 -0.18 -0.26, -0.10 -4.36 <0.0001 
      
Head circumference 5100 0.75 0.70, 0.81 26.91 <0.0001 
      
Ponderal index 5201 0.12 0.11, 0.13 27.61 <0.0001 
      
 
6.2 Association of sGC on birth size in the MBR (study IIb) 
 
Figure 12 shows the sequential steps, the distribution of data and descriptive birth 
measures from the analysis in the MBR. Even after controlling for varied number of 
confounders, the size of the population remains significantly large. In the MBR 
cohort, 1.8% (n=5090) of the expectant mothers received sGC for stimulating foetal 
lung maturation in threatened preterm birth. Of these expectant mothers that 
received sGC, 55.3% delivered prematurely i.e. before 37 GWs. Table 8 shows the 
univariate associations for maternal characteristics and birth outcomes, between 
those exposed to sGC treatment and those unexposed. Mothers exposed to sGC 
during pregnancy were more likely to deliver before the 37th GW (P<0.0001, mean 
(SD) 35.05(4.33)), have lower pre-pregnancy BMI (P<0.0001, mean 24.15(5.13)), 
smoke during pregnancy (P<0.0001), have a pathological glucose test during 
pregnancy (P=0.05) and be hospitalized for all hypertensive disorders (P<0.0001). 
As would be expected, preterm infants exposed to sGC for foetal lung maturation 
had a lower risk of death and hospitalization compared to preterm infants who did 
not receive sGC (Table 9). 
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Figure 12. Flow diagram showing sequential steps, distributions of  the data 
and descriptive birth measures  from the analysis 
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Table 8. Sample distribution by birth outcomes and maternal characteristics 
according to whether mothers received synthetic glucocorticoid  (sGC) 
treatment to stimulate fetal lung maturation, in live-born-singleton births from 
the Finnish Medical Birth Registry 2006-2010 [n=289013]. Global p-values for 
heterogeneity 
  Synthetic glucocorticoid treatment n (%) 
 All No Yes 
Birth outcomes:   
Gestational age (Week)    
Mean(SD) 39.42(1.70) 39.502(1.51)           35.05(4.33) 
    
<34  1164(0.4) 1761(34.60) 
34-36  8423(2.97) 1052(20.67) 
37-39  120015(42.27) 1467(28.82) 
40-42  154245(54.33) 809(15.89) 
43+  76(0.03) 1(0.02) 
Missing  0 0 
p value  <0.0001 
    
Birthweight (g)    
Mean(SD) 3526.5 (532.6) 3543.6(504.2) 2573.57 (1002.7) 
    
<1000  124(0.04) 372(7.31) 
1000-1500  273(0.10) 541(10.63) 
1500-2499  6021(2.12) 1412(27.74) 
2500-2999  28878(10.17) 739(14.52) 
3000-3999  198603(69.95) 1714(33.67) 
≥4000  49980 (17.60) 311(6.11) 
Missing  44(0.02) 1(0.02) 
p value  <0.0001 
Head circumference (cm)    
Mean(SD) 34.98(1.57) 35.02(1.48) 32.42(3.47) 
    
<33  14650(5.16) 1897(37.27) 
33-33.9  31751(11.18) 544(10.69) 
34-34.9  64825(22.83) 728(14.30) 
35-35.9  77423(27.27) 656(12.89) 
36-36.9  58469(20.59) 378(7.43) 
37-37.9  29(0.01) 0 
≥38  8364(2.95) 57(1.12) 
Missing  28412(10.01) 830(16.31) 
p value  <0.0001 
   
   
Birth length(cm)    
Mean(SD) 50.14(2.35) 50.22(2.18) 45.57(5.53) 
    
<47  12157(4.28) 2285(44.89) 
47-48.9  40536(14.28) 767(15.07) 
49-52.9  193921(68.30) 1575(30.94) 
53-55.9  34402(12.12) 206(4.05) 
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  Synthetic glucocorticoid treatment n (%) 
 All No Yes 
≥56  1282(0.45) 8(0.16) 
Missing  1625(0.57) 249(4.89) 
p value  <0.0001 
    
Maternal 
Characteristics: 
 
  
    
Maternal age (years)    
Mean(SD) 29.52(5.37) 29.52(5.36) 29.89(5.81) 
    
<20   12734(4.49) 266(5.23) 
21-34   219924(77.46) 3715(72.99) 
>35  51265(18.06) 1109(21.79) 
Missing  0 0 
P value  <0.0001 
    
Parity    
Nulliparous  91595(32.26) 1673(32.87) 
Multiparous  192262(67.72) 3417(67.13) 
Missing  66(0.02) 0 
p value  0.36 
    
Pre-pregnancy BMI 
(kg/m
2
) 
 
  
Mean(SD) 24.23(4.73) 24.23(4.73) 24.15(5.13) 
    
Underweight(<18.5)  10609(3.74) 288(5.66) 
Normal(18.5 -  25)  175433(61.79) 3101(60.92) 
Overweight (25 - 30)  58844(20.73) 1001(19.67) 
Obese(>30)  31569(11.12) 623(12.24) 
Missing  7468(2.63) 77(1.51) 
p value  <0.0001 
   
   
Smoking*    
Non-smoker  234701(82.66) 3983(78.25) 
Smoker  42260(15.88) 959(18.84)  
Missing  6962(2.45) 148(2.9) 
p value  <0.0001 
    
    
Glucose test**    
Pathological  27086(9.54) 528(10.37) 
Normal  256837(90.46) 4562(89.63) 
Missing  0 0 
p value  0.05 
    
Hospitalized for 
Hypertensive disorders 
 
  
Yes  6053(2.13) 333(6.54) 
No  277870(97.87) 4757(93.46) 
Missing  0 0 
p value  <0.0001 
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  Synthetic glucocorticoid treatment n (%) 
 All No Yes 
    
Social adversity***    
Yes  25962(9.14) 499(9.80) 
No  257961(90.86) 4591(90.2) 
Missing  0 0 
p value  0.11 
    
Socioeconomic status    
Upper white collar 
administrative 
 
53172(18.73) 862(16.94) 
Lower  white collar  91222(32.12) 1525(29.96) 
Blue collar  36777(12.95) 642(12.61) 
 
Others combined 
 
30161(10.62) 556(10.92) 
Missing  72591(25.57) 1505(29.57) 
p value  0.09 
    
Cohabiting    
Yes  258624(91.1) 4604(90.5) 
No  14997(5.3) 283(5.6) 
Missing  10302(3.6) 203(3.9) 
p value  0.35 
*Maternal smoking anytime during pregnancy. **Oral glucose tolerant test 
pathologic. *** Social adversity is positive if either one of the following is present= no 
cohabitation, maternal age <20 years, and/or manual labour/student/disability 
pension/unemployed.  
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Table 9. Multiple Logistic Regression Analysis for the association between in utero glucocorticoid exposure and 
hospitalization/ discharge/ death at 7 days, stratified by sex 
  
 
 
 
Stratified by sex 
Exposure Outcome 
n* 
 
Unadjusted 
Odds Ratio 
(95%CI) 
P-value 
 
Adjusted*Τ 
Odds Ratio 
(95%CI) 
P-value 
 
Unadjusted 
Odds Ratio 
(95%CI) P-value 
 
Adjusted* 
Odds Ratio 
(95%CI) 
P-value 
 
Unadjusted 
Odds Ratio 
(95%CI) P-value 
 
Adjusted* 
Odds Ratio 
(95%CI) 
P-value 
      male  Female 
ALL             
Glucocorticoids 
(yes, no[ref]) 
Home (ref) 
260212 
          
             
 
hospital 
15053 19.55 
(18.45, 20.71) 
<0.001 
2.66 
(2.44, 2.91) 
<0.001 
 
18.00 
(16.60, 19.45) 
<0.001 
 
2.43 
(2.15, 2.74) 
<0.001 
 
21.63 
(19.87, 23.55) 
<0.001 
 
2.95 
(2.59, 3.36) 
<0.001 
             
 
Died 
222 40.22 
(30.35, 53.29) 
<0.001 
1.43 
(0.99, 2.07) 
0.06 
 41.17 
(28.43, 59.61) 
<0.001 
 
1.19 
(0.73, 1.93) 
0.49 
 
35.56 
(24.97, 59.55) 
<0.001 
 
1.86 
(1.04, 3.32) 
0.04 
TERM ONLY             
Glucocorticoids 
(yes, no[ref]) 
Home (ref) 
254789    
       
             
 
hospital 
8973 2.49 
(2.14, 2.90) 
<0.001 
2.21 
(1.89, 2.58) 
<0.001 
 2.22 
(1.79, 2.75) 
<0.001 
 
1.97 
(1.59, 2.45) 
<0.001 
 
2.85 
(2.29, 3.54) 
<0.001 
 
2.51 
(2.01, 3.13) 
<0.001 
             
 
Died 
80 4.58 
(1.45, 14.50) 
0.01 
3.98 
(1.25, 12.68) 
0.02 
 9.69 
(3.00, 31.40) 
0.0002 
 
7.70 
(2.32, 25.48) 
0.0008 
 -  - 
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Stratified by sex 
Exposure Outcome 
n* 
 
Unadjusted 
Odds Ratio 
(95%CI) 
P-value 
 
Adjusted*Τ 
Odds Ratio 
(95%CI) 
P-value 
 
Unadjusted 
Odds Ratio 
(95%CI) P-value 
 
Adjusted* 
Odds Ratio 
(95%CI) 
P-value 
 
Unadjusted 
Odds Ratio 
(95%CI) P-value 
 
Adjusted* 
Odds Ratio 
(95%CI) 
P-value 
      male  Female 
PRE-TERM 
ONLY<34 
 
    
       
Glucocorticoids 
(yes, no[ref]) 
Home (ref) 
374    
       
             
 
hospital 
3721 1.86 
(1.50, 2.30) 
<0.001 
1.21 
(0.96, 1.53) 
0.10 
 1.61 
(1.21, 2.16) 
0.001 
 
1.05 
(0.77, 1.44) 
0.75 
 
2.22 
(1.62, 3.04) 
<0.001 
 
1.43 
(1.02, 2.02) 
0.04 
             
 
Died 
108 1.63 
(1.09, 2.43) 
0.02 
0.62 
(0.38, 0.99) 
0.05 
 1.40 
(0.83, 2.36) 
0.20 
 
0.47 
(0.25, 0.87) 
0.02 
 
2.00 
(1.06, 3.78) 
0.03 
 
0.86 
(0.40, 1.83) 
0.69 
             
PRE-TERM 
ONLY <32GW 
 
    
       
Glucocorticoids 
(yes, no[ref]) 
Home (ref) 
68    
       
 
hospital 
1777 1.08 
(0.67, 1.76) 
0.74 
0.96 
(0.57, 1.62) 
0.89 
 1.10 
(0.56, 2.16) 
0.79 
 
0.91 
(0.45, 1.86) 
0.80 
 
1.08 
(0.54, 2.16) 
0.82 
 
1.00 
(0.47, 2.15) 
1.00 
 
Died 
85 0.69 
(0.37, 1.27) 
0.23 
0.54 
(0.27, 1.07) 
0.07 
 0.65 
(0.28, 1.49) 
0.31 
 
0.38 
(0.15, 0.98) 
0.04 
 
0.78 
(0.31, 1.97) 
0.60 
 
0.80 
(0.27, 2.35) 
0.68 
*Adjusted for: GW, parity, maternal pre-pregnancy BMI, maternal smoking, maternal social adversity, pathological glucose test and 
hospitalization due to hypertension 
Τ Adjusted for sex 
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Table 10Table 10 shows the unadjusted and adjusted association of prenatal 
exposure to sGC on birth size. Prenatal exposure to sGC was associated with 
smaller birth size in both the unadjusted and adjusted models. After adjusting for 
GW, parity, maternal pre-pregnancy BMI, maternal smoking, maternal social 
adversity, pathological glucose test, and hospitalization due to any form of 
hypertension, prenatal exposure to sGCs was associated with lower birth weight by -
207.94g (95%CI -220.68, -195.19), birth length -1.26cm (95% CI -1.31, -1.20), head 
circumference by -0.94cm (95% CI -0.98, -0.90), and ponderal index by -0.91kg/m3 
(95% CI -1.02, -0.81). When stratifying by sex, the birth size difference was slightly 
larger in females than males; head circumference was -1.01cm (95%CI -1.07, -0.95) 
smaller in exposed females compared to -0.88cm (95%CI -0.94, -0.82) in males, and 
ponderal index by -1.02 kg/m3 (95%CI -1.20, -0.84) in females compared to -0.82 
kg/m3 (95%CI -0.94, -0.69) in males. The stepwise multivariable regression analysis 
was conducted to explore the extent of the association between the different 
covariates. In addition, confounders were removed and then added into the model to 
extrapolate the extent of the variation was a result of confounding.  
When examining the importance of different confounders on the association of sGC 
and birth size outcome, gestational age explained most of the reduction by sGC 
exposure on birth size seen in the univariate analyses (difference in birth weight of 
790.4g between unadjusted analysis and GW adjusted, in birth length 3.53cm, head 
circumference 1.71cm, and ponderal index 0.94cm, respectively). Overall, where 
entering other confounders (parity, maternal pre-pregnancy BMI, smoking, social 
adversity, pathological glucose test, hypertensive disorders) made a small difference 
in the  association estimates, adding the GW to the model, reduced them notably.  
The additional adjustment factors such as hospitalization due to threatened preterm 
birth including bleeding and other causes, mode of delivery, neonatal intubation, 
intensive care unit treatment, exchange transfusion, phototherapy, antibiotic therapy, 
birth malformations that were shown to associate with birth size and known to 
associate with sGC exposure did not substantially change the main associations of 
prenatal sGC exposure on birth size (Appendix 8).  
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Table 10. Multiple Linear Regression Analysis (GLM) of the association between prenatal synthetic glucocorticoid 
exposure and birth size [birth weight (g), length(cm), head circumference (cm) and ponderal index (kg/m3)] both 
unadjusted, adjusted and stratified by sex [n=289013]  
 
mean difference 
(95%CI) 
P-value 
Exposure: 
Glucocorticoid 
Birthweight (g) , N= 276448  Birth length(cm) N= 273725  Head circumference(cm) N=271441  Ponderal index(kg/m3) N= 273723 
n* Unadjusted Adjusted*  n* Unadjusted Adjusted*  n* Unadjusted Adjusted*  n* Unadjusted Adjusted* 
ALL: ґ                
no[ref] 270556    269070    267192    269068   
yes 4892 
 
-970.0 
(-984.4, 955.7) 
<0.001 
-207.9 
(-220.7, -195.2) 
<0.001 
 
4655 -4.65 
(-4.71, -4.58) 
<0.001 
-1.26 
(-1.31, 1.20) 
<0.001 
 
4249 -2.60 
(-2.65, -2.55) 
<0.001 
-0.94 
(-0.98, -0.90) 
<0.001 
 
4655 -1.89 
(-1.99, -1.79) 
<0.001 
-0.91 
(-1.02, -0.81) 
<0.001 
MALES ONLY:               
no[ref] 138455    137654    136650    137652   
yes 
 
2594 -1005.2 
(-1025.3, -985.2) 
<0.001 
-204.2  
(-222.0, -186.4) 
<0.001 
 
2465 -4.84 
(-4.93, -4.75) 
<0.001 
-1.25 
(-1.33, -1.17) 
<0.001 
 
2229 -2.63 
(-2.70, -2.57) 
<0.001 
-0.88 
(-0.94, -0.82) 
<0.001 
 
2464 -1.80 
(-1.92, -1.69) 
<0.001 
-0.82 
(-0.94, -0.69) 
<0.001 
FEMALES ONLY               
no[ref] 132101    131416    130542    131416   
yes 2298 -935.1 
(-955.3, -914.9) 
<0.001 
-212.0 
(-230.3, -193.7) 
<0.001 
 2191 
-4.46 
(-4.55, -4.37) 
<0.001 
-1.26 
 (-1.34, -1.18) 
<0.001 
 2020 
-2.58 
(-2.64, -2.52) 
<0.001 
-1.01 
(-1.07, -0.95) 
<0.001 
 2191 
-1.98 
(-2.14, -1.81) 
<0.001 
-1.02 
(-1.20, -0.84) 
<0.001 
*Adjusted for: gestational age, parity, maternal pre-pregnancy BMI, maternal smoking, maternal social adversity, pathological glucose test, and hospitalization for hypertension 
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Table 11 shows the unadjusted and adjusted association between prenatal exposure 
to sGC and birth size for term births only. The term births only (n= 263805) were 
analysed, in addition to the full sample analyses adjusted for GW, to remove 
potential residual confounding by preterm birth on birth size. In these more restricted 
analyses, after adjusting for confounders as in Table 10, prenatal exposure to sGC 
was associated with smaller birth weight by -44.92g (95% CI -62.46, -27.38), birth 
length by  -0.19cm (95% CI -0.26, -0.11), and head circumference by -0.13cm (95% 
CI -0.18, -0.08). This difference was larger in males, with birth weight -50.39g (95% 
CI-75.20, -25.58), and larger in females for head circumference -0.16cm (95% CI-
0.23, -0.08). 
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Table 11. Multiple Linear Regression Analysis (GLM) of the association between prenatal synthetic glucocorticoid 
exposure and birth size in term births only [birth weight(g), length(cm), head circumference(cm) and ponderal index] both 
unadjusted, adjusted and stratified by sex (n=263805) 
 
mean difference 
(95%CI) 
P-value 
Exposure:    
Glucocorticoid 
Birthweight (g) n=263805  Birth length(cm) n=262585  Head circumference(cm) n=261086  Ponderal index(kg/m3) n=262584 
n* Unadjusted Adjusted*  n* Unadjusted Adjusted*  n* Unadjusted Adjusted*  n* Unadjusted Adjusted* 
ALL: ґ                
no[ref] 261591    260389    258907    260388   
yes 2214 -146.8 
(-166.2, -127.5) 
<0.001 
-44.9 
(-62.5, -27.4) 
<0.001 
 
2196 -0.64 
(-0.72, -0.56) 
<0.001 
-0.19 
(-0.26, -0.11) 
<0.0001 
 
2179 -0.35 
(-0.41, -0.29) 
<0.001 
-0.13 
(-0.18, -0.08) 
<0.001 
 
2196 -0.13 
(-0.27, 0.003) 
0.06 
-0.07 
(-0.21, 0.07) 
0.32 
MALES ONLY:               
no[ref] 133362    132731    131954    132730   
yes 
 
1140 -156.0 
(-183.3, -128.8) 
<0.001 
-50.4 
(-75.2,-25.6) 
<0.001 
 
1127 -0.66 
(-0.78, -0.55) 
<0.001 
-0.19 
(-0.30, -0.09) 
0.0003 
 
1117 -0.34 
(-0.42, -0.26) 
<0.001 
-0.10 
(-0.18, -0.03) 
0.008 
 
1127 -0.11 
(-0.28, 0.06) 
0.21 
-0.06 
(-0.23, 0.12) 
0.52 
FEMALES ONLY               
no[ref] 128229    127658    126953    127658   
yes 1074 -137. 7 
(-164.5, -110.8) 
<0.001 
-39.3 
(-64.1, -14.5) 
0.001 
 
1069 -0.61 
(-0.73, -0.50) 
<0.001 
-0.18 
(-0.29, -0.08) 
<0.001 
 
1062 -0.36 
(-0.44, -0.28) 
<0.001 
-0.16 
(-0.23, -0.08) 
<0.001 
 
1069 -0.16 
(-0.38, 0.06) 
0.14 
-0.09 
(-0.31, 0.13) 
0.43 
*Adjusted for: gestational age, parity, maternal pre-pregnancy BMI, maternal smoking, maternal social adversity, pathological glucose test and hospitalized for hypertension 
Τ
 Adjusted for sex
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6.3 Social stress during pregnancy and the interplay of genetic variance near LEKR 
and CCNL1 on the association with size at birth (study III). 
 
These results and discussion have been published in PlosOne, where the author of 
this thesis is first author (255). This approach is novel and analyses designed and 
conducted for the first time ever. The NFBC team has been involved in the analyses 
of genetic determinants of foetal growth, using birth weight as a proxy. The study 
here is a continuum of those analyses using more extensive prenatal data available 
in the NFBC1986.   
Social adversity was classified with having at least one of the following: young 
maternal age, low maternal education, or non-cohabiting. In the NFBC1986, 24.6% 
of mothers experienced at least one type of social adversity during pregnancy, 3.1% 
experienced at least two types of social adversity and 0.5% experienced at least 
three types of social adversity. Of the women experiencing at least one adversity, 
36% had low education (<11years), 5% were single parents, and 4% were young 
mothers (<20 years) at the time of delivery. Table 12 shows the association analyses 
of social stress (composite variables) with birth outcomes and maternal 
characteristics. Mothers experiencing any social adversity were more likely to deliver 
before the 37th GW (P<0.0001), to be smokers (P<0.0001), and had higher maternal 
pre-pregnancy BMI (P<0.0001) (Table 12). Mothers from lower SES, by occupation, 
were also more likely to be smokers (P<0.0001) to be multipara (P<0.0001), have a 
higher pre-pregnancy BMI (P<0.0001) and report at least one adversity (P<0.0001). 
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Table 12. Background characteristics of the composite social adversity variable (maternal age, 
maternal education, cohabitation) 
 Total  Total  Total  Total 
 Social adversity  
n(%) 
 Maternal age  
n(%) 
 Maternal education  
n(%) 
 cohabitation  
n(%) 
 Yes No  <20 >20  <11yrs ≥11yrs  Yes No 
Gestational age (gw)           
<34 24(0.9) 53(0.8)  1(0.3) 76(0.8)  48(0.8) 29(0.9)  73(0.8) 4(0.9) 
34-36 104(4.0) 165(2.5)  15(3.8) 257(2.8)  157(2.7) 115(3.5)  243(2.8) 29(6.2) 
37-39 1110(43.1) 2681(41.0)  169(42.6) 3633(39.8)  2356(40.5) 1446(43.6)  3640(42.0) 162(34.8) 
40-42 1329(51.6) 3624(55.5)  206(51.9) 4757(52.1)  3247(55.8) 1716(51.7)  4695(54.2) 268(57.6) 
43+ 7(0.3) 9(0.1)  4(1.0) 12(0.1)  10(0.2) 6(0.2)  14(0.2) 2(0.4) 
Missing 0 0  2(0.5) 3(0.03)  0 5(0.2)  5(0.1) 0 
            
Birth weight (g)           
<1500 5(0.2) 14(0.2)  0 19(0.2)  13(0.2) 6(0.2)  18(0.2) 1(0.2) 
1500-2499 66(2.6) 141(1.6)  8(2.0) 203(2.3)  129(2.2) 82(2.5)  194(2.2) 17(3.7) 
2500-2999 283(11.0) 480(5.3)  53(13.4) 715(8.2)  438(7.5) 330(10.0)  68(8.1) 700(14.6) 
3000-3999 1750(68.0) 4506(49.5)  295(74.3) 5978(68.4)  4024(69.2) 2249(67.8)  5961(68.8) 312(67.1) 
≥4000 470(18.3) 1391(15.3)  41(10.3) 1823(20.9)  1214(20.9) 650(19.6)  1797(20.7) 67(14.4) 
Missing 0 0  0 0  0 0  0 0 
            
Head circumference (cm)           
≤33 104(4.0) 164(2.5)  18(4.5) 254(2.9)  153(2.6) 119(3.6)  245(2.8) 27(5.8) 
33-33.9 253(9.8) 493(7.6)  47(11.8) 703(8.1)  454(7.8) 296(8.9)  690(8.0) 60(12.9) 
34-34.9 506(19.7) 1200(18.3)  107(27.0) 1603(18.4)  1104(19.0) 606(18.3)  1599(18.4) 111(23.9) 
35-35.9 668(26.0) 1803(27.6)  108(27.0) 2367(27.1)  1588(27.3) 887(26.7)  2357(27.2) 118(25.4) 
36-36.9 603(23.4) 1608(24.6)  68(17.1) 2148(24.6)  1402(24.1) 814(24.5)  2131(24.6) 85(18.3) 
37-37.9 0 0  0 0  0 0  0 0 
≥38 104(4.04) 260(3.9)  10(2.5) 354(4.1)  239(4.1) 125(3.8)  351(4.1) 13(2.8) 
Missing 336(13.1) 1004(15.4)  39(9.8) 1309(15.0)  878(15.1) 470(14.2)  1297(15.0) 51(11.0) 
           
Birth length(cm)           
<47 n(%) 109(4.2) 208(3.2)  17(4.3) 305(3.5)  185(3.2) 137(4.1)  298(3.4) 24(5.2) 
47-48.9 336(13.1) 631(9.7)  64(16.1) 905(10.4)  568(9.8) 401(12.1)  894(10.3) 75(16.1) 
49-52.9 1744(67.8) 4513(69.1)  272(68.5) 6001(68.7)  4035(69.4) 2238(67.5)  5968(68.8) 305(65.6) 
53-55.9 352(13.7) 1085(16.6)  39(9.8) 1403(16.1)  940(16.2) 502(15.1)  1389(16.0) 53(11.4) 
≥56 15(0.6) 42(0.6)  1(0.3) 56(0.6)  43(0.7) 14(0.4)  53(0.6) 4(0.9) 
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 Total  Total  Total  Total 
 Social adversity  
n(%) 
 Maternal age  
n(%) 
 Maternal education  
n(%) 
 cohabitation  
n(%) 
 Yes No  <20 >20  <11yrs ≥11yrs  Yes No 
Missing 18(0.7) 53(0.8)  4(1.0) 68(0.8)  47(0.8) 25(0.8)  68(0.8) 4(0.9) 
            
Smoking            
Non-smoker 1650(64.1) 5422(83.1)  213(53.7) 6859(78.5)  4775(82.1) 2297(69.3)  6842(78.9) 230(49.5) 
Smoker 913(35.5) 1080(16.5)  175(44.1) 1819(20.8)  1038(17.8) 956(28.8)  1766(20.4) 228(49.0) 
Missing 11(0.4) 30(0.5)  9(0.1) 60(0.7)  5(0.1) 64(1.9)  62(0.7) 7(1.5) 
            
Alcohol consumption           
Non-drinker 2149(83.5) 5473(83.8)  317(79.9) 7305(83.6)  4963(85.3) 2659(80.2)  7297(84.2) 325(69.9) 
Drinker 337(13.1) 732(11.2)  57(14.4) 1012(11.6)  779(13.4) 290(8.7)  961(11.1) 108(23.2) 
Missing 88(3.4) 327(5.0)  23(5.8) 421(4.8)  76(1.3) 368(11.1)  412(4.8) 32(6.9) 
            
Parity            
Nulli-para 932(36.2) 2154(33.0)  350(88.2) 2736(31.3)  2135(36.7) 951(28.7)  2744(31.7) 342(73.6) 
Multi-para 1637(63.6) 4369(66.9)  41(10.3) 5966(68.3)  3674(63.2) 2333(70.3)  5886(67.9) 121(26.0) 
Missing 5(0.2) 9(0.1)  6(1.5) 36(0.4)  9(021) 33(1.0)  40(0.5) 2(0.4) 
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Single-parenthood was the component of the social adversity composite that showed 
the strongest association with birth size, compared to two-parent families, in a 
mutually adjusted analysis (Table 13). This reduction in  birth size associated with 
single parenthood  compared to two parent family status was significant in males but 
not in females (males: birth weight -114 g (95%CI -178.08, -50.13), birth length -0.40 
cm (95%CI -0.67, -0.14), head circumference -0.34 cm (95%CI -0.53, -0.15); 
females: birth weight 16.87 g (95%CI -43.15, 76.89) birth length 0.10 cm (95%CI -
0.16, 0.35), head circumference 0.03 cm (95%CI -0.15, 0.21).   
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Table 13. The association between social adversity and each of the component variables (maternal age, education and 
cohabitation) with the outcomes  (birth weight, length, head circumference and ponderal index) 
Parameter  
Unadjusted estimate 
(95% CI, P-value) 
 
adjusted estimate* 
(95% CI, P-value) 
   male  female   all┬  male  female 
Social Adversity:          
             
Birth weight 
  
-72.17 
(-105.19, -39.16) 
P<0.0001 
 
-79.47 
(-112.90, -46.03) 
P<0.0001 
  
-40.13 
(-60.88, -19.38) 
P=0.0002 
 
-37.95 
(-67.30, -8.60) 
P=0.01 
 
-41.91 
(-71.29, -12.53) 
P=0.005 
Birth length 
  
-0.27 
(-0.41, -0.14) 
P<0.0001 
 
-0.36 
(-0.49, -0.22) 
P<0.0001 
  
-0.14 
(-0.22, -0.05) 
P=0.002 
 
-0.1 
 (-0.23, 0.01) 
P=0.07 
 
-0.17  
(-0.29, -0.04) 
P=0.008 
Head circumference 
  
-0.19 
(-0.29, -0.10) 
P<0.0001 
 
-0.14 
(-0.23, -0.05) 
P=0.003 
  
-0.09 
(-0.15, -0.03) 
P=0.006 
 
-0.11 
 (-0.19, -0.02) 
P=0.02 
 
-0.07  
(-0.16, 0.02) 
P=0.12 
Ponderal index 
  
-0.01 
(-0.03, 0.002) 
P=0.01 
 
-0.01 
(-0.03, 0.004) 
P=0.15 
  
-0.01 
(-0.02, 0.0009) 
P=0.07 
 
-0.01  
(-0.03, 0.004) 
P=0.13 
 
-0.009 
 (-0.03, 0.008) 
P=0.30 
             
Maternal age (<20 years):          
Maternal age as continuous variable      
1.16 
(-0.29, 3.51) 
P=0.10 
-0.14 
  (-2.86, 2.58) 
P=0.92 
3.36 
(0.71, 6.02 ) 
P=0.01 
Birth weight 
  
-155.55                     
(-230.01, -81.10) 
p=<0.0001 
 
-164.41                       
(-236.73, -92.09) 
p=<0.0001 
  
-9.39 
(-56.70, 37.92) 
P=0.70 
 
-17.85 
(86.39, 50.70) 
P=0.61 
 
0.74 
(-64.64, 66.11) 
P=0.98 
Maternal age as continuous variable      
0.01 
(0.005, 0.02) 
P=0.001 
0.01  
(-0.002, 0.02) 
P=0.09 
0.02 
(0.005, 0.03) 
P=0.004 
Birth length 
  
-0.45                         
(-0.76, -0.14) 
p=0.004 
 
-0.53 
 (-0.83, -0.24) 
p=0.0004 
  
-0.10 
(-0.30, 0.10) 
P=0.31 
 
-0.17 
(-0.45, 0.12) 
P=0.25 
 
-0.03 
(-0.30, 0.24) 
P=0.83 
Maternal age as continuous variable      
0.007 
(0.0009, 0.01) 
P=0.02 
0.02  
(-0.007, 0.01) 
P=0.71 
0.01 
(0.004, 0.02) 
P=0.004 
Head circumference 
  
-0.57                     
(-0.79 ,-0.36) 
p=<0.0001 
 
-0.26 
 (-0.46, -0.07) 
 p=0.009 
  
-0.04 
(-0.18, 0.10) 
P=0.56 
 
-0.22 
(-0.42, -0.01) 
P=0.04 
 
0.12 
(-0.07, 0.32) 
P=0.22 
Maternal age as continuous variable    
 
 
-0.001  
(0.002, -0.00003) 
P=0.04 
-0.002  
(-0.003, -0.0003) 
P=0.02 
-0.0004  
(-0.002, 0.001) 
P=0.56 
Ponderal index 
  
-0.05 
 (-0.08, -0.01) 
p=0.008 
 
-0.05  
(-0.08, -0.01) 
 p=0.009 
  
0.01 
(-0.01, 0.04) 
P=0.40 
 
0.01 
(-0.02, 0.05) 
P=0.46 
 
0.009 
(-0.03, 0.05) 
P=0.64 
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Parameter  
Unadjusted estimate 
(95% CI, P-value) 
 
adjusted estimate* 
(95% CI, P-value) 
   male  female   all┬  male  female 
             
Maternal education(<11years):          
             
Birth weight 
  
-26.10 
(-56.92, 4.73) 
P=0.10 
 
-47.19 
(-78.68, -15.69) 
P=0.003 
  
-25.10 
(-44.8, -5.40) 
P=0.01 
 
-14.79  
(-42.64, 13.06) 
P=0.30 
 
-35.58 
(-63.48, -7.69) 
P=0.01 
Birth length 
  
-0.14 
(-0.27, -0.02) 
P=0.03 
 
-0.30 
(-0.43, -0.17) 
P<0.0001 
  
-0.10 
(-0.18, -0.02) 
P=0.02 
 
-0.03 
(-0.14, 0.09) 
P=0.66 
 
-0.18 
(-0.29, -0.06) 
P=0.003 
Head circumference 
  
-0.09 
(-0.17, 0.003) 
P=0.06 
 
-0.08 
(-0.17, 0.004) 
P=0.06 
  
-0.06 
(-0.12, -0.003) 
P=0.04 
 
-0.04 
(-0.12, 0.04) 
P=0.34 
 
-0.09 
(-0.17, -0.001) 
P=0.05 
Ponderal index 
  
0.002 
(-0.01, 0.02) 
P=0.81 
 
0.005 
(-0.01, 0.02) 
P=0.51 
  
-0.004 
(-0.02, 0.006) 
P=0.42 
 
-0.007 
(-0.02, 0.007) 
P=0.34 
 
-0.001 
(-0.02, 0.01) 
P=0.86 
             
Maternal cohabitation(single status):          
             
Birth weight 
  
-219.81          
 (-289.47, -150.15) 
P =<0.0001 
 
-103.30                      
(-169.79, -36.81) 
 P=0.002 
  
24.68  
(4.69, 44.68) 
P=0.02 
 
-114.10  
(-178.08, -50.13) 
P=0.0005 
 
16.87 
 (-43.15, 76.89) 
P=0.58 
Birth length 
  
0.68            
 (-0.97, -0.39)  
P =<0.0001 
 
-0.31                 
   (-0.58, -0.04)  
P=0.03 
  
0.10  
(0.02, 0.18) 
P=0.02 
 
-0.40 
 (-0.67, -0.14) 
P=0003 
 
0.10 
 (-0.16, 0.35) 
P=0.72 
Head circumference 
  
-0.61   
  (-0.81, -0.41)  
P =<0.0001 
 
-0.24                 
   (-0.42, -0.05)  
P=0.01 
  
0.06  
(-0.0009, 0.12) 
P=0.05 
 
-0.34  
(-0.53, -0.15) 
P=0.0005 
 
0.03 
 (-0.15, 0.22) 
P=0.72 
Ponderal index 
  
-0.06  
   (-0.09, -0.02)  
P =0.0005 
 
-0.04             
       (-0.07, -0.004) 
P=0.03 
  
0.004 
 (-0.006, 0.02) 
P=0.41 
 
-0.02 
 (-0.06, 0.01) 
P=0.17 
 
-0.004  
(-0.04, 0.03) 
 P=0.83 
             
*Controlling for, Gestational age, Smoking, Alcohol consumption, parity, and BMI. 
┬
Controlling for sex 
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Table 14 and Table 15 present the results of the multiple regression analysis, 
examining the association between social stress and birth size as well as the 
additive effects of the birth weight-lowering alleles on this association.  
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Table 14. Multiple Linear Regression Analysis (GLM) of the association between social stress and birth size [birth weight 
(g), length (cm), head circumference (cm) and ponderal index] in the whole NFBC1986 Cohort (n= 9135) and stratified by 
sex 
 
 
mean difference 
(95%CI) 
P-value 
 Birthweight (g)  Birth length(cm)  Head circumference(cm)  Ponderal index(kg/m
3) 
Exposure: 
n* 
(Yes/No) 
Unadjusted Adjusted**  
n* 
(Yes/No) 
Unadjusted Adjusted**  
n* 
(Yes/No) 
Unadjusted Adjusted**  
n* 
(Yes/No) 
Unadjusted Adjusted** 
                
Social adversity                
ALL: ґ                
Social Adversity ґ 
(yes, no[ref]) 
2278/ 
5857 
-76.3 
(-100.0, -52.6) 
<0.0001 
-40.4 
(-61.4, -19.5) 
0.0002 
 
2265/ 
5812 
-0.32 
(-0.42, -0.22) 
<0.0001 
-0.14 
(-0.23, -0.05) 
0.002 
 
2238/ 
5743 
-0.17 
(-0.24, -0.10) 
<0.0001 
-0.09 
(-0.15, -0.02) 
0.007 
 
2265/ 
5812 
-0.01 
(-0.02, -0.001) 
0.03 
-0.009 
(-0.02, -0.002) 
0.10 
MALES ONLY:                
Social Adversity 
(yes, no[ref]) 
1164/ 
2990 
-72.2 
(-105.2, -39.2) 
<0.0001 
-39.3 
(-68.8, -9.9) 
0.009 
 
1158/ 
2970 
-0.27 
(-0.41, -0.14) 
<0.0001 
-0.12 
(-0.24, 0.0009) 
0.051 
 
1148/ 
2941 
-0.19 
(-0.29, -0.10) 
<0.0001 
-0.09 
(-0.19, -0.007) 
0.04 
 
1158/ 
2970 
-0.01 
(-0.03, 0.002) 
0.01 
-0.009 
(-0.02, 0.005) 
0.20 
FEMALES ONLY:               
Social Adversity 
(yes, no[ref]) 
1114/ 
2867 
-79.5 
(-112.9, -46.0) 
<0.0001 
-41.8 
(-71.6, -12.0) 
0.006 
 
1107/ 
2842 
-0.36 
(-0.49, -0.22) 
<0.0001 
-0.16 
(-0.29, -0.04) 
0.01 
 
1090/ 
2802 
-0.14 
(-0.23, -0.05) 
0.003 
-0.09 
(-0.18, -0.006) 
0.07 
 
1107/ 
2842 
-0.01 
(-0.03, 0.004) 
0.15 
-0.009 
(-0.03, 0.008) 
0.30 
Neighbourhood social disparity              
ALL: ґ                
Neighbourhood 
social disparity vs 
none [ref] 
4431/ 
3528 
-5.7 
(-27.8, 16.4) 
0.61 
-27.1 
(-46.0, -8.3) 
0.005 
 
4397/ 
3504 
-0.06 
(-0.15, 0.03) 
0.19 
-0.11 
(-0.19, -0.04) 
0.005 
 
4353/ 
3454 
0.02 
(-0.04, 0.08) 
0.51 
-0.02 
(-0.08, 0.04) 
0.46 
 
4397/ 
3504 
0.003 
(-0.007, 0.01) 
0.51 
-0.004 
(-0.02, 0.006) 
0.39 
                
MALES ONLY:                
Neighbourhood 
social disparity vs 
none [ref] 
2276/ 
1793 
-5.3 
(-36.0, 25.5) 
0.74 
-31.1 
(-57.9, -4.3) 
0.02 
 
2261/ 
1782 
-0.12 
(-0.24, 0.01) 
0.07 
-0.18 
(-0.29, -0.07) 
0.002 
 
2244/ 
1759 
-0.0009 
(-0.09, 0.09) 
0.98 
-0.06 
(-0.15, 0.02) 
0.13 
 
2261/ 
1782 
0.01 
(-0.003, 0.03) 
0.11 
0.002 
(-0.01, 0.02) 
0.76 
                
FEMALES ONLY:               
Neighbourhood 
social disparity vs 
none [ref] 
2155/ 
1735 
-6.5 
(-37.8, 24.9) 
0.69 
-24.3 
(-50.9, 2.2) 
0.07 
 
2136/ 
1722 
-0.004 
(-0.13, 0.12) 
0.95 
-0.05 
(-0.16, 0.06) 
0.36 
 
2109/ 
1695 
0.04 
(-0.04, 0.13) 
0.34 
0.02 
(-0.06, 0.10) 
0.62 
 
2136/ 
1722 
-0.005 
(-0.02, 0.01) 
0.53 
-0.01 
(-0.03, 0.004) 
0.14 
*n in the adjusted model.  **Adjusting for gestational age, maternal smoking, maternal alcohol consumption, parity, maternal pre-pregnancy BMI, gestational diabetes and hypertension during 
pregnancy. ґ Additionally adjusting for sex. Neighbourhood social disparity= living in an environment different to individual SES.   
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Table 15. Mean differences (95% confidence intervals, CI) in birth size, as predicted by the additive effects of social stress 
and the presence of at least one risk allele (CCNL1/LEKR1- rs900400) 
 Mean difference 
(95%CI)          
    P-value 
 Birthweight (g) 
 
Birth length(cm)  Head circumference(cm)  Ponderal index(kg/m
3) 
Exposure: n* Unadjusted Adjusted**  n* Unadjusted   Adjusted** 
 
n* Unadjusted   Adjusted**  n* Unadjusted   Adjusted**  
Social Adversity                
Neither adversity nor risk 
allele [ref] 
1546 
 
  
1540 
 
  
1517 
  
 
1540 
  
At least one risk allele only 
 
 
1873 -55.6 
(-88.6, -22.6) 
0.001 
 
-76.6 
(-105.0, -48.3) 
<0.0001 
 
 
1856 -0.03 
(-0.17, 0.11) 
0.68 
 
-0.13 
(-0.25, -0.02) 
0.03 
 
 
1836 -0.10 
(-0.19, -0.01) 
0.03 
 
-0.16 
(-0.25, -0.07) 
0.0003 
 
 
1856 -0.35 
(-0.50, -0.20) 
<0.0001 
 
-0.37 
(-0.52, -0.22) 
<0.0001 
 
Social adversity only 535 -106.4 
(-153.8, -59.1) 
<0.0001 
 
-74.0 
(-115.8, -32.1) 
0.0005 
 
 
530 -0.34 
(-0.54, -0.15) 
0.0008 
 
-0.20 
(-0.38, -0.02) 
0.03 
 
 
526 -0.25 
(-0.39, -0.12) 
0.0002 
 
-0.18 
(-0.31, -0.05) 
0.005 
 
 
530 -0.29 
(-0.50, -0.08) 
0.008 
 
-0.27 
(-0.50, -0.05) 
0.02 
 
Both adversity and at least 
one risk allele 
666 -106.8 
(-151.1, -62.6) 
<0.0001 
-118.4 
(-156.9, -79.9) 
<0.0001 
 
665 -0.29 
(-0.48, -0.11) 
0.002 
-0.30 
(-0.46, -0.14) 
0.0002 
 
655 -0.19 
(-0.32, -0.06) 
0.003 
-0.23 
(-0.35, -0.11) 
0.0001 
 
665 -0.41 
(-0.61,-0.21) 
<0.0001 
-0.47 
(-0.67, -0.26) 
<0.0001 
P value for trend 
  <0.0001 
 
  0.0001 
 
 
 
<0.0001    <0.0001 
  
  
  
  
 
  
    
Neighbourhood social disparity  
  
  
  
 
  
    
Neither disparity nor risk 
allele [ref] 
875 
 
  
871 
 
  
858 
  
 
871 
  
At least one risk allele only 
 
 
1158 -39.7 
(-84.1, 4.6) 
0.07 
 
-63.5 
(-101.4, -25.6) 
0.001 
 
 
1048 
-0.006 
(-0.19, 0.18) 
0.95 
 
-0.10 
(-0.26, 0.05) 
0.20 
 
 
1024 
-0.11 
(-0.23, 0.02) 
0.10 
 
-0.17 
(-0.30, -0.06) 
0.003 
 
 1038 
-0.34 
(-0.54, -0.14) 
0.0008 
 
-0.35 
(-0.56, -0.15) 
0.0007 
 
Social disparity only 1427 -11.82 
(-55.2, 31.5) 
 
0.59 
-35.51 
(-72.1, 2.0) 
0.06 
 
 
1151 
-0.12 
(-0.30, 0.06) 
0.18 
 
-0.16 
(-0.32, 0.007) 
0.04 
 
 
1137 
-0.06 
(-0.19, 0.06) 
0.30 
 
-0.12 
(-0.24, -0.01) 
0.03 
 
 1151 
0.02 
(-0.17, 0.22) 
0.83 
 
-0.05 
(-0.25, 0.15) 
0.65 
 
Both disparity and at least 
one risk allele 
875 
-54.67 
(-96.3, -13.0) 
0.01 
-108.54 
(-144.1, -72.9) 
<0.0001 
 
1415 
-0.14 
(-0.31, 0.04) 
0.12 
-0.31 
(-0.46, -0.16) 
<0.0001 
 
1403 
-0.12 
(-0.24, -
0.006) 
0.04 
-0.25 
(-0.35, -0.14) 
<0.0001 
 1415 
-0.24 
(-0.43, -0.05) 
0.01 
-0.37 
(-0.56, -0.17) 
0.0002 
P value for trend 
  <0.0001 
 
  <0.0001 
 
 
 
<0.0001    0.008 
*n in the adjusted model **controlling for gestational age, maternal smoking, maternal alcohol consumption, parity, maternal pre-pregnancy BMI, sex, gestational diabetes 
and hypertension during pregnancy  
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Table 13 shows the association between social adversity and birth size after 
adjusting for gestational age, sex, maternal smoking, alcohol consumption, pre-
pregnancy BMI, parity, gestational diabetes and hypertensive disorders during 
pregnancy. After adjustment, infants of mothers who experienced at least one social 
adversity had smaller birth sizes, compared to infants of mothers with no adversity; 
birth weight of -40.4g (95%CI -61.4, -19.5), birth length -0.14cm (95%CI -0.23, -
0.05), head circumference -0.09cm (95%CI -0.15, -0.02). Once stratified by sex, this 
difference remained statistically significant in males and females for birth weight, but 
only in females for birth length (-0.16cm, 95%CI -0.29, -0.04) and in males for head 
circumference, (-0.09cm, 95%CI -0.19, -0.007), respectively. These results may be 
affected by a smaller sample size; consequently decreasing statistical power.   
When genetic variance was added to the analysis (Table 15), belonging to social 
adversity categories one, two or three (as described previously) was associated with 
smaller birth size compared to reference group (no social adversity and no birth 
weight-lowering risk allele at rs900400; i.e. reference category 0 in the Table 15). 
The association with birth size was magnified in category three, containing both 
social adversity and risk allele at rs900400, compared to the results for social 
adversity only or carrying one risk allele only. Category three showed a reduction in 
birth weight by a total of -118g (95%CI-156.9, -79.9), birth length of -0.30cm ( 95%CI 
-0.46, -0.14), head circumference by -0.23cm ( 95%CI -0.35, -0.11), and ponderal 
index of -0.47(95%CI -0.67, -0.26); i.e. in the presence of birth size lowering allele 
the association between social adversity and birth size was stronger.  The P-value 
for trend for effect sizes by exposure categories was significant for all birth size 
outcomes. When stratified by sex (Appendix 9), this difference in birth size, though 
not always reaching statistical significance due to reduced sample size, was more 
prominent in females. The results for rs9883204 (Appendix 10) showed no 
association across the categories, which may be attributed to insufficient sample size 
in the fully adjusted analyses.  A test for interaction was conducted between social 
adversity and the various SNPs, however, there was no evidence to suggest an 
interaction (Appendix 11).  
Analysis on other SNPs, identified in the NFBC1986, to associate with smaller birth 
size, showed no additive effect with social adversity (these include HMGA2, 
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CDKAL1, 5q11.2, LCORL) (58). This work is ongoing and I was not able to include 
detailed results into the thesis (Appendix 12). 
Neighbourhood social disparity was associated with smaller birth size, more 
specifically with a difference in birth weight of -27.1g (95% CI -46.0, -8.3) and birth 
length of -0.11cm (95% CI -0.19, -0.04), in the adjusted model (Table 15). In the 
stratified model, the association of neighbourhood social disparity with birth size, was 
statistically significant in males only. When examining the association of 
neighbourhood social disparity and genetic vulnerability (rs900400), compared to the 
reference group (category zero), those belonging to categories one, two or three 
were associated with smaller birth size. However, the results did not reach statistical 
significance in all categories, though the P-values for trend of effect sizes by 
exposure categories were significant for all birth size outcomes.  Here again, having 
both neighbourhood social disparity and carrying at least one birth weight-lowering 
risk allele (rs900400), magnified the association with smaller birth size, compared to 
having neighbourhood social disparity only or risk allele rs900400 only.  The 
association analyses for rs9883204 were non-significant.  
 
6.4 Social stress during pregnancy and metabolic outcomes at age 16 years (study 
IV) 
 
6.4.1 Metabolic syndrome and its components 
 
According to the IDF, metabolic syndrome is defined as having at least three of five 
of the following conditions; obesity, elevated blood pressure, elevated serum 
triglycerides and total cholesterol levels, low serum high-density lipoprotein (HDL), 
impaired glucose tolerance or insulin resistance (47;256). Table 16  shows the 
Paediatric IDF cut-off criteria. After removing all type 1 diabetics and those who did 
not fast for blood draw, the final population of adolescents reviewed for this study 
was 6567, of which 213 (3.2%) met the criterion for metabolic syndrome for 
adolescents. Of these, examining the distribution of the variables; more boys had 
higher measured blood pressures (systolic >130mmHg or diastolic >85mmHg) and 
increased blood glucose levels (>5.6mmol/L) compared to girls in the population. 
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Girls smoked more often than boys, consumed more alcohol, and had a waist 
circumference that was more likely to fit the criterion for metabolic syndrome. 
However, girls had higher levels of HDL than boys. 
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Table 16. Distribution of metabolic syndrome (criteria according to the 
International Diabetic Federation) and its components by sex and potential 
confounders in the NFBC1986 (n=6567)   
Outcome 
Frequency n (%) 
Males Females 
Metabolic syndrome   
Yes  176(5.6) 37(1.1) 
No 2957(94.4) 3397(98.9) 
Blood Glucose levels   
≥5.6mmol/L 600(19.2) 202(5.9) 
<5.6mmol/L 2533(80.9) 3232(94.1) 
Waist circumference   
≥87.4cm boys /≥80cm girls 284 (9.1) 298(11.6) 
 2849(90.9) 3036(88.4) 
Triglycerides    
≥1.7(mmol/l) 96 (3.1) 94(2.7) 
<1.7(mmol/l) 3037(96) 3340(97.3) 
High density lipoprotein   
>1.03(mmol/l) 2278(72.7) 2677(78.0) 
≤1.03(mmol/l) 855(27.3) 757(22.0) 
Blood Pressure:   
*high 67(2.1) 16 (0.5) 
 3066(97.9) 3418(99.5) 
Adolescent Smoking 
cigarettes ** 
    
Yes 938(46.1) 1299(55.5) 
No 1099(53.9) 1040(44.5) 
Adolescent Alcohol 
consumption 
    
Yes 2294(74.0) 2636(77.1) 
No 807(26.0) 786(22.9) 
*≥130mmHg systolic or ≥85mmHg diastolic, ** ever smoked compared to never smoked. 
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I present here firstly the overall final results, then individual metabolic syndrome 
component-wise analyses, and analyses on the impact of potential confounding 
factors. Table 17 shows the logistic regression analysis examining the association of 
maternal social adversity during pregnancy and its association on metabolic 
syndrome at sixteen years in the offspring, stratified by gender. Both the univariate 
and multivariate analyses adjusting for birth weight, gestational age, adolescent 
smoking and alcohol consumption suggested that girls have higher risk for metabolic 
syndrome compared to boys at age 16 years. However, these results did not reach 
statistical significance either in the univariate or multivariate analyses. The individual 
components of metabolic syndrome were also examined separately, both as 
categorical and continuous variables, to identify individual associations, i.e. for waist 
circumference, blood pressure, triglycerides, HDL and blood glucose levels. Prenatal 
exposure to maternal social adversity was associated, in females only, with 
increased waist circumference of 1.25cm (95% CI 0.44, 2.06), lower HDL measures 
by -0.04mmol/l (95%CI -0.06, -0.005) and higher glucose measures by 0.06mmol/l 
(95%CI 0.007, 0.13) at age 16years. These associations were statistically significant 
only for continuous variables (Table 18). In order to further understand the role 
confounders, gestational age and birth weight played on the outcomes, the data was 
(re-) examined with and without adjusting for these confounders. The addition or 
removal of either birth weight or gestational age did not significantly change the 
results (Table 19).  Birth weight  or gestational age are not necessarily confounding 
factors as such but could lie on the causal pathway between social adversity during 
pregnancy and the metabolic outcomes.  However, there was no clear indication of 
mediation either when comparing unadjusted and adjusted analyses (Table 19).    
 Insulin is another precursor of development of T2D later in life. The association of 
prenatal exposure to maternal social adversity and the percentage change of insulin 
levels at 16 years of age was examined. The data on insulin was not normally 
distributed and first needed to be log transformed before been analysed. The results 
shown here are back transformed into percentage change in the outcome. The 
results indicate a disparity between the genders; with statistically significant 
percentage change in blood fasting insulin in those girls (%change 5.95, 95%CI 2.5, 
131 
 
9.51) whose mothers had suffered social adversity during their pregnancy. However, 
after adjusting for known confounders, these results were no longer statistically 
significant (Table 20).     
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Table 17. Association between prenatal exposure to maternal social adversity and 
metabolic syndrome in offspring at age 16 years using logistic regression (removing 
diabetics and non-fasting samples). Total n=6567 (n(males)= 3133, n(females)= 3434) 
 Metabolic syndrome 
 Males Females 
 Unadjusted Adjusted Unadjusted adjusted 
 OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
Exposure:     
Social adversity vs no 
social adversity 
 
1.14 
(0.81, 1.59) 
0.46 
1.25 
(0.82, 1.90) 
0.30 
1.71 
(0.88, 3.33) 
0.12 
1.77 
(0.82, 3.83) 
0.15 
     
*adjusted for birth weight and gestational age. Adolescent smoking and alcohol consumption 
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Table 18. Association of maternal social adversity on the binary components of metabolic syndrome  (see text for cut-off  
values) at age 16 years in offspring using logistic regression, and the metabolic syndrome components as continuous 
variables using GLM (removing diabetics and non-fasting participants in both analyses) 
 Waist circumference Blood pressure triglycerides HDL Glucose 
 Unadjusted adjusted* Unadjusted adjusted* Unadjusted adjusted* Unadjusted adjusted* Unadjusted adjusted* 
 OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
OR 
(95%CI) 
P Value 
Exposure:           
Social adversity vs no social adversity        
Males only 
1.26 
(0.97, 1.65) 
0.09 
1.15 
(0.81, 1.64) 
0.43 
1.35 
(0.80, 2.27) 
0.27 
1.48 
(0.75, 2.89) 
0.26 
1.41 
(0.91, 2.18) 
0.12 
1.44 
(0.81, 2.57) 
0.22 
1.18 
(0.99, 1.41) 
0.07 
1.04 
(0.84, 1.30) 
0.71 
1.02 
(0.84, 1.25) 
0.82 
1.15 
(0.89, 1.49) 
0.75 
           
Females only 
1.24 
(0.98, 1.55) 
0.07 
1.30 
(1.00, 1.71) 
0.06 
1.27 
(0.44, 3.66) 
0.66 
1.34  
(0.458, 3.97) 
0.60 
1.13 
(0.72, 1.77) 
0.61 
0.96 
(0.56, 1.63) 
0.87 
1.20 
(1.00, 1.44) 
0.05 
1.09 
(0.89, 1.36) 
0.40 
1.05 
(0.76, 1.44) 
0.78 
1.31 
(0.88, 1.95) 
0.02 
           
 
Estimate 
cm 
(95%CI) 
P Value 
Estimate 
cm 
(95%CI) 
P Value 
  
Estimate 
Percentage 
change 
(95%CI) 
P Value 
Estimate 
Percentage 
change 
(95%CI) 
P Value 
Estimate 
mmol/l 
(95%CI) 
P Value 
Estimate 
mmol/l 
(95%CI) 
P Value 
Estimate 
mmol/l 
(95%CI) 
P Value 
Estimate 
mmol/l 
(95%CI) 
P Value 
           
Social adversity vs no social adversity        
Males only 0.98 
(0.18, 1.78) 
0.02 
0.88 
(-0.05, 1.81) 
0.06 
  
3.41 
(-0.54, 7.53) 
0.09 
2.94 
(-1.78, 7.87) 
0.23 
-0.01 
(0.04, 0.01) 
0.34 
-0.008 
(-0.04, 0.02) 
0.61 
-0.01 
(-0.05, 0.03) 
0.62 
-0.009 
(-0.06, 0.05) 
0.75 
           
Females only 0.98 
(0.31, 1.65) 
0.004 
1.25 
(0.44, 2.06) 
0.003 
  
5.16 
(1.64, 8.80) 
0.004 
2.58 
(-1.53, 6.85) 
0.22 
-0.02 
(-0.05, 0.001) 
0.06 
-0.04 
(-0.06, -0.005) 
0.02 
0.03 
(-0.009, 0.07) 
0.12 
0.06  
(0.007, 0.128) 
0.03 
*adjusted for birth weight and gestational age. Adolescent smoking and alcohol consumption 
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Table 19. The association between maternal social 
adversity during pregnancy with metabolic 
syndrome in offspring: exploring the confounders of 
birth weight and gestational age at birth 
Outcome OR 
(95% CI) 
P value 
Metabolic syndrome 
(adjusted for: sex, birth weight, gestational age, 
Adolescent smoking and alcohol consumption) 
1.31 
(0.91-1.88) 
0.14 
 
Metabolic syndrome  
(adjusted for: sex, gestational age, Adolescent 
smoking and alcohol consumption) 
1.30 
(0.90-1.88) 
0.15 
 
Metabolic syndrome 
(adjusted for: sex, birth weight, Adolescent 
smoking and alcohol consumption) 
1.30 
(0.91-1.88) 
0.15 
 
Metabolic syndrome 
(adjusted for: sex, Adolescent smoking and 
alcohol consumption) 
1.31 
(0.91-1.88) 
0.14 
 
Table 20. The association between prenatal exposure to maternal 
social adversity and insulin levels in offspring at age 16 years, 
stratified by sex 
 Insulin 
 Males Females 
 Unadjusted Adjusted* Unadjusted Adjusted* 
 Estimate 
Percentage 
change 
(95%CI) 
P Value 
Estimate 
Percentage 
change 
 (95%CI) 
P Value 
Estimate 
Percentage 
change 
(95%CI) 
P Value 
Estimate 
Percentage 
change 
 (95%CI) 
P Value 
Exposure:     
Social adversity 
vs no social 
adversity 
4.16 
(0.12, 8.36) 
0.04 
3.51 
(-1.41, 8.69) 
0.17 
5.95 
(2.51, 9.51) 
0.0006 
3.39 
(-0.69, 7.62) 
0.10 
*adjusted for birth weight and gestational age. Adolescent smoking and alcohol consumption 
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6.4.2 Dyslipidaemia 
 
The overall means and  distributions of lipid, lipoprotein profiles and blood pressure 
valuses are presented in Appendix 18. Table 21 shows these profiles by social adversity 
and potential confounding factors.The data exploration showed that the distributions of 
IDL, VLDL, apolipoprotein B and apolipoprotein B to apoliporpotein A ratio were skewed, 
and consequently they were log transformed for further association analyses. The lipid 
profile distribution for those adolescents exposed to prenatal maternal social adversity 
showed statistically significantly higher levels of IDL, LDL, VLDL, apolipoprotein B, 
apolipoprotein B/A ratio, and triglycerides, compared to those unexposed.  Adolescents 
exposed to prenatal maternal social adversity also showed lower levels of HDL, which 
were not statistically significant, in the univariate analysis. HDL is the only lipid where 
high levels are considered to be protective against development of CVD (Table 21). 
There was also a significant disparity between male and female lipid profiles, with 
teenage boys having lower IDL, LDL, VLDL, triglyceride, and apolipoprotein B levels, 
compared to girls.  
Lower birth weight (2500-2999g), compared to normal range (3000-3999g), was 
associated with increased levels of IDL, LDL, VDL, apolipoprotein B, and triglyceride 
levels.  Maternal smoking during pregnancy was associated with increased levels of IDL, 
VLDL and triglycerides at age 16 years, compared to adolescents whose mothers did not 
smoke. Adolescent smoking was associated with higher levels of VLDL and triglyceride 
levels, while alcohol consumption was associated with increased levels of IDL, VLDL and 
triglyceride levels, at age 16 years. Teenagers who smoked, compared to those who did 
not smoke, had increased levels of VLDL (%change 11.09, P<0.0001), and triglycerides 
(%change 6.41, P<0.0001). Teenagers who consumed alcohol had higher levels of IDL 
(%change 2.13, P=0.03), VLDL (%change11.3, P<0.0001) and triglycerides (%change 
8.32, P<0.0001), compared to those who did not drink. Teenagers whose mothers were 
obese based on prepregnancy weight  and height  (BMI)  had poorer lipid profiles, with 
significantly higher levels of IDL, VLDL, apolipoprotein B, apolipoprotein B/A and 
triglycerides, and with lower levels of HDL, compared to those whose mothers had BMI in 
normal ranges before start of  pregnancy. Teenagers who were themselves overweight 
or obese also had poorer lipid profiles with increased levels of IDL, LDL, VLDL, 
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apolipoprotein B, apolipoprotein B/A ratio and triglycerides, and  lower levels of HDL, 
than teenagers within the normal BMI range.  
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Table 21. Descriptive univariate analysis of lipids and lipoproteins. Means between groups by 
social adversity and confounding factors [non- fasting participants and those with Type I 
diabetics excluded] 
 IDL VLDL ApoB ApoB/A 
 n % change n % change n % change n % change 
Exposure:         
SADv         
Yes 1363 3.54 1363 5.67 1254 2.16 1254 2.34 
No 4006  4002  3624  3624  
P value 0.0003 0.006 0.02 0.03 
         
Sex         
Male (1) 2591 -2.85 2589 -2.99 2306 -3.14 2306 6.57 
Female(2) 2785  2783  2579  2579  
P value 0.0006 0.08 <0.0001 <0.0001 
         
Gestational age (gw)        
<34 40 -4.63 39 0.90 34 0.74 34 0.25 
34-36 156 5.20* 156 15.46* 148 2.08 148 2.83 
37-39 2212 1.51 2211 1.57 2018 0.73 2018 1.12 
40-42(ref) 2959  2957  2676  2676  
43+ 8 -2.64 8 -11.15 8 -5.03 8 -4.21 
         
Birth weight (g)         
<1500 12 2.02 12 -9.04 11 2.09 11 -1.35 
1500-2499 117 2.65* 116 9.49 106 3.16 106 2.571 
2500-2999 414 5.05* 414 8.67* 384 3.50* 384 1.10 
3000-3999(ref) 3713  3711  3384  3384  
≥4000 1120 -0.83 1119 -4.14* 1000 -0.72 1000 0.70 
         
Maternal Smoking         
Non-smoker(ref) 4334  4331  3917  3917  
Smoker 1017 2.23 1016 9.23 946 1.13 946 0.89 
             p-value 0.04 <0.0001 0.13 0.30 
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 IDL VLDL ApoB ApoB/A 
 n % change n % change n % change n % change 
         
Maternal Alcohol  
Consumption 
      
Non-drinker 4542  4538  4122  4122  
Drinker 613 0.15 613 3.68 561 -0.30 561 -0.88 
p-value 0.91 0.19 0.75 0.40 
         
Adolescent Smoking        
Non-smoker(ref) 1781  1780  1616  1616  
Smoker 1762 1.82 1760 11.09 1626 0.98 1626 0.81 
p-value 0.08 <0.0001 0.18 0.33 
         
Adolescent Alcohol  
Consumption 
      
Non-drinker 1347  1345  1201  1201  
Drinker 3992 2.13 3990 11.33 3648 0.91 3648 -0.15 
              p-value 0.03 <0.0001 0.19 0.85 
         
Maternal BMI         
Extremely low 
(<16) 
9 -12.42 9 -21.34 8 -5.91 8 -14.02 
Low  
(16-18.5) 
356 -1.33 356 -1.09 323 -1.24 323 -1.24 
Normal 
(>18.5, ≤  25) (ref) 
4021  4018  3653  3653  
Overweight 
 (>25, ≤30) 
681 3.04* 680 3.95 621 2.25* 621 2.67* 
Obese 
(>30) 
196 5.51* 196 11.14* 178 3.65* 178 7.25** 
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 IDL VLDL ApoB ApoB/A 
 n % change n % change n % change n % change 
         
Adolescent BMI         
Extremely low 
(<16) 
58 -4.17 58 -20.31* 46 1.72 46 -5.63 
Low 
(16-18.5) 
925 -5.61** 923 -11.36** 811 -2.96** 811 -4.70** 
Normal 
(>18.5, ≤  25) (ref) 
3763  3761  3415  3415  
Overweight 
(>25, ≤30) 
463 24.09** 463 52.71** 452 13.66** 452 19.51** 
Obese 
(>30) 
144 47.32** 144 86.13** 140 28.54** 140 36.33** 
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 Triglycerides  HDL LDL cholesterol 
 n %change 
 
n 
means 
difference 
n 
means 
difference 
Exposure:        
SADv        
Yes 1361 4.43  1361 -0.008 1361 0.06 
No 3994   3994  3993  
P value 0.0008  0.36 0.04 
        
Sex        
Male 2599 -5.33  2600 -0.17 2600 -0.13 
Female 2763   2763  2762  
P value <0.0001  <0.0001 <0.0001 
        
Gestational age (gw)       
<34 44 6.56  44 0.01 44 0.06 
34-36 157 10.70*  157 -0.03 157 0.07 
37-39 2213 1.13  2213 -0.005 2212 0.02 
40-42(ref) 2939   2939  2939  
43+ 9 -18.09  9 0.01 9 0.07 
        
        
Birth weight (g)        
<1500 14 6.72  14 0.07 14 0.14 
1500-2499 120 7.45  120 0.01 120 0.06 
2500-2999 417 8.17**  418 0.02 418 0.11* 
3000-3999 (ref) 3707   3707  3706  
≥4000 1104 -3.25  1104 -0.03* 1104 -0.03 
        
Non-smoker 4328   4328  4327  
Smoker(ref) 1009 4.61  1009 -0.003 1009 0.04 
p-value 0.008     
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 Triglycerides  HDL LDL cholesterol 
 n %change 
 
n 
means 
difference 
n 
means 
difference 
Maternal Alcohol 
consumption 
 
 
  
  
Non-drinker 4534   4534  4533  
Drinker 611 4.00  611 0.003 611 -0.02 
              p-value 0.03  0.84 0.53 
        
Adolescent Smoking       
Non-smoker 1769   1770  1770  
Smoker 1761 6.41  1761 0.001 1761 0.03 
p-value <0.0001  0.88 0.23 
        
Adolescent Alcohol  
Consumption 
 
  
  
Non-drinker 1359   1359  1358  
Drinker 3966 8.32  3967 0.009 3967 0.02 
p-value <0.0001  0.32 0.47 
        
Maternal BMI        
Extremely low 
(<16) 
12 
-14.44 
 
12 0.14 12 -0.27 
Low  
(16-18.5) 
360 
-0.39 
 
360 0.003 360 -0.05 
Normal 
(>18.5, ≤  25) 
(ref) 
3996 
 
 
 
3996  3996  
Overweight 
 (>25, ≤30) 
687 
1.56 
 
687 -0.02 687 0.05 
Obese 
(>30) 
196 
6.56* 
 
196 -0.06* 195 0.11* 
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 Triglycerides  HDL LDL cholesterol 
 n %change 
 
n 
means 
difference 
n 
means 
difference 
Adolescent BMI        
Extremely low 
(<16) 
61 -5.51 
 
61 0.14** 61 0.003 
Low  
(16-18.5) 
925 -6.77** 
 
926 0.05** 926 -0.09** 
Normal 
(>18.5, ≤  25)  
(ref) 
3747  
 
3747  3746  
Overweight 
 (>25, ≤30) 
460 30.40** 
 
460 -0.15** 460 0.33** 
Obese 
(>30) 
147 56.60** 
 
147 -0.21** 147 0.75** 
*<0.05, **<0.001 
[log] =(EXP(estimate)-1)*100
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In the multivariate analyses, examining the association of social adversity with lipid 
profile (Table 22), controlling for gender, birth weight, GW, and maternal factors 
(maternal smoking, maternal alcohol consumption and maternal BMI), social 
adversity was associated with increased levels of IDL (%change 2.73, P 0.008), LDL 
(0.05 mmol/L, P 0.02), apolipoprotein B and apolipoprotein B/A (%change1.74 and 
1.92, P 0.02), and triglycerides (%change 2.80, P 0.04). In these teenagers, HDL ( -
0.007 mmol/L, P 0.46) levels were also lower, though not reaching statistical 
significance.  
In order to further understand the extent of influence of confounders (GW, birth 
weight, maternal BMI, maternal alcohol consumption) on the association between 
social adversity  and  the metabolic outcomes, the data was examined with and 
without adjusting for these confounders. Having birth weight and gestational age in 
the final model, showed a weaker association between the exposure and outcome; 
with lower final estimate for apolipoprotein B, apolipoprotein B/A, triglycerides and 
little difference for LDL. For apolipoprotein B (considered a sum of IDL, LDL and 
VLDL), the effect size decreased  slightly, the P-value indicating somewhat weaker  
statistical significance (from % change of  1.87, P 0.009 in unadjusted analyses to % 
change of 1.74, P 0.02 in birth weight and GW adjusted model). When considering 
the biological pathway along which social adversity is associated with lipid profile, 
the possibility arises that both birth weight and gestational age may either lie on the 
causal pathway or be mediators (Figure 13).   Similarly, once maternal BMI was 
added in the final model, it also  decreased the  effect size of prenatal maternal 
social adversity on apolipoprotein B levels (from %change 2.01, P 0.005 in 
unadjusted for maternal BMI to %change 1.74, P 0.02 in adjusted model).  I also 
explored the role of possible adolescent confounders by only controlling for 
adolescent factors (adolescent BMI, alcohol consumption, and smoking).  These 
analyses showed no association between prenatal social adversity and lipid profile at 
age 16 (Table 23). However, when removing adolescent BMI from the model, the 
association with IDL, apolipoprotein B/A and LDL, became significant, indicating the 
important role of body mass and potential effect modification (i.e. interaction with 
social adversity). A test for interaction was then run between maternal social 
adversity and adolescent BMI, with results being statistically significant (P<0.0001). 
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The analysis was run again, stratified by adolescent BMI, the results showed that low 
BMI or being overweight/obese, compared to normal BMI, was associated with 
poorer lipid profile, however, not reaching statistical significance partly due to low 
numbers in extreme strata (Appendix 16). Therefore adolescent BMI was removed 
from the final analysis which results showed a significant association with IDL 
(%change 2.69 P 0.02), Apolipoprotein B/A (%change 2.21, P 0.02) as well as LDL 
(%change 0.06, P 0.03).  
 
Figure 13. Social adversities and the association with lipid profile at age 16 
years, understanding confounders 
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Table 22. Multivariate analysis* of lipid profile at 16 years for offspring of 
mothers experiencing social adversity during pregnancy (removing diabetics 
and non-fasting participants) 
Outcome variable 
Social 
adversity 
N 
%change         
(95% CI)                             
P-value* 
 
 
 
Unadjusted 
for gestation 
week and birth 
weight 
Unadjusted for  
Maternal BMI 
 
Unadjusted 
for maternal 
alcohol 
IDL  No 3774     
 Yes 1292 2.73 
 
 
 
 
1.38 1.39 1.21 
   (0.72, 4.79) (0.07, 2.70) (0.09, 2.71) (-0.08,2.52) 
   0.008 0.04 0.04 0.06 
VLDL  No 3770     
 Yes 1292 2.80 
 
3.11 3.79 3.01 
   (-1.36, 7.12) 
 
(-1.05, 7.45) (-0.36, 8.11) (-1.09, 7.29) 
   0.19 0.15 0.07 0.15 
ApoB No 3416     
 Yes 1185 1.74 
 
1.87 2.01 1.63 
   (0.33, 3.17) 
 
 
(0.47, 3.36) (0.61, 3.44) (0.24, 3.03) 
   0.02 0.009 0.005 0.02 
ApoB/A  No 3416     
 Yes 1185 1.92 
 
2.01 2.01 1.88 
   (0.34, 3.52) 
 
(0.43, 3.62) (0.43, 3.62) (0.32, 3.46) 
   0.02 0.01 0.003 0.02 
       
Triglycerides  No 3766     
 Yes 1292 2.80 3.08 3.45 2.82 
   (0.11, 5.56) (0.38, 5.85) (0.77, 6.20) (0.17, 5.55) 
   0.04 0.03 0.01 0.04 
Outcome variable 
Social 
adversity 
N 
Estimate (95% CI)                          
    P-value* 
 
       
Apo A-I No 3416     
 Yes 1185 -0.002 -0.0009 
 
-0.004 -0.002 
   (-0.02, 0.01) (-0.02, 0.01) (-0.02, 0.009) (-0.02, 0.01) 
   0.83 0.89 0.54 0.70 
HDL mmol/L No 3766     
 Yes 1292 -0.007 -0.007 -0.01 -0,07 
   (-0.02, 0.01) (-0.03, 0.01) (-0.03, 0.007) (-0.03, 0.01) 
   0.46 0.48 0.24 0.41 
LDL mmol/L No 3765     
 Yes 1292 0.05 0.05 0.02 0.05 
   (0.003, 0.09) (0.006,0.09) (0.01,0.10) (0.003, 0.09) 
   0.02 0.03 0.02 0.04 
       
*Controlling for sex, birth weight, gestational week, maternal smoking, maternal alcohol consumption and 
maternal BMI.  
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Table 23. Multivariate analysis* of lipid profile at 16 years of offspring of mothers 
experiencing social adversity during pregnancy controlling for adolescent BMI, 
smoking and alcohol consumption 
Outcome 
variable 
 All  
Social 
adversity 
N 
%change                
(95% CI)                             
P-value* 
 
Un-adjusted for 
gestational 
week and                 
birth weight 
Un-adjusted 
for  BMI 
Un-adjusted 
for alcohol 
IDL  No 2415     
 Yes 888 1.49 
 
1.84 
 
2.69 1.47 
   (-0.70, 3.73) (-0.36, 4.10) (0.35, 5.07) (-0.72, 3.71) 
   0.18 0.10 0.02 0.19 
VLDL  No 2412     
 Yes 888 1.40 
 
2.09 
 
3.29 1.55 
   (-3.13, 6.14) 
 
(-2.47, 6.87) (-1.45, 8.25) (-3.00, 6.30) 
   0.55 0.37 0.17 0.51 
 No 2341     
ApoB Yes 818 0.33 
 
1.05 
 
1.53 0.76 
   (-0.77, 2.32) 
 
(-0.49, 2.61) (-0.08, 3.16) (-0.77, 2.31) 
   0.33 0.18 0.06 0.33 
 No 2202     
ApoB/A Yes 818 1.24 1.50 2.21 1.17 
   (-0.46, 2.97) (-0.21, 3.23) (0.39, 4.07) (-0.51, 2.93) 
   0.16 0.09 0.02 0.17 
Triglycerides No 2533     
 Yes 924 1.75 2.21 2.95 1.83 
   (-1.19, 4.76) (-0.73, 5.25) (-0.10, 6.10) (-1.10, 4.86) 
   0.25 0.14 0.06 0.22 
Outcome variable 
Social 
adversity 
N 
Estimate (95% CI)  
P-value* 
 Apo A-I No 2341     
 Yes 872 -0.007 
 
-0.007 -0.01 -0.007 
   (-0.02, 0.009) (-0.02, 0.009) (-0.03, 0.006) (-0.02, 0.01) 
   0.38 0.41 0.22 0.42 
HDL mmol/L No 2533     
 Yes 924 0.007 -0.007 -0.01 -0.006 
   (-0.03,0.01) (-0.03, 0.01) (-0.03, 0.007) (-0.03, 0.01) 
   0.50 0.50 0.22 0.54 
LDL mmol/L No 2533     
 Yes 924 0.04 0.04 0.06 0.04 
   (-0.01, 0.09) (-0.007, 0.09) (0.005, 0.11) (-0.01, 0.09) 
900.17 
   0.16 0.09 0.03 0.17 
*Controlling for sex, birth weight, gestational week, adolescent smoking, adolescent alcohol consumption and 
adolescent BMI 
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7 Conclusions and discussion  
 
The general aim of this thesis was to study birth size, influenced by exposure to 
glucocorticoids, either administered clinically in cases of threatened preterm birth or 
inferred as a result of exposure to maternal social stress.  The results converged and 
showed that exposure to sGC and social stress were negatively associated with 
measurements of birth size, measured by; birth weight, ponderal index, birth length, 
and head circumference.  When studying exposure to social stress in conjunction 
with genetic risk for poorer foetal growth, the results showed that the negative 
association between stress exposure and birth size remained. This suggests, at least 
partly, an independent pathway by stress on foetal growth.  Moreover, the presence 
of genetic risk factor magnified the the association  of social stress with  size at birth.  
Taken together, the results presented in this thesis are novel and have clinical 
implications, indicating a need for greater attention to glucocorticoid and stress 
exposure in pregnant women.   
The work  presented here  (a) systematically reviewed the published literature on the 
association of in utero sGC exposure and birth size (6.1-6.2), (b) studied the 
association between sGC exposure and birth size in the largest sample to date (6.2),  
(c) examined the impact of maternal social stress in pregnancy on birth size, also  
using a genetically informative design (6.3), and (d)  finally studied the long term 
impact of maternal social stress during pregnancy on offspring metabolic outcomes 
at 16 years of age (6.4). The analytic strategies were; 1) descriptive, as little is 
known about potential confounders related to sGC treatment (frequencies and 
percentages, normality and linearity, examined using graphical tools, Pearson and 
Spearman correlations for multicolinearity, statistical tests as appropriate for 
unadjusted association analyses) and 2) multivariable analysis using the general 
linear models or logistic regression to examine the adjusted association between the 
exposures (sGC, social adversity, genetic variance) and the outcomes (birth size, 
metabolic syndrome, its components and other metabolites). The results are  
discussed based on current literature and the DOHaD framework. In this chapter, I 
will discuss the results of the individual studies (chapter 7), followed by a discussion 
on ways in which the current research contributes to the DOHaD hypothesis. This 
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chapter also includes a discussion on overall methodology, strengths, limitations and 
concludes with suggestions for future work. 
 
7.1 Summary and Discussion study IIa 
 
This study tested the hypothesis that women exposed to sGC during pregnancy 
(given for threatened preterm delivery) are likely to have infants of smaller birth size 
than unexposed counterparts. The NFBC1986 was used for this analysis.  
The results show, that though the beneficial effects of sGC have already been 
established fifteen years previous to this birth cohort (135), the use of sGC to 
stimulate foetal lung maturation in threatened preterm birth were still not widespread 
in the Northern provinces of Finland; with less than one fifth receiving the treatment, 
despite clinical indications. This slow uptake of sGC as regular treatment in 
threatened preterm birth, was not isolated to Finland and was seen across the globe, 
as it took nearly 20 years before sGC were accepted as a routine treatment for foetal 
lung maturation in threatened preterm birth. In this study, due to the small sample 
size of those exposed to sGC, a matched (exposed subject was matched for all 
available unexposed subjects) analysis was carried out to examine any association 
between in utero GC exposure and birth size. The results here showed that in utero 
sGC exposure was associated with a difference in birth size, but only showed 
smaller birth length in those exposed prenatally to sGC; the other associations were 
in the opposite direction to that expected. These results, which were maybe due to 
chance finding, were not in keeping with findings of previous studies, where majority 
of the larger and better quality studies indicated overall smaller birth size in those 
infants exposed prenatally to sGC (151;155;159;160;163;167). Caution is 
recommended when interpreting our results, as insufficient power due to sample size 
is one of the main limiting factors of this study. In conclusion, though an association 
is noted between prenatal sGC exposure and birth size, further studies are required 
with large sample sizes and statistical approaches being able to extrapolate potential 
causal associations. Therefore, a second analysis, examining the association of sGC 
given due to threatening preterm birth on birth size, was done on a younger cohort 
using data from the Finnish Birth registry.  
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7.2 Summary and Discussion Study IIb 
 
This study tested the hypothesis that women exposed to sGC during pregnancy 
given for threatened preterm delivery are likely to have infants of smaller birth size 
than unexposed counterparts. The MBR was used for these analyses. 
In contrast to the study on the NFBC1986 cohort, in the MBR, prenatal exposure to 
sGC was associated consistently with smaller size at birth. Even though half of the 
mothers exposed to sGC went on to deliver at term, a significant association 
remained between prenatal sGC exposure and smaller birth size. This confirms our 
previous suggestion, that the NFBC1986 cohort was under-powered to test the 
association between sGC and birth size. We were not able to take into account the 
time between the sGC exposure and birth because of unavailability of these data, 
which would have been beneficial to evaluate the nature of potential growth inhibitory 
action of this drug.  
This study is novel in that it is the first to include an entire newborn population 
covering a whole nation over several years (about 55,000 births per year), to study 
the association of prenatal sGC exposure (given for threatened preterm birth) on 
birth size.  Confounding due to access or quality in prenatal care is unlikely, given 
the extensive availability of tax-payer funded, high quality prenatal care in Finland. 
The prescription of this medication should therefore not be affected, for example by 
mother’s SES.    
The average foetal growth in normal gestation is 200g/week during the 32nd-38th 
GW(257). Therefore, a birth weight difference of 207g, as seen in this study, is 
equivalent to a week of foetal growth, and is clinically significant. The birth weight 
difference seen in infants exposed to sGC is also comparable to similar effects seen 
on birth weight in offspring of mothers smoking circa 8 cigarettes per day during the 
entire gestation (258). In term only infants, this association between sGC exposure 
and lower birth weight continues to be significant, albeit to a smaller degree. This 
could be the result of a greater time interval between exposure to sGC and birth for 
term infants, allowing a longer recovery and catch up growth period. However, due to 
lack of data on time lag between exposure and delivery, I was not able to explore 
this further. Postnatal growth patterns as a continuum from foetal period, particularly 
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catch up growth (early growth velocity), are considered important indicators for 
developing CVD later in life. Studies and a recent systematic review have examined 
postnatal catch up growth, showing that both low birth weight, as well as catch up 
growth increased the risk of developing CVD later in life (259). Therefore, even 
though some of the  neonates exposed to sGC due to threatened preterm birth go on 
to be born at term, the question remains whether this in utero catch up growth 
increases the risk of developing disease later in life. This would help understand the 
progress of disease development through the different stages of growth.   
By examining term only infants, we exclude associations resulting from intrauterine 
complications that lead to preterm birth, and may have direct impact on foetal growth 
such as early infections (187). Previous studies suggest that birth size is affected 
already by other factors in infants who are born preterm and therefore may mask the 
effects of synthetic glucocorticoids (188). Besides increased neonatal morbidity and 
mortality related to reduced birth size, other life course consequences are possible 
(260). Small birth size has been associated with many poorer health outcomes 
spanning into adulthood, as well as low academic and economic attainment(260) 
(261).   
As described earlier, the pathway in which sGCs associates with birth size may be 
akin to the way maternal nutrition affects birth size (81). The animal studies have 
shown that maternal protein restriction, for example, reduces placental 11beta-
hydroxysteroid dehydrogenase-2 activity, which then possibly leads to increased 
maternal glucocorticoid activity (81). This enzyme is known to protect the foetus from 
the effect of exogenous GC. Nonetheless, sGC crosses the placenta at a higher 
concentration, despite 11beta-hydroxysteroid dehydrogenase-2 activity, and has a 
higher affinity for GR and MR. This increases the likelihood that the difference in 
birth size noted in this study maybe  through sGC (65). These observations suggest 
that the link between the environment and birth size may occur through GCs, in 
addition to other potential mechanisms, such as epigenetic modifications. Studies 
have also shown that in utero exposure to sGC at specific times during pregnancy 
results in alteration to GC responses in animals, and changes to  the HPA axis 
response to stress. These changes have been shown to persist through the life 
course(262).  Animal models also suggest that the long term effects of sGC may 
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have an epigenetic component, as these risks for developing CVD and metabolic 
diseases are carried on to the next generation (263). 
One centimetre difference in head circumference represents 11% brain volume (190-
192). Brain growth has impact on growth of the cranium, which in turn impacts head 
circumference. In this study, the difference in head circumference would average a 
9% difference in brain volume. A recent large prospective study reported a difference 
of 1.5 cm in head circumference associated with ADHD symptoms, and suggested 
that small birth size affects long-term psychological development (190;191;192;264). 
The changes in head circumference here may therefore have clinical consequences. 
Likewise, both shorter birth length and low ponderal index have previously been 
linked to increased risk of hospitalization, poor development, as well as development 
of chronic diseases in later life (265;266). Ponderal index is an indication of thinness, 
and reflects disproportionate growth in the later stages of gestation. These 
differences in ponderal index in the present study, further indicate poor weight gain 
of the infant at some stage during pregnancy.  
Previous studies have shown sexual dimorphism in relation to birth size, with the 
male foetuses more vulnerable to intrauterine insult (174). However, in this Finnish 
population, the association between in utero sGC exposure and birth size was noted 
to be stronger in female infants. Head circumference in particular showed no 
overlapping confidence intervals between the male and female results, indicating 
that this association was not due to chance. These results indicate that the exposed 
females may be more vulnerable to cognitive and developmental problems later in 
life.  
As to be expected, infants receiving sGC for threatened preterm birth were more 
likely to be hospitalised and have a higher mortality. The odds ratio, however, drops 
significantly when controlling for gestational age, as would be expected. Most infants 
exposed to sGC are born prematurely, and therefore have a naturally higher risk for 
death and skew the results when this variable is uncontrolled.  
Low birth weight has been linked to long and short term childhood morbidity and 
mortality, (264;267) which includes development of diseases later in life, such as 
CVD and metabolic disease (4;5). There is, however, no direct link as yet reported 
between sGC exposure and morbidity in childhood and later life, therefore we must 
152 
 
be cautious when inferring any causal affect. Nonetheless, the relatively large 
difference in birth size reported here indicates the possibility of a more significant 
effect of sGC on foetal development than previously thought. This therefore gives 
further weight to the hypothesis that the HPA axis, and through it GC, are important 
components in foetal programming. Though a randomized control trial would be an 
ideal study method to examine causality, this is, however, not possible due to ethical 
issues. This is because sGC is important in threatened preterm birth, as since its 
induction into medical use for foetal lung maturation in threatened preterm birth, 
foetal morbidity and mortality from complications of prematurity have drastically been 
reduced. Randomising mothers in suspected preterm labour, as to whether they 
should receive sGC treatment or not, would be detrimental to the neonate should it 
be born prematurely and also unethical based on the current data on immediate 
benefits of sGC treatment for neonate. The existing studies do not explain the role of 
endogenous GC, produced, for example, in situations such as social stress and 
adversity. This therefore led to the next step of this thesis; the examination of 
maternal social stress, the interplay by susceptibility genes and birth size.  
In conclusion, prenatal exposure to sGC is associated with smaller birth size even for 
infants born at term. To reduce unnecessary exposure to sGC, a more stringent 
diagnosis for threatened preterm labour is suggested. Infants exposed to sGC 
should also be evaluated for potential chronic disease risk factors early in life. 
 
7.3 Summary and Discussion study III 
 
Because both social stress, at individual and neighbourhood levels, and specific 
genetic factors are each associated with smaller birth size, it is expected that 
exposure to both risks will magnify the association. 
That many human diseases stem from a complex interplay between environment 
and individual susceptibility is not a new concept. This study examines how and 
whether specific genetic susceptibility modulates the association with adverse 
outcomes from environmental exposures, such as social stress. The results here 
show that maternal social stress during pregnancy, both at the individual and 
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neighbourhood levels, was associated with smaller infant birth size and that carrying 
the birth weight-lowering rs900400 C allele (located near CCNL1/LEKR), magnified 
this association. These results provide support for the hypothesis that an individual 
with a genetic or other biological risk may be more vulnerable to environmental 
adversity, tested for the first time ever. Though the magnitude of the reduction in 
birth size attributable to genetic variants is of significant proportion (79g per risk 
allele), these results still are indicative and would benefit of further replication. 
Though both social stress and the birth weight lowering allele rs9883204 at ADCY5 
are independently associated with smaller birth size, this study was not able to show 
any significant additive effects on birth size. This is most likely due to limitations   in 
sample size for genetic studies and relatively low frequency of the allele in this 
cohort. Therefore, in order to extrapolate further the additive effect of genetic liability 
and environmental adversity on foetal development, studies with larger sample size 
are needed.  The future work could  include additional analyses in other comparable 
datasets in the Early Growth Genetics (EGG) consortium.  
Though variants near CCNL1/LEKR are known to be linked with lower birth weight, 
the biological process behind this is still unclear (57). Insulin is the most important 
foetal growth hormone, and the foetal insulin hypothesis suggests that genetic 
variants in glucose and insulin metabolism may affect foetal growth (268;269). The 
variation CCNL1/LEKR has not yet firmly been linked to either T2D or adult 
glycaemic traits.   A recent study has, however,  shown an association between the 
C-allele, birth weight decreasing allele of rs900400 (located near CCNL1/LEKR1) 
and increased insulin response to oral glucose stimulation in non-diabetic individuals 
(270). 
The impact maternal social stress has on infant birth weight is comparable to 
mothers smoking two cigarettes per day (177;258). Smoking is also often linked with 
social adversity, having potential additive effect on foetal wellbeing. This highlights 
the importance of maternal social stress, both at individual and neighbourhood 
levels, as an indicator for increased risk for lower infant birth size and potential  
development of disease in later life.  
Small head circumference is linked with poor developmental and cognitive outcomes 
in the offspring (218;219). In this study, maternal social stress was associated with 
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both smaller infant head circumference and birth length; however, the differences 
were small. Measurement error cannot be excluded, e.g. head circumference is a 
measure of occipital-frontal circumference and is subject to some degree of 
unreliability. However, measurement error is unlikely to be systematically associated 
with social stress, thus should be considered as random variance and evenly 
distributed by exposure status.  
Previous studies have shown that male foetuses are more vulnerable to intrauterine 
insults (174). However, this is not always the case as we can see in this study where 
some significant differences were more notable in females e.g. for head 
circumference; however, as the confidence intervals often overlap between the 
males and females, these differences may be attributed to chance. The sexual 
dimorphic association with birth size reported in systematic review in the present 
study indicates differential response to foetal environmental factors between the 
sexes. This may help explain some of the gender differences involved in the cascade 
of development of diseases, as seen later in life.   
In this study, it was hypothesized that maternal perceived stress translates into one 
of the biological pathways through which social stress related to mother’s 
characteristics or neighbourhood disparity affects foetal growth and ultimately birth 
size. Perceived stress has been linked to changes in maternal stress hormone levels 
(i.e. cortisol) during pregnancy (271).  Social adversity, as defined here is a measure 
of stress related to biological and individual adversity, rather than just as financial 
and economic adversity. Maternal stress during pregnancy is also known to be 
associated with physiological and cognitive outcomes in offspring (100;121;250). 
Animal studies have shown that increased levels of maternal glucocorticoids, which 
are a major component of the stress response, are associated with smaller birth size 
in offspring (141-145;272;273). In the MBR study, using a large sample, sGC was 
associated with smaller birth size, further adding to the already published data on the 
relevance of GC on growth. The foetus reacts to stress in a manner analogous to the 
adult reaction, i.e. with increased levels of foetal cord cortisol during late pregnancy 
(213;274). However, studies have yet to show an increase in foetal cortisol levels 
due to maternal stress (213). Other biological pathways that may link maternal stress 
to reduced placental blood flow and birth size such as  maternal non-optimal 
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nutrition; undernutrition (275-277) and especially nowadays the impact of 
overnutrition and  obesity are yet to be further tested. 
This study also highlights the importance of using three indicators of social adversity 
in the clinical setting for identifying pregnant women at risk of poor birth outcomes. 
The factors used to define social adversity are indicative of potential economic 
hardship and biological risk (198). The results here showed that women experiencing 
some social adversity were more likely to deliver prematurely and smoke, risk factors 
known to predict small birth size (177;258). Importantly, the presence of only a single 
index of adversity was enough to result in lower birth weight, with maternal single 
marital status having the strongest association. Social adversity is also important as 
it may not only affect foetal development, but also influence postnatal development 
in terms of poor maternal resources.  
The association of neighbourhood social disparity with smaller birth size is likely to 
be explained by stress related to access to amenities. In Finland, despite uniformly 
distributed tax-paid health care, many individuals in rural areas may have long 
distances to travel in order to access health care and other amenities. Interestingly, 
although these types of neighbourhood deprivations are small compared to other 
industrialized nations, they still account for clinically significant differences in birth 
size.   
Strengths of this study include the prospective data collection with extensive 
maternal and infant demographic and medical information. The study population is 
known to be genetically homogenous, consisting of white Caucasians, therefore, 
reducing bias introduced by race. Moreover, major confounders were adjusted for, 
which had not been possible at this scale in previous studies. The study had, 
however, limited statistical power to report the additive effects of genetic variants on 
birth size with higher precision, or to test for any interactions between the genetic 
variants and social stress. These aspects should ideally be addressed in larger 
meta-analyses, combining several studies, but the availability of such data has 
become a key issue. Another limitation is that the hypothesis testing involved 
assumption that social stress experienced by mother correspond or convey to the 
biological stress response e.g. in hypothalamic pituitary adrenal-axis functioning. It 
would have been a strength to have maternal blood cortisol samples, which were not 
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available in the NFBC1986 cohort. However, cortisol in relation to perceptions of 
stress is fraught with measurement difficulties, as shown by Hansen et al (278). 
Nonetheless, the indices that were used here have been previously correlated with 
perceived stress (279-282). In addition, residual confounding could not be controlled 
for.  
This study shows that genetic susceptibility magnified the association between social 
stress (both at the individual and neighbourhood levels) and birth size. The fact that 
social stress was associated with smaller birth size, even in a society where there is 
relatively little social inequality compared with other high-income countries and 
where tax–payer health care is universally available, is alarming and highlights the 
importance of the association.  These results also emphasize the use of indicators of 
social stress in clinical settings. It is promising that the addition of the genetic 
variants made a significant additional contribution, which calls for further work in 
identifying groups of genetic variants and their interaction with environment. 
Now that a link was made between sGC, social stress and birth size, how this 
translates into development of disease later in life needs to be examined. This led to 
the next study, where the association of social adversity (a biological proxy for GC) 
on development of metabolic syndrome and poor lipid profile in adolescents was 
examined.   
 
7.4 Summary and Discussion study IV 
 
If the social adversity in childhood is related to development of metabolic syndrome 
later in life, then may social adversity in the foetal period also be associated with 
metabolic outcomes in adolescence. In addition, if the social adversity during 
pregnancy is associated with smaller size at birth, then will it also associate with 
more adverse metabolic status in adolescence.   
Although in the multivariate analysis no statistically significant association was noted 
between prenatal exposure to maternal social adversity and metabolic syndrome at 
age 16; there was none the less a gender disparity in lipid profiles, where girls had 
poorer lipid profiles than boys, once again highlighting that the male child is not 
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necessarily always worse off. This may be explained by girls in this population being 
more likely to smoke, and have an increased waist circumference than boys. 
Visceral obesity, as reflected in increased waist circumference, is considered to be a 
significant risk factor for developing CVD later in life (283). Additionally, when 
examining the derivatives of metabolic syndrome (waist circumference, blood 
pressure, triglycerides, HDL, blood glucose), using them as continuous variables, an 
association was noted between prenatal maternal social adversity and increased 
waist circumference as well as blood glucose levels, and lower levels of HDL. No 
association was noted when these variables were categorised as used to define 
metabolic syndrome; this disparity can be explained through the loss of power of 
analysis when categorising continuous variables. Also, adjusting for potential 
confounders of GW and birth weight, both previously been associated with metabolic 
syndrome, did not affect the outcome of our results. We can assume that  GW and 
birth weight may lie on the causal pathway between prenatal social adversity and 
metabolic syndrome. However, this study did not give any strong evidence for it. An 
explanation for no observed association between prenatal social adversity and 
metabolic syndrome at age 16 year may be that metabolic syndrome has low 
prevalence at this age, which has an impact on statistical inferences. Alternately, 
these results may simply indicate that prenatal exposure to maternal social stress 
may not be sufficient to re-program foetal and later life metabolism for fully 
developed metabolic syndrome. However, longer term follow-up is necessary 
because there were clear indications for some adverse metabolic profiles at more 
refined molecular level, especially among the girls. 
The development of CVD later in life is not a straightforward chain of events, but  a 
web of interlinked metabolic interactions, as described previously. Therefore, even 
though no association between prenatal exposure to maternal social adversity and 
metabolic syndrome at age 16 was noted, there was as indicated above some link 
noted with dyslipidaemia, which is a major risk factor for developing atherosclerosis 
and a precursor to developing CVD later in life (123-125). Besides the traditional 
total cholesterol and LDL, other lipoprotein and apolipoprotein measures are 
considered in the National Heart, Lung and Blood Institute, USA (NHLBI) guidelines 
as a powerful, even better, predictors of atherosclerosis (288). The advantage of 
apolipoprotein B/A calculations, is that they can also be done in the non-fasting 
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states (284;288).  IDL itself is also considered the part of LDL cholesterol which is 
attributed to the risk of developing disease later in life. Therefore examining 
associations with also this lipoprotein increases our ability to identify individuals 
susceptible to CVD, later in life (132).  The multivariate analysis showed an 
association between prenatal maternal social adversity and statistically significant 
increased blood levels of IDL, LDL, apolipoprotein B, apolipoprotein B/A, and 
triglycerides, with lower levels of HDL the latter not being statistically significant. The 
lack of an association with all the outcomes variables (i.e. HDL), may again be due 
to the young age of the study population. The association of social adversity with 
apolipoprotein B/A ratio reflects the underlying lipoprotein profile of the individual and 
this ratio, which represent a wider range of lipid measures,  is considered a better 
predictor of development of CVD later in life (134). Apolipoprotein B is a reflection of 
the sum of all the lipoproteins LDL, IDL and VLDL, and apolipoprotein A the sum of 
HDL subfractions (134). Therefore, even though an association between prenatal 
social adversity and metabolic syndrome at age sixteen was not noted, an 
association with a metabolic profile is seen, which is conducive to development of 
CVD later in life. As a result, metabolic syndrome as a standalone predictor of 
development of CVD is not sufficient and a more in-depth approach is needed.  
These results strongly indicate and confirm what the NHLBI guidelines report, that 
further research on populations of different ages are needed, especially studies on 
child populations to recognise the indicators for health promotion as early as 
possible (289).  
There are some limiting factors, such as un-accounted potential confounding factors 
or bias that may impact the results. There was missing data on early childhood social 
adversity, and change of social status after birth could not be accounted in the 
present analyses, which may bias the results as those children whose mothers 
suffered social adversity during pregnancy, were very likely to continue to live in poor 
social circumstances.  However, the NFBC1986 has relatively little missing data, 
measurements are accurate according to the designed protocols (e.g. fasting 
samples) and overall sample size is large lending credibility to these results. In spite 
of that  an ssue is still whether data collection methods were sufficient to capture the 
adversity during the foetal period. However, the measures used have not only been 
tested here, but in other studies and analyses, and they seem to capture social 
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adversities relatively well (250). In addition, our measure of social stress, though 
potent enough to be significantly associated with birth size, may not be correctly 
operationalized for long term metabolic outcomes. As the population is still ageing, to 
further understand the significance of our findings, a follow up analysis would be 
needed, when the population is older, to examine whether those with poorer lipid 
profiles do go on to develop CVD later in life or not. Finally, the sample size in some 
analyses may not be large enough to detect smaller associations.     
8 Overall discussion 
 
8.1 Overall summary 
 
DOHaD highlights the importance of prenatal environment on the growing foetus and 
the long-term associations to disease later in life (3). The prenatal environment is a 
multifactorial and complex system; there are numerous biologically plausible 
pathways by which there is potential for reprogramming of foetal development(45). 
These pathways, however, remain poorly understood. The focus here was on one 
candidate pathway;the HPA axis. Glucocorticoids in the form of cortisol is the main 
effector hormone in the HPA axis, with GR ubiquitously distributed throughout the 
body (61). Animal studies have demonstrated using tight experimental methodology 
that disrupted HPA axis activity during early pregnancy is linked to adverse cognitive 
and health outcomes in the offspring (44;79-82). Animal studies have further 
demonstrated excess sGC, experimentally administered during pregnancy or 
endogenously induced via exposure to stress, results in premature organ maturation 
and reduction in overall growth (139;140). Small birth size in these offspring is 
consequently reported to be associated with adverse outcomes in the offspring such 
as increased blood pressure (81). However, study of disrupted HPA axis function in 
humans is fraught with methodological problems and limited mostly to observational 
studies as experimentation is unethical. However, here we make use of the routine 
administration of sGC in cases of threatened pre-term birth to study whether prenatal 
exposure to sGC is associated with birth size in humans, in a quasi-experimental 
manner. Examining the associations of birth size with sGC given for threatened 
preterm birth would give insight, in an ethical way, to help understand whether the 
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HPA axis, through GC, plays a role in foetal programming of birth size. Because 
research has focused on the benefits over the risks, little attention has been paid to 
the adverse effects of sGC on the foetus, in particular to birth size.  
A systematic literature review was conducted for the purpose of this thesis in order to 
explore current published literature that examined the association of sGC during 
pregnancy for threatened preterm birth on birth size (chapter 3.1) (168). In the 
systematic literature review there were 19 papers that examined the association of 
sGC for threatened preterm birth on birth size (149-167), relatively few when 
considering that sGC have now been in regular use over the past 30 years. In order 
to sum the results, a meta-analysis would have been ideal, but due to the difference 
in methods and representation of results, this was not possible. The type of sGC 
used and dosage also varied across studies, which indicated a lack of uniformity of 
guidelines with regard to sGC usage in threatened preterm birth. In Finland, for 
example, a national guideline for the usage of sGC in threatened preterm birth was 
first introduced in 2011, till then doctors used varied international guidelines, 
according to their experience. In order to examine the quality of the papers to 
extrapolate whether sGC given during pregnancy was associated with a smaller birth 
size in the offspring, a protocol was needed. The general qualities of the studies was 
examined using a checklist by Tooth et al (148), which allowed parallel comparison 
between studies  by international guidelines on general conduct of the observational 
studies. Though the Tooth et al checklist was sufficient to compare the general 
quality between the studies, it does not consider the unique methodological issues 
related to the study of sGC exposure. Therefore, for the purpose of this thesis, a 
second check list on design, analytical strategies and confounders (DAC) was 
created by the authors and evaluated by two further epidemiologists. This second 
checklist allowed a more specific comparison, in a quantitative way, between 
studies. The assessment showed a wide spead in resulting quality scores between 
the studies. Overall, studies that scored higher on quality, in both general study 
design and specific criteria related to sGC use, reported a link between sGC 
exposure during pregnancy and smaller birth size (151;155;159;160;163;167). 
Though the previously published studies indicated a possible link between sGC 
exposure during pregnancy and birth size, none could be used as a gold standard, 
showing a need for more comprehensive and larger studies.  
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In the next step of this thesis using the entire pregnant Finnish population between 
2004 and 2010, the largest study to date which examined the association between 
sGC and birth size was conducted (chapter 6.2). The results showed that sGC given 
during pregnancy was associated with smaller birth weight, head circumference, 
birth length and ponderal index. The magnitude of the size difference when 
compared to known measures of normal foetal growth (200g/GW between 32-
38GW) suggest that the change in 207g reported was equivalent to a loss of one 
week of growth. The difference in head circumference was equivalent to a loss of 9% 
brain volume. Small birth size has been linked to development of disease later in life, 
such as CVD, and T2D (1;4-19). When examining those born at term only, a 
significant difference of birth weight was still noted, though smaller than when 
examining the whole population. This gives further weight to the idea that a change 
in HPA axis during pregnancy, has long term consequences on foetal programming.  
However, as there were no actual measures of GC in foetal blood at the time, the 
exact pathway through the GC cannot be confirmed but only inferred. Small birth 
size also is just a proxy for development of disease later in life and not the cause 
itself. It is more likely the metabolic changes occurring, which result in small birth 
size, are actual causal events for disease development later in life. Nonetheless, this 
study, with its large population size and ability to control for many critical 
confounding factors supports strongly  the association between sGC use and smaller 
birth size seen in previous smaller or lower quality studies.  
Another form of exposure to GC during pregnancy can be through stress. The HPA 
axis is vital in maintaining homeostasis in the human body (61)(62). GC is one of the 
main effector hormones of the HPA axis and is controlled through the  negative 
feedback mechanism (62). In periods of psychosocial stress, the body reacts by 
releasing GC, therefore, examining the association of stressors during pregnancy on 
the outcome of birth size is another way to infer the link between endogenous GC 
and long term effects on the offspring. Using data from the NFBC1986 (Chapter 6.3), 
social adversity was operationalized using young maternal age, maternal low 
education and maternal single marital status.  These factors are associated with low 
household income and poor social circumstances, as well as each has been linked 
with lower birth weight (199-212). Though previous studies have reported 
associations with social adversity to small birth size, different definitions of social 
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adversity have been used, where, for example, maternal and/or paternal income, 
and occupation have been used, or maternal psychosocial stress measured, making 
it difficult to compare between studies (112;114;184-186). In this thesis, by using 
operationalized social adversity, we have an exposure variable that can be 
reproduced in different populations and which would be more easily available. We 
used for neighbourhood social disparity the definitions of the difference between 
individual individual SES versus the collective SES of the neighbourhood, which also 
is easily available for different populations. Both situations, whether experiencing 
social adversity at the individual level or at the neighbourhood level, were 
significantly associated with smaller birth size. However, it can only be inferred that 
the link is through GC, as neither measured foetal GC nor that of mothers were 
available. GC crosses the placenta less readily that sGC (69-71), but the fact that we 
are still seeing an association of maternal social adversity with birth size, when levels 
of GC are assumed to be most likely lower than sGC, suggests the potency of GC in 
foetal development.  
When discussing DOHaD, it is important to remember that foetal programming is 
multifactorial, and that the mechanisms are complex. Genetic factors are important 
to consider when examining foetal programming. It may be the case that genetic 
vulnerabilities underlie both maternal propensity to stress and reduced birth weight.  
Thus, it is essential to study the interplay between known genetic risk alleles (57) 
and exposure to stress.  In this way, we can begin to disentangle the associations. If 
the results showed, when genetic factors were also considered, the association 
between stress exposure and birth size as non-significant, this would suggest 
genetic vulnerability as the underlying causal factor which “explains off” the impact of 
maternal stress.  In contrast, if the results show additive effects (i.e. the impact of 
social stress is magnified on birth measures in the presence of birth weight lowering 
allele),  would suggest shared pathways by genes and by stress exposure. However, 
the additive effects by genetic variation and  stress do not exclude possibility of 
independent pathways; i.e. metabolic pathways by different mechanisms.   
Variations at/near the CCNL1, LEKR and ADCY5 genes have in recent GWAS 
studies been associated with lower birth weight (57). Using the birth weight-lowering 
alleles, the association between social adversity and birth size was analysed to 
assess any interplay between genetic variance and social adversity (maternal 
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stress). The results showed a magnified affect when both social adversity and at 
least one birth weight lowering allele was present. These results also suggest that 
environmental exposures, in this case, maternal social stress are important for foetal 
development regardless of genetic predisposition and that pre-existing genetic 
vulnerability enhances the impact  of maternal stress on foetal growth.  It is also 
notable that in my analyses I was able to control for large number of potential 
confounding factors.  
Risk of disease later in life, such as T2D, high blood pressure and CVD diseases, 
dyslipidaemia and obesity, often occur in clusters in the same individual, known as 
metabolic syndrome (47). In an attempt to link up the prenatal period with post-natal 
consequences, the association between social adversity during pregnancy and 
metabolic outcomes in adolescents were examined. Social adversity in childhood 
and adult life has previously been examined and linked with development of CVD 
disease later in life (102-104). However, social adversity during pregnancy has 
received little attention with regard to metabolic syndrome in adolescence. The 
results in this thesis showed no association between maternal social adversity and 
metabolic syndrome in adolescents. Even when removing birth weight and 
gestational age, possible mediators for metabolic syndrome, from the model, no 
substantial change  in results was noted. However, a significant association was 
noted with derivatives of metabolic syndrome, specifically in girls, between exposure 
to prenatal maternal social adversity and increased waist circumference, glucose 
levels and lower HDL levels, when used as continuous variables. Of particular 
interest is the significant association between prenatal social adversity and 
apolipoprotein B/A, where apolipoprotein B reflects the sum of specified lipids in the 
body and apolipoprotein A, the sum of HDL subclasses. This apolipoprotein B/A 
ratio, is now increasingly being considered as a more sensitive predictor for 
development of CVD than the individual lipoproteins themselves (284). Though our 
sample size in the NFBC1986 with those exposed to social adversity may be too 
small for a link to be detected for metabolic syndrome, the fact that we were able to 
observe an association between apolipoprotein B/A may suggest that it is a more 
sensitive indicator. Other factors to consider are whether there may be an 
accumulative effect of social adversity across the life span that is not being counted 
here, or maybe social adversity in childhood plays a greater role, that has not been 
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controlled for. Whether this means reduction of social adversity after birth can 
counter the effects of maternal social adversity is unclear. This study shows the need 
for further work.  
In conclusion, the studies reported in this thesis, some of which have already been 
published, add to the knowledge and give weight to the idea that the HPA axis plays 
a role in foetal programing of birth size. From the clinical prospective, with regards to 
sGC treatment administered during pregnancy, though undeniably of significant 
importance for immediate neonatal outcome, suggests that more stringent criteria 
should be used when deciding whether or not a preterm birth is imminent and sGCs 
needed.  Thus, reducing unnecessary exposure.  These results also indicate that 
further research is warranteed. Even in a society such as in Finland, with a widely 
available tax-payer funded healthcare system, social adversity still plays a significant 
role in foetal programing. With the operationalized social adversity variable used 
here makes it easier to identify those that may need extra support during pregnancy.  
 
8.2 Discussion of methodology 
 
Both the MBR and NFBC1986 are ideal resources for analysis of these associations, 
with the large sample size in a defined geographical area, and where the participants 
were followed prospectively. In the NFBC1986, the original data, though very 
detailed, did not contain sufficient information on sGC given for threatened preterm 
birth to mature foetal lung. A meticulous search was done through hospital records to 
identify those pregnant women who had received sGC. The results showed a low 
number of women exposed to sGC for threatened preterm. This followed the trends 
at the time and indicated that though sGC for threatened preterm birth had been 
introduced over a decade earlier, physicians were still cautious about prescribing it in 
the clinical setting. In terms of low number of exposed, available on sGC for 
threatened preterm birth in the NFBC1986 cohort, a matched exposed – unexposed 
analysis was conducted in order to maximise the power of the analyses. Though less 
efficient than a full-cohort analysis, it does give us insight into the use of sGC for 
threatened preterm birth at the time.  Based on the NFBC1986 exploration of sGC 
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used during pregnancy, it was decided to expand the study to include the entire 
annual birth cohorts from Finland, using the high quality data from MBR. 
Detailed information on sGC given during pregnancy in a whole population of a 
country is not often available, making this study on the MBR unique, but replication 
as a population wide study is challenging. In addition, we were unable to take into 
account some confounders, such as time of sGC exposure for threatened preterm 
birth, type and dose of sGC used, and potential residual confounders. Nonetheless, 
the MBR sample size being sufficiently large and well maintained, gives additional 
statistical power and validity to the results, which provides further support to the 
hypothesis. 
When examining the interplay of social adversity and genetic vulnerability on birth 
size (study III); In the attrition analysis, when examining the association of social 
adversity on birth size in both the whole sample and the sub-set used for genetic 
interplay, the results were similar with overlapping confidence intervals. This 
indicated that in this respect the sub-set sufficiently represented the whole 
population. Study III showed an additive effect of gene-environment on birth size, 
which can confidently only be suggestive, as the results are restricted due to 
relatively small sample size for genetic studies (especially to assess interaction), as 
a consequence, further analysis in a larger population sample is suggested. The 
advantage of using social adversity, defined by the composite of low education, 
young maternal age and co-habitation status, is that this information is more readily 
available across different populations, where the definition stays the same, unlike 
SES, where definition may differ in different cohorts, and not always be comparable 
across populations. Analysis of social adversity during pregnancy and association 
with metabolic outcomes at 16 years of age was limited by the confounders available 
during adolescence. 
Causality in epidemiology studies is a complex issue. The Bradford Hill criteria have 
been developed to advance  causal inferences from observational studies but  these 
criteria only can give indication of potential causal association (285).  If we apply 
these criteria on sCG and birth size analyses then the most of the nine criteria are 
full-filled except dose response relationship and specificity in the causes.  Although 
the sample size was large in the MBR, with previous studies suggesting an 
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association of sGC with small birth size, and the presence of  a plausible biological 
pathway, with the effect seen here unlikely to be by chance,  we cannot confidently 
exclude any other explanation for the association.  In the present study, it was not 
possible to conduct more formal causality analyses for example using Mendelian 
randomization approach because no genetic data were available or to apply specific  
causal structural equation models the the longitudinal data analyses (286).  
 
8.3 Discussion with regard to DOHaD 
 
Chapter 1 outlines the DOHaD hypothesis and the association of poor foetal growth 
with increased risk of developing disease later in life (3). The study specific 
discussions can be found in chapter 7. Using data from Finland for this PhD project, 
it was possible to delve further into DOHaD as well as gene-environmental interplay.  
As previous studies have indicated, both undernutrition and sGC exposure during 
pregnancy are associated with smaller birth size in offspring (77;78). Malnutrition can 
result  in a stress response with increased GC secretion resulting in growth 
restriction (78). This links the HPA axis as an important factor in foetal programming.  
In the current studies of this thesis, not only exposure to sGC in utero was 
associated with smaller birth, but social stress both at an individual and 
environmental level associated with smaller birth size. The present work also shows 
an additive effect of gene-environment association with smaller birth size.  The 
metabolic pathways  related to insulin secretion and action are suggested partly to 
explain the genetic link with birth size (57;58;270).  This may also explain why there 
is an additive effect with stress on birth size in the presence of birth size decreasing 
allele, i.e. foetal growth being affected from two separate pathways.  The impact  of 
stressful environment on foetal growth may also be mediated through epigenetic 
mechanisms which affect  IGF-1 gene expression (49)  and may lead to lower IGF 
levels and associated insulin resistance (50).  However,  the research on 
mechanisms explaining the association between genetic variants and birth size  
shows inconsistent results and further research is needed (270).      
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Our results do not show a link between maternal social stress and metabolic 
syndrome at age 16 years. However, an association with more adverse metabolic 
phenotypes, especially for apolipoprotein B/A ratio,  was noted. There are several 
reasons for lack of confirmation of this hypothesis.  Firstly, prenatal exposure to 
maternal social stress may not be sufficient to reprogram foetal metabolism. 
Secondly, our measure of social stress, though potent enough to be significantly 
associated with birth size, may not be correctly operationalized for long term 
metabolic outcomes. Thirdly, young age and relatively  small sample size to detect 
an association with metabolic syndrome.   Fourthly, the factors within the postnatal 
and childhood periods may have countered potential negative effect of prenatal 
social adversity. 
 
8.4 Strengths and limitations 
 
Strengths of this study: This thesis consists of the largest study published to date 
including several annual birth cohorts from entire country to examine the association 
of sGC on birth size in the MBR. Finland is a largely homogenous population with 
small social differences relative to other countries, with an extensive high quality tax-
payer funded healthcare system and high uptake of healthcare services by pregnant 
women. The large sample size and availability of key variables enabled control of a 
number of confounders. Data was collected directly after birth, using standardized 
methods, reducing bias due to recall or differences in measurement methods. The 
NFBC1986 is prospectively followed up from early pregnancy, with a detailed rich 
database on socio-demographic and disease related factors and genetic information. 
The systematic re-examination of the hospital records to search for sGC in the 
NFBC1986 cohort gave insight into practices at the time.  
Limitations of this study: In the systematic review, a meta-analysis would have been 
the preferred method of examining the association of sGC exposure during 
pregnancy and birth size. However, due to methodological differences between the 
studies this was not possible. Though sGC were introduced in Finland more than 20 
years ago for routine use to stimulate foetal lung maturation in threatened preterm 
birth, national regulations on dose and type were not introduced until 2011. 
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Therefore, detailed information on the type and time sGC was given for threatened 
preterm birth in the MBR was missing, limiting better interpretation of results. The 
time and dose of sGC given for threatened preterm birth would have allowed us  to 
analyse whether a recovery period or wearing off effect was present. Information on 
GC levels in the foetus and/or pregnant mothers would have added to the 
interpretation of the results, which was not available at the time. In the main 
NFBC1986 cohort, there were no available data on sGC given for preterm birth, and 
after a re-examination of hospital records, only a small number were found. A 
matched exposed-unexposed cohort design  was required examining the association 
of sGC during pregnancy on birth size. In the NFBC1986, when examining the gene-
environment interplay, especially interaction between genetic variant and social 
adversity, sample size was relatively small. The study needs further exploration  in 
other larger samples for interaction and to verify if the additive effect of genetic 
variant on the association between social adversity and birth size will replicate.  The 
Finnish population being largely homogenous, is both advantage, reducing 
confounding by ethnicity, and disadvantage not allowing to explore the differences by 
ethnicity.  
 
8.5 Suggestions for further work 
 
The analysis of sGC on birth size in the MBR should be replicated to include timing 
of exposure as well as type and dose of sGC from future datasets. This would 
enable the understanding of whether there is a possibility for the foetus to recover 
from any effect of possible foetal programming. Likewise, in a larger sample, 
possible gene-environment interaction should also be studied. The interplay between 
genetic variation and environment in relation to birth size merits further work, 
especially including objective measures of maternal cortisol levels. Interaction of 
maternal and adolescent social status needs to be examined in regard to metabolic 
phenotypes.  
Detailed analysis of the association of sGC and stress on metabolic outcomes at age 
16 years needs to be further explored to advance our understanding of the 
mechanisms  in the foetal origins of disease.  
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Appendix 1 Examining collinearity between social adversity, its composites and birth outcomes 
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Gestational age 
-0.03
 a
 
0.008 
                
Birth weight 
-0.07
 a
 
<0.0001 
0.48
b 
<0.0001 
               
Head circumference 
-0.05
 a
 
<0.0001 
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 b
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0.68
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-0.07
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Appendix 2  Characteristics of women and births exposed to sGC during pregnancy 
 
cause 
sex 
Placenta 
weight 
Placenta 
size (cm) 
Type of GC 
Dose 
(mg) 
Time to 
birth for 
GC 
exposure 
Birth 
weight 
Birth 
length 
Head 
circumf
erence 
Ponder
al index 
Gestational 
week 
Smo
king 
Maternal 
pre-
pregnancy 
BMI 
par
ity 
Social 
adversit
y 
hospitalis
ation 
ADHD 
Met 
synd 
1.  
Partus 
praematurus 
imminens 
M 
820 342 
DEX 
(oradexon) 
-- 0 3700 50 35 2.96 36 2 22.7 1 1 yes No No 
2.  
Partus 
praematurus 
imminens 
grav. 
M 
630 289 
DEX 
(oradexon) 
1x10, 
1x5 
43 3030 48 34 2.74 38 . 18.03 1 No . . No 
3.  
Partus 
praematurus 
imminens h 
31+5 
M 
710 384 
DEX 
(oradexon) 
1x15 
1x5 
43 4260 52 40 3.03 38 1 21.47 1 1 yes No No 
4.  
Hypertonia 
gravidarum. 
SGA foetus. 
Partus cum 
ablatio 
placentae 
partialis. 
Prae-
eclampsia 
levis 
F 
290 238 
DEX 
(oradexon) 
1x10 
1x5 
14 1910 45 32 2.10 36 2 19.33 5 1 yes 3 No 
5.  
Albuminuria 
gravidarum h 
29 
Partus sine 
complicate 
Albuminuria 
chornica 
gravidarum h 
31 
F 
600 224 
DEX  
(oradexon) 
1x10 
1x5 
32 3360 50 35 2.69 38 2 18.49 0 0 yes No No 
6.  
Insufficientia 
cervix uteri 
Incompatibilita
s systematis 
Rh 
Partus 
normalis 
M 
840 351 
DEX 
(oradexon) 
1x8 
1x12 
14 3090 49 34 2.62 36 2 17.65 1 0 . 2 No 
7.  
------ 
M 
500 288 DEX 
(oradexon) 
1x15 
1x5 
36 2800 48 34 2.53 36 1 18.31 1 1 1 0 . 
8.  
Partus 
praematurus 
imminens 
grav. 
M 
400 272 
DEX 
(oradexon) 
1x10 
1x5 
34 2190 44 33 2.57 36 2 18.67 0 0 1 5 . 
9.  
Contractions 
praematurales 
gravid H 30 
Partus 
praematurus 
F 
800 306 
DEX 
(oradexon) 
1x15 39 3980 50 37 3.18 39 2 23.88 0 2 . 2 1 
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cause 
sex 
Placenta 
weight 
Placenta 
size (cm) 
Type of GC 
Dose 
(mg) 
Time to 
birth for 
GC 
exposure 
Birth 
weight 
Birth 
length 
Head 
circumf
erence 
Ponder
al index 
Gestational 
week 
Smo
king 
Maternal 
pre-
pregnancy 
BMI 
par
ity 
Social 
adversit
y 
hospitalis
ation 
ADHD 
Met 
synd 
imminens 
10.  
Partus 
praematurus h 
31+6 
M 
430 256 
DEX 
(oradexon) 
1x10 
1x5 
4 1910 44 30 2.24 31 1 18.87 1 0 1 0 . 
11.  
Partus 
praematurus 
imminens 
grav. H 34+0 
F 
700 272 
DEX 
(oradexon) 
1x10 
1x5 
45 3260 48 34 2.95 38 1 27.68 0 0 1 0 No 
12.  
Partus cum 
haemorrhagia 
gravidarum h 
33 et 
contractions 
praematurales 
F 
800 228 
DEX 12mg 0 2370 45 30 2.6 32 1 21.88 2 0 1 0 No 
13.  
Partus 
prematurus 
immenens. 
Appendicitis 
acuta 
perforata 
F 
600 374 
DEX 12mg 53 3160 49 35 2.69 31 1 18.56 1 0 . 0 No 
14.  
Partus 
praematurus 
imminens 
M 
750 374 
DEX 
(oradexon) 
1x15 38 4040 51 36 3.05 39 1 20.94 0 0 . 3 No 
15.  
Partus 
praematurus 
imminens grav 
h 36+2. 
Praesentatio 
clunium 
primiparae 
F 
750 368 
DEX 
(oradexon) 
1x15 
1x5 
58 2910 53 36 2.63 40 1 20.82 0 0 . 0 No 
16.  
LED 
Gravidatas h 
26 
F 
. . 
PRED 150mg 14 670 . . . 28 1 20.08 0 . 1 . . 
17.  
Partus 
praematurus 
imminens h 
33-34 
M 
400 256 BETAM 
(Celestone 
chronodose
) 
-- 44 2620 48 34 2.37 39 1 18.13 0 1 . 4 No 
18.  
Partus 
praematurus 
imminens 
M 
500 288 BETAM 
(Celestone 
chronodose
) 
2ml 68 3320 51 35 2.50 39 1 20.43 0 1 . 1 . 
19.  
Partus cum 
tetentio 
placentae 
totalis 
M 
. . 
DEX 12mg 4 990 . . . 28 1 26.67 2 . 1 . . 
20.  
Partus 
praematurus 
cum 
praesentatio 
F 
300 238 
DEX 12mg 8 1050 35 . 2.49 27 2 26.04 2 0 1 0 No 
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cause 
sex 
Placenta 
weight 
Placenta 
size (cm) 
Type of GC 
Dose 
(mg) 
Time to 
birth for 
GC 
exposure 
Birth 
weight 
Birth 
length 
Head 
circumf
erence 
Ponder
al index 
Gestational 
week 
Smo
king 
Maternal 
pre-
pregnancy 
BMI 
par
ity 
Social 
adversit
y 
hospitalis
ation 
ADHD 
Met 
synd 
pedis. 
Section 
caesarea 
isthmica 
transversa 
21.  
Insuff. Cervicis 
uteri h 29+5 M 
410 240 DEX 
(oradexon) 
1x10 
1x5 
56 3010 50 36 2.41 36 2 20.83 2 1 . 1 No 
22.  
Partus 
praematurus 
imminens 
Insufficientiac
ervicis   
M 
500 234 
DEX 
(oradexon) 
1x10 
3x5 
64 3330 49 37 2.83 39 2 22.15 0 0 . 2 No 
23.  
Graviditas 32, 
LED F 
580 420 
PRED 6mg 0 3850 51 34 3.90 40 2 18.75 0 0 . . . 
24.  
Partus 
praematurus 
imminens h 31 
Hypertensio 
arterialis 
F 
400 324 
DEX 
(oradexon) 
1x10 
1x5 
67 3580 49 35 3.04 39 1 19.57 1 0 . 0 No 
25.  
Partus 
praematurus 
imminens h 
32, Infectio 
viarum urinae 
M 
750 324 
DEX 
(oradexon) 
1x10 
1x5 
52 4550 53 38 3.06 39 1 22.76 3 0 . 2 . 
26.  
Partus cum 
effluxus 
ligam.amni 
pretemp. Et 
ablatio 
placentae 
partialis. 
Endometritis 
post partum. 
Sectio 
caesarea 
isthmica 
transversa. 
Oedema 
gravidarum 
F 
460 300 
DEX 
(oradexon) 
1x10 6 1800 42 30 2.43 32 2. 25.40 2 1 1 0 . 
27.  
Partus 
praematurus 
imminens 28-
34 
F 
670 437 
DEX 
(oradexon) 
1x10 
3x5 
74 4300 54 35 2.73 39 1 22.15 3 0 . 0 No 
28.  
hypertension 
M 
. . 
PRED 10mg 0 690 34 22 1.76 26 1 . 13 . . . . 
29.  
Partus 
praematurus 
imminens. 
Partus sine 
M 
550 288 
DEX 12mg 0 2680 48 36 2.42 32 1 18.29 9 0 1 0 No 
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cause 
sex 
Placenta 
weight 
Placenta 
size (cm) 
Type of GC 
Dose 
(mg) 
Time to 
birth for 
GC 
exposure 
Birth 
weight 
Birth 
length 
Head 
circumf
erence 
Ponder
al index 
Gestational 
week 
Smo
king 
Maternal 
pre-
pregnancy 
BMI 
par
ity 
Social 
adversit
y 
hospitalis
ation 
ADHD 
Met 
synd 
complicantion
e 
30.  
Pro 
sterilisatione. 
Effluxus 
liquoris amnii 
pretemporariu
s gravidatas h 
29, 
presentation 
clunium, 
amnionitis 
incipiens 
F 
610 360 
DEX 
1x12m
g 
1 1410 40 28 2.20 28 2 20.03 1 2 1 0 No 
31.  
Status post 
operatio a.m. 
Jones-Jones. 
Sectio antea 
n:o 1. 
Sectio 
caesarea 
isthmica 
transversa 
7461. 
Insufficcientia 
cervicis uteri. 
Partus 
praematurus 
imminens. 
F 
700 360 
DEX 
(oradexon) 
1x10 
1x5 
28 3260 48 36 2.95 38 1 21.09 1 0 . 0 No 
32.  
Contractions 
et 
haemorrhagia 
h.31 
Partus sine 
compicatus 
M 
540 255 
DEX 1x12 47 2710 49 35 2.30 37 1 21.45 2 1 1 0 No 
33.  
Partus 
praematurus 
imminens 
F 
460 240 
DEX 
(oradexon) 
1x15 
1x5 
38 2500 49 33 2.41 37 1 27.29 1 0 . 0 No 
34.  
Partus 
praematurus 
cum 
praesentation 
blunium 
Polydydramni
on h28 
Gravidatas 
h.28 cum 
presentation 
clunium, 
F 
. . 
DEX 1x12 2 920 . . . 27 1 . 0 . 1 . . 
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cause 
sex 
Placenta 
weight 
Placenta 
size (cm) 
Type of GC 
Dose 
(mg) 
Time to 
birth for 
GC 
exposure 
Birth 
weight 
Birth 
length 
Head 
circumf
erence 
Ponder
al index 
Gestational 
week 
Smo
king 
Maternal 
pre-
pregnancy 
BMI 
par
ity 
Social 
adversit
y 
hospitalis
ation 
ADHD 
Met 
synd 
polyhydramnio
n, anomalia 
gravis fetus 
35.  
Hamangionma 
placentae 
Polyhydramni
on cum gravid 
F 
1170 345 
DEX 1x12 0 2610 43 32 3.29 32 1 19.71 1 0 1 0 No 
36.  
Partus 
praematurus 
imminens 
M 
650 270 
DEX 
(oradexon) 
1x15 
1x5 
41 3870 49 36 3.29 38 1 22.96 1 0 . 1 No 
37.  
Partus 
praematurus 
imminens h34 
M 
630 306 
DEX 1x12 45 3790 51 33 2.86 38 1 22.06 1 0 . 4 . 
38.  
Partus 
praematurus 
imminens grav 
h 27-29 
F 
600 361 
DEX 1x12 72 3150 49 35 2.68 37 1 20.45 1 0 . 0 No 
39.  
Partus 
praematurus 
imminens. 
Partus cum 
inertia uteri 
(partus 
protractus 
secundarius) 
M 
500 195 
DEX 
(oradexon) 
1x15 
1x5 
29 2480 45 33 2.72 35 . 24.38 1 0 1 0 No 
40.  
Partus 
praematurus 
imminens h 
34. 
Sympyseolysi
s gravidarum 
h 36 
F 
670 255 
BETAM 
(Celestone 
chr) 
1x12 45 3450 49 35 2.93 39 1 18.37 2 1 . 1 . 
41.  
St.Post 
oper.manches
ter. 
Partus 
praematurus 
imminens. 
Placenta 
praevia 
margninalis. 
M 
570 320 
DEX 1x12 44 2850 49 33 2.42 37 1 23.15 3 1 1 0 No 
42.  
Parts cum 
praesentatio 
cllunium h 32 
Section 
caesarea 
ithmica 
transversa 
M 
580 315 
hydrocor 1x500 0 2170 45 . 2.38 32 1 24.34 2 0 1 2 No 
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cause 
sex 
Placenta 
weight 
Placenta 
size (cm) 
Type of GC 
Dose 
(mg) 
Time to 
birth for 
GC 
exposure 
Birth 
weight 
Birth 
length 
Head 
circumf
erence 
Ponder
al index 
Gestational 
week 
Smo
king 
Maternal 
pre-
pregnancy 
BMI 
par
ity 
Social 
adversit
y 
hospitalis
ation 
ADHD 
Met 
synd 
43.  
Partus 
praematurus 
imminens 
grav. H 34+0. 
Contractiones 
praematurales 
h 29 
F 
610 340 
DEX 
(oradexon) 
1x10 
1x5 
37 3320 50 35 2.67 38 1 18.29 2 1 . 0 . 
44.  
Infectio resp 
superior 
matris. 
Partu sine 
complication h 
33+2 
F 
570 221 
DEX 1x12 2 2140 43 . 2.69 33 1 19.61 1 0 1 0 No 
45.  
----- 
F 
850 350 BETAM 
(celeston) 
1x12 32 3840 52 37 2.73 38 2 19.14 1 0 . 0 No 
46.  
Partus 
praemat 
imminens 
F 
560 306 
BETAM 
(celeston) 
---- 38 3360 50 35 2.69 39 1 19.49 0 0 . . . 
47.  
Section 
caesarea 
isthmica 
transversa. 
Teratoma foeti 
M 
. . 
DEX 1x12 8 3300 . . . 32 1 20.55 0 
. 
 
1 . . 
48.  
Partus sine 
complication 
h. 35+3 
Partus 
praematurus 
imminens 
grav. H.29-35 
M 
570 306 
DEX 1x12 45 2740 48 33 2.48 35 1 22.57 1 0 1 1 No 
49.  
Chorionamnio
nisits 
suspecta. 
Effluxus 
liquoris amnii 
grav. H. 30-
31. 
Section 
casesarea 
isthmica 
transversa. 
Uterus 
arcuatus. 
M 
430 143 
DEX 1x12 6 1660 40 29 2.59 30 2 23.80 1 0 1 4 No 
50.  
Contractiones 
praematurales
, Small for 
date.. 
M 
. . 
DEX 
(oradexon) 
1x15 35 2550 44 34 2.99 40 2 23.05 1 . . . . 
51.  
Partus 
praematurus F 
670 330 DEX 
(oradexon) 
1x5 
1x15 
34 2800 48 31 2.53 37 1 19.63 0 0 1 1 No 
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cause 
sex 
Placenta 
weight 
Placenta 
size (cm) 
Type of GC 
Dose 
(mg) 
Time to 
birth for 
GC 
exposure 
Birth 
weight 
Birth 
length 
Head 
circumf
erence 
Ponder
al index 
Gestational 
week 
Smo
king 
Maternal 
pre-
pregnancy 
BMI 
par
ity 
Social 
adversit
y 
hospitalis
ation 
ADHD 
Met 
synd 
imminens h 
31-36. 
Extractio 
vacuum. 
Partus cum 
resistentia 
mollae. 
52.  
Partus cum 
asphyxia 
foetus 
imminens. 
Uterus 
myomatosus. 
Praesentaio 
clunium 
primiparae. 
Sectio 
caesarea 
isthmica 
transversa. 
M 
380 240 
DEX 
(oradexon) 
1x10 
2x5 
 
31 2650 47 34 2.55 37 1 20.66 0 0 1 0 No 
53.  
Partus 
praematurus 
imminens grav 
h 34 + 6 
F 
660 360 
DEX 
(oradexon) 
1x10 
1x5 
14 3150 48 35 2.84 36 1 19.49 1 0 . 0 No 
54.  
Graviditas h 
31. 
Hypertensio 
arterialis. 
Insufficientia 
placentae. 
Pro obs 
funiculi 
umbilicalis. 
Hypertonia 
arterialis 
gravidarum. 
Excisio naevi 
colli 9034. 
Naevus 
vulgaris colli l. 
Sin.. 
Partus cum 
insufficientia 
placentae et 
suspicio 
complicatio 
funiculi 
umbilicalis. 
Sectio 
M 
200 150 
DEX 
(oradexon) 
1x15 0 1810 44 32 2.12 34 2 23.80 2 0 1 0 No 
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cause 
sex 
Placenta 
weight 
Placenta 
size (cm) 
Type of GC 
Dose 
(mg) 
Time to 
birth for 
GC 
exposure 
Birth 
weight 
Birth 
length 
Head 
circumf
erence 
Ponder
al index 
Gestational 
week 
Smo
king 
Maternal 
pre-
pregnancy 
BMI 
par
ity 
Social 
adversit
y 
hospitalis
ation 
ADHD 
Met 
synd 
caesarea isth 
trans. 
55.  
Partus 
praematurus 
imminens h 34 
+ 2 
F 
550 270 
DEX 
(oradexon) 
1x10 
1x5 
32 3150 49 34 2.68 38 1 20.89 2 0 . 1 No 
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Appendix 3 Examination of the association of social adversity and possible confounders of birth size 
 Gestational age Maternal age BMI Smoking Alcohol consumption parity 
 n β (95%CI) n β (95%CI) n β (95%CI) No Yes β (95%CI) No Yes β (95%CI) n β (95%CI) 
Boys               
Birth size               
               
Birth weight 4679 162.89 (154.31, 
171.47) 
P=<0.0001 
4684 6.63(3.94,9.31) 
P=<0.0001 
4572 24.55(20.26,28.84) 
P=<0.0001 
3597 1046 -156.67(-192.06,-
121.27) 
P=<0.0001 
3905 537 -67.00(-113.77, -20.23) 
P=0.005 
4660 34.03(25.73, 
42.32) 
P=<0.0001 
Birth length 4647 0.72(0.69, 0.76) 
P=<0.0001 
4652 0.02(0.006,0.03) 
P=0.003 
4540 0.06(0.04,0.08) 
P=<0.0001 
3571 1040 -0.64(-0.79, -0.49) 
P=<0.0001 
3879 533 -0.29(-0.48, -0.09) 
P=0.004 
4628 0.06(0.03, 0.09) 
P=0.0007 
Head 
circumference 
4601 0.40(0.37, 0.43) 
P=<0.0001 
4606 0.02(0.01,0.03) 
P=<0.0001 
4494 0.06(0.05,0.07) 
P=<0.0001 
3531 1034 -0.39(-0.49, -0.29) 
P=<0.0001 
3844 526 -0.14(-0.28, -0.01) 
P=0.03 
4582 0.08(0.06, 0.10) 
P=<0.0001 
Ponderal index 4647 0.02(0.01, 0.02) 
P=<0.0001 
4652 0.002(0.001,0.004) 
P=<0.0001 
4540 0.009(0.007,0.01) 
P=<0.0001 
3571 1040 -0.02(-0.03, -0.003) 
P=0.02 
3879 533 -0.008(-0.03,0.02) 
P=0.45 
4628 0.02(0.01, 0.02) 
P=<0.0001 
               
Girls               
Birth weight 4451 164.99(156.63, 
173.34) 
P=<0.0001 
4451 9.41(6.68, 12.014) 
P=<0.0001 
4334 25.56(21.26,29.88) 
P=<0.0001 
 
3475 948 -197(-233.53,-160.78) 
P=<0.0001 
3717 532 -79.72(-126.26, -33.18) 
P=0.0008 
4433 27.59(19.47, 
35.72) 
P=<0.0001 
Birth length 4411 0.71(0.67,0.74) 
P=<0.0001 
4411 0.03(0.01,0.04) 
P=<0.0001 
4297 0.07(0.05,0.09) 
P=<0.0001 
3451 934 -0.81(-0.95, -0.66) 
P=<0.0001 
3687 527 -0.24(-0.43,-0.05) 
P=0.01 
4394 0.05(0.02, 0.09) 
p=0.002  
Head 
circumference 
4348 0.35(0.33,0.38) 
P<0.0001 
4348 0.03(0.02, 0.04) 
P=<0.0001 
4236 0.06(0.05,0.07) 
P=<0.0001 
3402 922 -0.31(-0.41,-0.21) 
P=<0.0001 
3627 525 -0.10(-0.23,0.03) 
P=0.13 
4332 0.07(0.04,0.09) 
P=<0.0001 
Ponderal index 4411 0.02(0.02,0.03) 
P=<0.0001 
4411 0.003(0.001,0.004) 
P=<0.0001 
4297 0.008(0.006,0.01) 
P=<0.0001 
3451 934 -0.03(-0.04, -0.009) 
P=0.003 
3687 527 -0.03(-0.05,-0.004) 
P=0.02 
4394 0.01(0.008, 0.02) 
P=<0.0001 
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Appendix 4 Association between social adversity and birth weight, examining the confounders 
  Male     Female   
 
Birth weight 
β (95%CI) 
Birth length 
β (95%CI) 
Head 
circumference 
β (95%CI) 
Ponderal index 
β (95%CI) 
 
Birth weight 
β (95%CI) 
Birth length 
β (95%CI) 
Head 
circumference 
β (95%CI) 
Ponderal index 
β (95%CI) 
Model1 -72.17                     
(-105.19, -39.16) 
p=<0.0001 
-0.27                          
(-0.41, -0.14) 
p=<0.0001 
-0.19                      
(-0.29, -0.10) 
p=<0.0001 
-0.01                          
(-0.03, 0.002)   
p=0.10 
 -79.47                    (-
112.90, -46.03) 
p=<0.0001 
-0.36                
(-0.49, -0.22) 
p=<0.0001 
-0.14                   
(-0.23 ,-0.05) 
p=0.003 
-0.01                
(-0.03, 0.004) 
p=0.15 
Model2 -55.43                      
(-84.45, -26.41) 
p=0.0002 
-0.20                        
(-0.32, -0.08) 
p=0.001 
-0.15                   
(-0.23, -0.06) 
p=0.0009 
-0.01                                  
(-0.03, 0.004)           
p=0.15  
-62.69                   (-
91.66, -33.71) 
p=<0.0001 
-0.28              
(-0.39, -0.16) 
p=<0.0001 
-0.09                 
(-0.18, -0.008) 
p=0.03 
-0.009              
(-0.02, 0.007) 
p=0.26 
Model3 -64.15                      
(-92.92, -35.37) 
p=<0.0001 
-0.21                    
(-0.33, -0.09) 
p=0.0004 
-0.14                   
(-0.23, -0.06) 
p=0.001 
-0.02                              
(-0.03, -0.0004) 
p=0.05 
-73.70                   (-
102.46, -44.94) 
p=<0.0001 
-0.30              
(-0.42, -0.18) 
p=<0.0001 
-0.10                           
(-0.18, -0.01)  
p=0.03 
-0.01                
(-0.03, 0.002) 
p=0.10 
Model4 -41.34                       
(-70.47, -12.21) 
p=0.005 
-0.012                      
(-0.24, 0.003) 
p=0.06 
-0.10                         
(-0.18, -0.007) 
p=0.03 
-0.02                               
(-0.03, 0.002)          
p=0.09 
-41.99                    (-
71.25, -12.74) 
p=0.005 
-0.17               
(-0.29 ,-0.05) 
p=0.007 
-0.06                     
(-0.15, 0.03) 
p=0.20 
-0.009               
(-0.03, 0.007) 
p=0.28 
Model5 -41.83                        
(-71.49, -12.17) 
p=0.006 
-0.12                         
(-0.24, 0.003) 
p=0.06 
-0.10                    
(-0.19, -0.01) 
p=0.02 
-0.01                         
(-0.03, 0.002)           
p=0.09 
 -45.16                   
(74.81, -15.52) 
p=0.003 
-0.17              
(-0.29, -0.05) 
p=0.006 
-0.07               
(-0.16, 0.02) 
p=0.14 
-0.01                
(-0.03, 0.006) 
p=0.21 
Model6 -37.95                        
(-67.30, -8.60) 
p=0.01 
-0.11                     
(-0.23, 0.01) 
p=0.07 
-0.11                   
(-0.19, -0.02) 
p=0.02 
-0.01                                   
(-0.03, 0.004)            
p=0.13 
-41.91                      
(-71.29, -12.53) 
p=0.005 
-0.17              
(-0.29, -0.04) 
p=0.008 
-0.07               
(-0.15, 0.02) 
p=0.15 
-0.009                   
(-0.03, 0.008) 
p=0.30 
Model7 -81.47                    
(-114, -48.50) 
p=<0.0001 
-0.29                         
(-0.43, -0.15) 
p=<0.0001 
-0.21                    
(-0.31, -0.12) 
p=<0.0001 
-0.02                               
(-0.03, -0.002) 
p=0.03 
-90.89                        
(-124.27, -57.52) 
p=<0.0001 
-0.38                 
(-0.52, -0.24) 
p=<0.0001 
-0.17               
(-0.26, -0.07) 
p=0.0004 
-0.02                
(-0.03, 0.00005) 
p=0.05 
Model8 -57.88                   
(91.32, -24.44) 
p=0.0007 
-0.19                        
(-0.33, -0.05) 
p=0.008 
-0.15                    
(-0.25, -0.06) 
p=0.002 
-0.01                                
(-0.03, 0.0006) 
p=0.06 
-57.10               
(91.03, 23.16) 
p=0.001 
-0.24                
(-0.38, -0.10) 
p=0.0008 
-0.11                
(-0.21, -0.02) 
p=0.02 
-0.01                 
(-0.03, 0.005) 
p=0.18 
Model 9 -60.68                    
(-94.73, -26.63) 
-0.20                   
(-0.34, -0.06) 
-0.17                   
(-0.26, -0.07) 
-0.02                            
(-0.03, -0.00008) 
-59.66                   (-
94.21, -25.12) 
-0.24              
(-0.38, -0.10) 
-0.12               
(-0.22, -0.02) 
-0.01                
(-0.03, 0.004) 
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p=0.0005 p=0.005 p=0.0007 p=0.05 p=0.0007 p=0.0009 p=0.01 p=0.14 
Model10 -57.70                    
(-91.55, -23.84) 
p=0.0008 
-0.20                   
(-0.34, -0.06) 
p=0.006 
-0.16                    
(-0.26, -0.06) 
p=0.001 
-0.01                            
(-0.03, 0.002)             
p=0.08 
-56.84                   (-
91.21, -22.46) 
p=0.001 
-0.24               
(-0.38, -0.10) 
p=0.001 
-0.11                 
(-0.21, -0.02) 
p=0.02 
-0.01                
(-0.03, 0.006) 
p=0.20 
Model11 -46.29                      
(-79.79, -12.80) 
p=0.007 
-0.16                   
(-0.30, -0.03) 
p=0.02 
-0.13                   
(-0.22, -0.03) 
p=0.009 
-0.01                              
(-0.03, 0.005)             
p=0.21 
-42.25                   
(76.18, -8.32) 
p=0.02 
-0.21              
(-0.34, -0.07) 
p=0.003 
-0.08                     
(-0.17, 0.02) 
p=0.11 
-0.006               
(-0.02, 0.01) 
p=0.44 
Model12 -48.87                    
(-83.02, -14.72) 
p=0.005 
-0.17                    
(-0.31, -0.03) 
p=0.02 
-0.14                      
(-0.24, -0.04) 
p=0.005 
-0.01                          
(-0.03, 0.005)          
p=0.17 
 -42.02                       
(-76.57, -7.47) 
p=0.02 
-0.20              
(-0.34, -0.06) 
p=0.005 
-0.08               
(-0.17, 0.02) 
p=0.12 
-0.007                      
(-0.02, 0.009) 
p=0.39 
Model13 -45.97                    
(-79.82, -12.12) 
p=0.008 
-0.17                   
(-0.31, -0.03) 
p=0.02 
-0.13                   
(-0.23, -0.04) 
p=0.007 
-0.009                              
(-0.02, 0.006)           
p=0.23 
-40.52                   (-
74.82, -6.22) p=0.02 
-0.20              
(-0.33, -0.06) 
p=0.006 
-0.07                    
(-0.17, 0.02) 
p=0.13 
-0.006               
(-0.02, 0.01) 
p=0.044 
 Model14 -71.75                    
(-105.44, -38.06) 
p=<0.0001 
-0.26                       
(-0.40, -0.13) 
p=0.0002 
-0.20                   
(-0.29, -0.10) 
p=<0.0001 
-0.01                         
(-0.03, 0.001)          
p=0.07 
 -76.37                   (-
110.38, -42.35 ) 
p=<0.0001 
-0.34              
(-0.48, -0.21) 
p=<0.0001 
-0.13                    
(-0.22, -0.03) 
p=0.007 
-0.01                
(-0.03, 0.004) 
p=0.15 
Model15 -67.05                     
(-100.44, -33.66) 
p=<0.0001 
-0.26                     
(-0.39, -0.12) 
p=0.0003 
-0.19                   
(-0.28, -0.09) 
p=<0.0001 
-0.01                            
(-0.03, 0.003)   
p=0.12 
-73.14                    (-
106.89, -39.39) 
p=<0.0001 
-0.34              
(-0.48, -0.20) 
p=<0.0001 
-0.12               
(-0.21, -0.03) 
p=0.01 
-0.01                 
(-0.03, 0.006) 
p=0.22  
Model16 -66.96                        
(-99.72, -34.20) 
p=<0.0001 
-0.26                    
(-0.40, -0.13) 
p=0.0002 
-0.18                   
(-0.27, -0.09) 
p=0.0002 
-0.01                                   
(-0.02, 0.005)          
p=0.18 
-74.55                    (-
107.75, -41.35) 
p=<0.0001 
-0.35                
(-0.49, -0.21) 
p=<0.0001 
-0.13                   
(-0.22, -0.03) 
p=0.007 
-0.009                
(-0.03, 0.007) 
p=0.25 
Model 1= Social adversity 
Model 2= social adversity +gestational age 
Model3= social adversity +gestational age + BMI 
Model4= social adversity +gestational age BMI +smoking 
Model5= social adversity +gestational age + +BMI +smoking +alcohol consumption 
Model6= social adversity +gestational age + +BMI +smoking +alcohol consumption +parity 
Model7= social adversity +BMI 
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Model8= social adversity + BMI +smoking 
Model9= social adversity + BMI +smoking +alcohol consumption 
Model10= social adversity + BMI +smoking +alcohol consumption +parity 
Model11= social adversity + smoking 
Model12= social adversity + smoking +alcohol consumption 
Model13= social adversity + smoking +alcohol consumption +parity 
Model14= social adversity + alcohol consumption 
Model15= social adversity + alcohol consumption +parity 
Model16= social adversity + parity 
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Appendix 5 Association between maternal age below 20years and birth weight, examining the confounders 
  Male     Female   
 
Birth weight 
β (95%CI) 
Birth length 
β (95%CI) 
Head 
circumference 
β (95%CI) 
Ponderal 
index 
β (95%CI) 
 
Birth weight 
β (95%CI) 
Birth length 
β (95%CI) 
Head 
circumference 
β (95%CI) 
Ponderal index 
β (95%CI) 
Model1 -155.55                     
(-230.01, -81.10) 
p=<0.0001 
-0.45                         
(-0.76, -0.14) 
p=0.004 
-0.57                     
(-0.79 ,-0.36) 
p=<0.0001 
-0.05                   
(-0.08, -0.01) 
p=0.008 
 -164.41                       
(-236.73, -92.09) 
p=<0.0001 
-0.53               
(-0.83, -0.24) 
p=0.0004 
-0.26                 
(-0.46, -0.07) 
p=0.009 
-0.05                 
(-0.08, -0.01) 
p=0.009 
Model2 -158.99                   
(-224.59, -93.40) 
p=<0.0001 
-0.48                    
(-0.74, -0.21) 
p=0.0005 
-0.57                    
(-0.77, -0.38) 
p=<0.0001 
-0.04                  
(-0.08, -0.01) 
p=0.01 
 -140.61                 
(-203.17, -78.05) 
p=<0.0001 
-0.41                
(-0.66, -0.15) 
p=0.002 
-0.19                
(-0.38, 0008) 
p=0.04 
-0.04                 
(-0.08, -0.008) 
p=0.02 
Model3 -129.33                  
(-195.55, -63.12) 
p=0.0001 
-0.41                      
(-0.69, -0.14) 
p=0.003 
-0.37                   
(-0.58, -0.16) 
p=0.0006 
-0.03                       
(-0.07, 0.001) 
p=0.06 
-114.71                      
(-177.91, -51.51) 
p=0.0004 
-0.31                   
(-0.57, -0.05) 
p=0.02 
0.10                   
(-0.10, 0.30) 
p=0.34 
-0.04                  
(-0.07, -0.005) 
p=0.03 
Model4 -102.44                     
(-168.71, -36.17) 
p=0.003 
-0.30                          
(-0.58, -0.03) 
p=0.03 
-0.35                    
(-0.56, -0.14) 
p=0.001  
-0.03                  
(-0.06, 0.005) 
p=0.10 
 -69.80                   
(-132.78, -6.63) 
p=0.03 
-0.12               
(-0.38, 0.14) 
p=0.36 
0.13                    
(-0.07, 0.33) 
p=0.20 
-0.03                   
(-0.07, 0.002) 
p=0.07 
Model5 -96.87                       
(-164.24, 29.49) 
p=0.005 
-0.30                       
(-0.57, -0.02) 
p=0.04 
-0.32                    
(-0.54, -0.11) 
p=0.003 
-0.03                       
(-0.06, 0.008) 
p=0.14 
-68.90                   
(-133.0, -4.80) 
p=0.04 
-0.14                       
(-0.40, 0.13) 
p=0.32 
0.15                    
(-0.05, 0.36) 
p=0.14 
-0.03                   
(-0.07, 0.006) 
p=0.10 
Model6 -17.85                      
(-86.39, 50.70) 
p=0.61 
-0.17                    
(-0.45, 0.12) 
p=0.25 
-0.22                    
(-0.44, -0.01) 
p=0.04 
0.01                    
(-0.02, 0.05) 
p=0.46 
 0.74                        
(-64.64, 66.11) 
p=0.98 
-0.03                     
(-0.30, 0.24) 
p=0.83 
0.23                     
(0.02, 0.44) 
p=0.03 
0.009                    
(-0.03, 0.04) 
p=0.64 
Model7 128.60                      
(-204.56, -52.64) 
p=0.0009 
-0.41                    
(-0.73, -0.09) 
p=0.01 
-0.51                   
(-0.72, -0.29) 
p=<0.0001 
-0.03                        
(-0.07, 0.002) 
p=0.06 
-135.70                      
(-209.09, -62.31) 
p=0.0003 
-0.42                    
(-0.72, -0.12) 
p=0.007 
-0.21                 
(-0.42,-0.01) 
p=0.04 
-0.04                 
(-0.08, -0.008) 
p=0.02 
Model8 -99.33                    
(175.50, -23.17) 
p=0.01 
-0.29                   
(-0.61, 0.03) 
p=0.08 
-0.44                     
(-0.66, -0.22) 
p=<0.0001 
-0.03                  
(-0.06, 0.006) 
p=0.11 
 -86.37                      
(-159.67, -13.06) 
p=0.02 
-0.22                   
(-0.52, 0.09) 
p=0.16 
-0.14                
(-0.35, 0.06) 
p=0.17 
-0.04                    
(-0.07, -
0.0004) 
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p=0.05 
Model 9 -98.31                        
(-175.76, -20.86) 
p=0.02 
-0.30                      
(-0.62, 0.02) 
p=0.07 
-0.43                    
(-0.65, -0.21) 
p=0.0001 
-0.03                       
(-0.06, 0.008) 
p=0.14 
-86.92                    
(-161.63, -12.21) 
p=0.02 
-0.23                   
(-0.54, 0.07) 
p=0.14 
-0.12                 
(-0.33, 0.09) 
p=0.27 
-0.03                   
(-0.07, 0.003) 
p=0.08 
Model10 -30.04                    
(-109.21, 49.12) 
p=0.50 
-0.21                      
(-0.54, 0.12) 
p=0.21 
-0.25                          
(-0.47, -0.02) 
p=0.03 
0.01                         
(-0.02, 0.05) 
p=0.50 
-27.14                     
(103.66, 49.37) 
p=0.49 
-0.18                
(-0.50, 0.13) 
p=0.26 
0.04                    
(-0.18, 0.25) 
p=0.72 
0.004                   
(-0.03, 0.04) 
p=0.84 
Model11 -121.69                   
(-196.79, -46.59) 
p=0.002 
-0.33                   
(-0.64, -0.02) 
p=0.04 
-0.49                   
(-0.71, -0.28) 
p=<0.0001 
-0.04                       
(-0.07, -
0.003) 
p=0.03 
-102.36                        
(-175.06, -29.67) 
p=0.006 
-0.29               
(-0.59, 0.002) 
p=0.05 
-0.16                
(-0.37, 0.04) 
p=0.11 
-0.04                
(-0.07, -
0.0009) 
p=0.05 
Model12 -120.23                  
(-196.91, -43.55) 
p=0.002 
-0.33                     
(-0.65, -0.02) 
p=0.04 
-0.49                    
(-0.71, -0.27) 
p=<0.0001 
-0.04                         
(-0.07, 0.002) 
p=0.04 
-101.37                      
(-175.46, -27.28) 
p=0.007 
-0.31                
(-0.61, -0.005) 
p-0.05 
-0.14                
(-0.34, 0.07) 
p=0.19 
-0.03                
(-0.07, 0.003) 
p=0.07 
Model13 -33.51                           
(-111.95, 44.92) 
p=0.40 
-0.20                     
(-0.53, 0.12) 
p=0.22 
-0.26                        
(-0.49, -0.04) 
p=0.02 
0.009                          
(-0.03, 0.04) 
p=0.61 
-29.91                      
(-105.73, 45.91) 
p=0.44 
-0.22                    
(-0.53, 0.09) 
p=0.16 
0.05                    
(-0.16, 0.26) 
p=0.63 
0.008                     
(-0.03, 0.04) 
p=0.67 
 Model14 -146.48                   
(-223.32, -69.64) 
p=0.0002 
-0.44                    
(-0.76, -0.13) 
p=0.006 
-0.56 (-0.78, -
0.34) p=<0.0001 
-0.04                           
(-0.07, -
0.006) 
p=0.02 
-151.28                       
(-225.30, -77.26) 
p=<0.0001 
-0.52                  
(-0.82, -0.22) 
p=0.0007 
-0.21                       
(-0.42, 0.01) 
p=0.04 
-0.04                  
(-0.07, -0.003) 
p=0.03 
Model15 -56.36                    
(-135.00, 22.28) 
p=0.16 
-0.30                       
(-0.63, 0.03) 
p=0.07 
-0.32                   
(-0.54, -0.10) 
p=0.005 
0.007                   
(-0.03, 0.04) 
p=0.72 
-77.40                      
(-153.23, -1.57) 
p=0.05 
-0.43                
(-0.74, -0.12) 
p=0.007 
-0.02               
(-0.23, 0.19) 
p=0.86 
0.002                
(-0.03, 0.04) 
p=0.90 
Model16 -61.54 (-138.31, 
15.24) p=0.12 
-0.31                    
(-0.63, 0.008) 
p=0.06 
-0.32                         
(-0.54, -0.10) 
p=0.004 
0.005                         
(-0.03, 0.04) 
p=0.76 
-82.05                    
(-156.58, -7.52) 
p=0.03 
-0.42                
(-0.73, -0.12) 
p=0.006 
-0.05                       
(-0.25, 0.16) 
p=0.64 
-0.001                    
(-0.04, 0.03) 
p=0.94 
Model 1= Maternal age 
Model 2= maternal age +gestational age 
Model3= maternal age +gestational age + BMI 
Model4= maternal age +gestational age +BMI +smoking 
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Model5= maternal age +gestational age + BMI +smoking +alcohol consumption 
Model6= maternal age +gestational age + BMI +smoking +alcohol consumption +parity 
Model7= maternal age +BMI 
Model8= maternal age + BMI +smoking 
Model9= maternal age + BMI +smoking +alcohol consumption 
Model10= maternal age + BMI +smoking +alcohol consumption +parity 
Model11= maternal age + smoking 
Model12= maternal age + smoking +alcohol consumption 
Model13= maternal age + smoking +alcohol consumption +parity 
Model14= maternal age + alcohol consumption 
Model15= maternal age + alcohol consumption +parity 
Model16= maternal age + parity 
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Appendix 6 Association between maternal education and birth size, examining the confounders 
  Male     Female   
 
Birth weight 
β (95%CI) 
Birth length 
β (95%CI) 
Head 
circumference 
β (95%CI) 
Ponderal index 
β (95%CI) 
 
Birth weight 
β (95%CI) 
Birth length 
β (95%CI) 
Head 
circumference 
β (95%CI) 
Ponderal index 
β (95%CI) 
Model1 26.10                      
(-4.72, 56.92) 
p=0.10 
0.14                    
(0.02, 0.27) 
p=0.03 
0.09                    
(-0.003, 0.17) 
p=0.06 
-0.002                  
(-0.02, 0.01) 
p=0.81 
 47.19                        
(15.70, 78.68) 
p=0.003 
0.30                 
(0.17, 0.43) 
p=<0.0001 
0.08                
(-0.004, 0.17) 
p=0.06 
-0.005              
(-0.02, 0.01) 
p=0.51 
Model2 7.09                              
(-20.00, 34.17) 
p=0.61 
0.06                    
(-0.05, 0.17) 
p=0.28 
0.03                        
(-0.05, 0.11) 
p=0.47 
-0.004                
(-0.02, 0.01) 
p=0.59 
 35.19                       
(7.93, 62.44) 
p=0.01 
0.23                 
(0.12, 0.34) 
p=<0.0001 
0.05                 
(-0.03, 0.13) 
p=0.22 
-0.007                    
(-0.02, 0.008) 
p=0.35 
Model3 15.05                      
(-11.92, 42.01) 
p=0.27 
0.07                    
(-0.04, 0.18) 
p=0.22 
0.05                    
(-0.03, 0.13) 
p=0.20 
0.0008                
(-0.01, 0.01) 
p=0.91 
 44.63              
(17.45, 71.80) 
p=0.001 
0.26                  
(0.15, 0.37) 
p=<0.0001 
0.09                 
(0.008, 0.17) 
p=0.03 
-0.003                
(-0.02, 0.01) 
p=0.66 
Model4 -0.57                      
(27.58, 26.44)           
p=0.97 
0.005                  
(-0.11, 0.12) 
p=0.93 
0.01                          
(-0.07,0.10) 
p=0.72 
-0.001                   
(-0.01, 0.01) 
p=0.89 
 22.77                    
(-4.49, 50.03) 
p=0.10 
0.16               
(0.05, 0.28) 
p=0.005 
0.06                
(-0.02, 0.14) 
p=0.15 
-0.005                    
(-0.02, 0.01) 
p=0.48 
Model5 3.50                           
(-24.59, 31.58) 
p=0,81 
0.007                    
(-0.12, 0.12) 
p=0.91 
0.02                     
(-0.06, 0.10) 
p=0.66 
0.002                    
(-0.01, 0.02) 
p=0.82 
 24.75                    
(-3.32, 52.82) 
p=0.08 
0.16                
(0.05, 0.28) 
p=0.006 
0.07                      
(-0.01, 0.15) 
p=0.10 
-0.004                     
(-0.02, 0.01) 
p=0.60 
Model6 14.79                        
(-13.06, 42.64) 
p=0.30 
0.03                     
(-0.09, 0.14) 
p=0.66 
0.04                       
(-0.04, 0.12) 
p=0.34 
0.007                    
(-0.007, 0.02) 
p=0.34 
 35.58                      
(7.69, 63.48) 
p=0.01 
0.06 (0.06,0.29) 
p=0.003 
0.09               
(0.004, 0.17) 
p=0.04 
0.001               
(-0.01, 0.02) 
p=0.86 
Model7 34.17                       
(3.28, 65.06) p=0.03 
0.15                   
(0.03, 0.28) 
p=0.02 
0.10                     
(0.01, 0.19) 
p=0.03 
0.003                  
(-0.01, 0.02) 
p=0.70 
 53.77                    
(22.22, 85.33) 
p=0.0008 
0.32             (0.19, 
0.45) p=<0.0001 
0.11                 
(0.02, 0.20) 
p=0.01 
-0.002                    
(-0.02, 0.01) 
p=0.84 
Model8 18.79                       
(-12.2, 49.79) 
p=0.23 
0.09                    
(-0.04, 0.22) 
p=0.17 
0.06                    
(-0.03, 0.15) 
p=0.19 
 0.001                   
(-0.01, 0.02) 
p=0.89 
 31.19                       
(-0.44, 62.81) 
p=0.05 
0.22                
(0.09, 0.35) 
p=0.001 
0.07                
(-0.01, 0.16) 
p=0.10 
-0.004               
(-0.02, 0.01) 
p=0.63 
Model 9 23.18                            
(-9.07, 55.43) 
0.09                          
(-0.04, 0.23) 
0.07                    
(-0.03, 0.16) 
0.004                  
(-0.01, 0.02) 
 34.58                     
(1.87, 67.30) 
0.22 (0.09,0.36) 0.09                    
(-0.004, 0.18) 
-0.002                 
(-0.02, 0.01) 
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p=0.16 p=0.17 p=0.16 p=0.61 p=0.04 p=0.001 p=0.06 p=0.77 
Model10 33.22                     
(1.09, 65.36)             
p= 0.04 
0.11                    
(-0.03, 0.25) 
p=0.12 
0.09                    
(0.0008, 0.18) 
p=0.05 
0.009                     
(-0.005, 0.02) 
p=0.22 
 44.45                       
(11.80, 77.10) 
p=0.008 
0.23                
(0.10, 0.37) 
p=0.0007 
0.11                  
(0.02, 0.21) 
p=0.01 
0.003               
(-0.01, 0.02) 
p=0.70 
Model11 7.80                            
(-23.20, 38.80) 
p=0.62 
0.07                         
(-0.06, 0.20) 
p=0.29 
0.04                    
(-0.05, 0.12) 
p=0.43 
-0.004                       
(-0.02, 0.01) 
p=0.57 
21.69                      
(-9.84, 53.21) 
p=0.18 
0.19                
(0.06, 0.32) 
p=0.003 
0.04                
(-0.05, 0.13) 
p=0.38 
-0.008                 
(-0.02, 0.007) 
p=0.32 
Model12 11.34                         
(-20.93, 43.62) 
p=0.50 
0.07                    
(-0.06, 0.20) 
p=0.31 
0.04                    
(-0.05, 0.13) 
p=0.39 
-0.001                      
(-0.02, 0.01) 
p=0.86 
21.75                        
(-10.90, 54.41) 
p=0.19 
0.19                
(0.05, 0.32) 
p=0.006 
0.05                 
(-0.05, 0.14) 
p=0.33 
-0.007               
(-0.02, 0.008) 
p=0.37 
Model13 24.39                      
(-7.69, 56.48)         
p= 0.14 
0.09                      
(-0.04, 0.22) 
p=0.18 
0.07                         
(-0.02, 0.16) 
p=0.12 
0.005                    
(-0.009, 0.02) 
p=0.50 
 35.38                      
(2.81, 67.95) 
p=0.03 
0.21               
(0.07, 0.34) 
p=0.003 
0.08                 
(-0.01, 0.17) 
p=0.08 
-0.0001                  
(-0.02, 0.02) 
p=0.99 
 Model14 26.12                      
(-6.10, 58.34) 
p=0.11 
0.13                       
(-0.005, 0.26) 
p=0.06 
0.08                         
(-0.01, 0.17) 
p=0.09 
0.0008                 
(-0.01, 0.02) 
p=0.91 
 45.69                      
(13.11, 78.26) 
p=0.006 
0.29              
(0.15, 0.42) 
p=<0.0001 
0.08                
(-0.008, 0.17) 
p=0.07 
-0.004               
(-0.02, 0.01) 
p=0.62 
Model15 38.49                     
(6.51, 70,47)  
p=0.02 
0.15                   
(0.02, 0.28) 
p=0.03 
0.11                   
(0.02,0.2)          
p=0.02 
0.007                           
(-0.008, 0.02) 
p=0.37 
 58.82                    
(26.39, 91.25) 
p=0.0004 
0.31               
(0.17, 0.44) 
p=<0.0001 
0.12                  
(0.03, 0.21) 
p=0.01 
0.002               
(-0.01, 0.02) 
p=0.75 
Model16 36.41                     
(5.73, 67.09)  
p=0.02 
0.07                    
(0.03, 0.28) 
p=0.02 
0.11                      
(0.02, 0.20) 
p=0.02 
0.004                     
(-0.01, 0.02) 
p=0.60 
 54.78                   
(23.41, 86.15) 
0.0006 
0.30              
(0.17, 0.43)   
p=<0.0001 
0.11                   
(0.02, 0.19) 
p=0.02 
0.0003                   
(-0.01, 0.02) 
p=0.96 
Model 1= Maternal education 
Model 2= maternal education +gestational age 
Model3= maternal education +gestational age + BMI 
Model4= maternal education +gestational age +BMI +smoking 
Model5= maternal education +gestational age + BMI +smoking +alcohol consumption 
Model6= maternal education +gestational age + BMI +smoking +alcohol consumption +parity 
Model7= maternal education +BMI 
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Model8= maternal education + BMI +smoking 
Model9= maternal education + BMI +smoking +alcohol consumption 
Model10= maternal education + BMI +smoking +alcohol consumption +parity 
Model11= maternal education + smoking 
Model12= maternal education + smoking +alcohol consumption 
Model13= maternal education + smoking +alcohol consumption +parity 
Model14= maternal education + alcohol consumption 
Model15= maternal education + alcohol consumption +parity 
Model16= maternal education + parity 
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Appendix 7 Association of maternal cohabitation and birth weight, examining the confounders 
  Male     Female   
 
Birth weight 
β (95%CI) 
Birth length 
β (95%CI) 
Head 
circumference 
β (95%CI) 
Ponderal index 
β (95%CI) 
 
Birth weight 
β (95%CI) 
Birth length 
β (95%CI) 
Head 
circumference 
β (95%CI) 
Ponderal index 
β (95%CI) 
Model1 -219.81                  
(-289.47, -150.15) 
p=<0.0001 
-0.68                   
(-0.97, -0.39) 
p=<0.0001 
-0.61                     
(-0.81, -0.41) 
p=<0.0001 
-0.06                    
(-0.09, -0.02) 
p=0.0005 
 -103.30                      
(-169.79, -36.81) 
p=0.002 
-0.31                   
(-0.58, -0.04) 
p=0.03 
-0.24                   
(-0.42, -0.05) 
p=0.01 
-0.04                   
(-0.07, -0.004) 
p=0.03 
Model2 -226.41                   
(-287.42, -165.40) 
p=<0.0001 
-0.73                   
(-0.98, -0.48) 
p=<0.0001 
-0.62                     
(-0.80, -0.44) 
p=<0.0001 
-0.06                     
(-0.09, -0.03) 
p=0.0003 
 -96.75                   
(-154.25, -39.25) 
p=0.001 
-0.28                    
(-0.52, -0.05) 
p=0.02 
-0.21                       
(-0.38, -0.04) 
p=0.02 
-0.03                      
(-0.07, -0.003) 
p=0.03 
Model3 -205.60                  
(-266.44, -144.76) 
p=<0.0001 
-0.67                       
(-0.92, -0.42) 
p=<0.0001  
-0.52                    
(-0.70, -0.34) 
p=<0.0001 
-0.05                       
(-0.08, -0.02) 
p=0.002 
-72.40                      
(-129.83, -14.88) 
p=0.01 
-0.19                  
(-0.42, 0.05) 
p=0.12 
-0.09                       
(-0.26, 0.08) 
p=0.29 
-0.03                     
(-0.06, -0.0002) 
p=0.05 
Model4 -163.08                  
(-224.89, -101.28) 
p=<0.0001 
-0.48                        
(-0.73, -0.22) 
p=0.0002 
-0.44                   
(-0.63, -0.26) 
p=<0.0001 
-0.05                       
(-0.08, -0.02) 
p=0.003 
-36.86                   
(-94.41, 20.68) 
p=0.21 
-0.02                    
(-0.26, 0.22) 
p=0.88 
-0.04                  
(-0.22, 0.13) 
p=0.62 
-0.03                 
(-0.06, 0.004) 
p=0.08 
Model5 -164.86                  
(-228.40, -101.33) 
p=<0.0001 
-0.49                    
(-0.75, -0.23) 
p=0.0002 
-0.43                     
(-0.62, -0.24) 
p=<0.0001 
-0.05                       
(-0.08, -0.02) 
p=0.004 
-38.90                   
(-98.24, 20.43) 
p=0.20 
0.007                 
(-0.24, 0.25) 
p=0.95 
-0.06                   
(-0.24, 0.12) 
p=0.51 
-0.03                     
(-0.07, -0.0002) 
p=0.05 
Model6 -114.10                     
(-178.08, -50.13) 
p=0.0005 
-0.40                      
(-0.67, -0.14) 
p=0.003 
-0.34                     
(-0.53, -0.15) 
p=0.0006 
-0.02                    
(-0.06, 0.01) 
p=0.17 
 16.87                        
(-43.15, 76.89) 
p=0.58 
0.10                
(-0.16, 0.35) 
p=0.46 
0.04                        
(-0.14, 0.22) 
p=0.68 
-0.004                    
(-0.04, 0.03) 
p=0.83 
Model7 -202.09                     
(-271.95, -132.24) 
p=<0.0001 
-0.64                     
(-0.93, -0.35) 
p=<0.0001 
-0.57                     
(-0.77, -0.37) 
p=<0.0001 
-0.05                     
(-0.08, -0.02) 
p=0.002 
 -81.79                       
(-148.60, -14.98) 
p=0.02 
-0.22                    
(-0.50, 0.05) 
p=0.11 
-0.19                    
(-0.37, -0.0004) 
p=0.05 
-0.03                  
(-0.06, -0.001) 
p=0.04 
Model8 -158.03                     
(-229.09, -86.96) 
p=<0.0001 
-0.44                        
(-0.73, -0.14) 
p=0.004 
-0.47                      
(-0.67, -0.27) 
p=<0.0001 
-0.05                      
(-0.08, -0.02) 
p=0.004 
 -44.19                        
(-110.97, 22.59) 
p=0.20 
-0.04                     
(-0.31, 0.24) 
p=0.78 
-0.12                
(-0.30, 0.07) 
p=0.22 
-0.03                    
(-0.06, 0.003) 
p=0.08 
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Model 9 -162.91                     
(-235.99, -89.83) 
p=<0.0001 
-0.46                       
(-0.76, -0.15) 
p=0.003 
-0.47                   
(-0.68, -0.26) 
p=<0.0001 
-0.05                   
(-0.08, -0.02) 
p=0.005 
 -54.86                     
(-124.02, 14.30) 
p=0.12 
-0.05                    
(-0.33, 0.24) 
p=0.75 
-0.15                      
(-0.34, 0.04) 
p=0.13 
-0.04                       
(-0.07, -0.002) 
p=0.04 
Model10 120.60                    
(-194.51, -46.70) 
p=0.001 
-0.41                           
(-0.71, -0.1) 
p=0.01 
-0.36                       
(-0.57, -0.15) 
p=0.0009 
-0.02                         
(-0.06, 0.01) 
p=0.17 
-6.63                           
(-76.89, 63.63) 
0.85 
0.0004                  
(-0.29, 0.29) 
p=0.99 
-0.03                    
(-0.23, 0.17) 
p=0.77 
-0.007                    
(-0.04, 0.03) 
p=0.70 
Model11 -171.07                       
(-242.01, -100.12) 
p=<0.0001 
-0.46                         
(-0.75, -0.16) 
p=0.002 
-0.50                      
(-0.70, -0.30) 
p=<0.0001 
-0.05                  
(-0.09, -0.02) 
p=0.001 
 61.18                           
(-127.58, 5.21) 
p=0.07 
-0.11                   
(-0.38, 0.16) 
p=0.42 
-0.16                      
(-0.34, 0.03) 
p=0.10 
-0.03                         
(-0.06, 0.001) 
p=0.06 
Model12 176.66                       
(-249.69, -103.64) 
p=<0.0001 
-0.47                        
(-0.77, -0.17) 
p=0.002 
-0.50                    
(-0.70, -0.29) 
p=<0.0001 
-0.05                         
(-0.09, -0.02) 
p=0.001 
-68.98                       
(137.69, -0.27) 
p=0.05 
-0.11                      
(-0.39, 0.17) 
p=0.43 
-0.18               
(-0.38, 0.006) 
p=0.06 
-0.04                     
(-0.07, -0.003) 
p=0.03 
Model13 -122.47                        
(-196.35, -48.59) 
p=0.001 
-0.39                        
(-0.70, -0.09) 
p=0.01 
-0.37                     
(-0.58, -0.16) 
p=0.0006 
-0.03                       
(-0.06, 0.006) 
p=0.11 
-10.98                      
(-80.73, 58.77) 
p=0.76 
-0.04                    
(-0.32, 0.25) 
p=0.80 
-0.04                      
(-0.23, 0.16) 
0.69 
-0.004                   
(-0.04, 0.03) 
p=0.79 
 Model14 -216.63                      
(-288.95, -144.30) 
p=<0.0001 
-0.64                        
(-0.94, -0.34) 
p=<0.0001 
-0.60                          
(-0.80, -0.39) 
p=<0.0001 
-0.06                        
(-0.09, -0.03) 
p=0.0003 
-109.97                      
(-178.82, -41.12) 
p=0.002 
-0.29                
(-0.57, -0.009) 
p=0.04 
-0.25                  
(-0.44, -0.06) 
p=0.01 
-0.04                   
(-0.07, -0.008) 
p=0.01 
Model15 -159.47                  
(-232.72 , -86.21) 
p=<0.0001 
-0.55                        
(-0.85, -0.25) 
p=0.0004 
-0.46                    
(0.67, -0.25) 
p=<0.0001 
-0.03                       
(-0.06, 0.002) 
p=0.07 
-49.09                     
(119.03, 20.84) 
p=0.17 
-0.21                
(-0.49, 0.08) 
p=0.16 
-0.10                   
(-0.29, 0.10) 
p=0.33 
-0.009                  
(-0.04, 0.02) 
p=0.61 
Model16 -165.38                           
(-235.82, -94.94) 
p=<0.0001 
-0.60                    
(-0.89, -0.31) 
p=<0.0001 
-0.48                   
(-0.68, -0.28) 
p=<0.0001 
-0.03                      
(-0.06, 0.004) 
p=0.09 
 -43.49                         
(-110.93, 23.95) 
p=0.21 
-0.23                      
(-0.51, 0.05) 
p=0.10 
-0.08                     
(-0.27, 0.10) 
p=0.39 
-0.002                    
(-0.03, 0.03) 
p=0.89 
Model 1= Maternal cohabitation 
Model 2= maternal cohabitation +gestational age 
Model3= maternal cohabitation +gestational age + BMI 
Model4= maternal cohabitation +gestational age +BMI +smoking 
Model5= maternal cohabitation +gestational age + BMI +smoking +alcohol consumption 
Model6= maternal cohabitation +gestational age + BMI +smoking +alcohol consumption +parity 
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Model7= maternal cohabitation +BMI 
Model8= maternal cohabitation + BMI +smoking 
Model9= maternal cohabitation + BMI +smoking +alcohol consumption 
Model10= maternal cohabitation + BMI +smoking +alcohol consumption +parity 
Model11= maternal cohabitation + smoking 
Model12= maternal cohabitation + smoking +alcohol consumption 
Model13= maternal cohabitation + smoking +alcohol consumption +parity 
Model14= maternal cohabitation + alcohol consumption 
Model15= maternal cohabitation + alcohol consumption +parity 
Model16= maternal cohabitation + parity 
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Appendix 8 The association of prenatal GC exposure on the outcome of birth size; controlling for additional confounders 
 Birth weight (g) 
Estimates 
(95%CI) 
P-value 
Birth length (cm) 
Estimates 
(95%CI) 
P-value 
Head circumference(cm) 
Estimates 
(95%CI) 
P-value 
Ponderal index (cm) 
Estimates 
(95%CI) 
P-value 
New variable 
to control for 
n* 
Yes/no 
GC 
GC + variable  Multivariate* n* 
Yes/no 
GC 
GC + variable  Multivariate* n* 
Yes/no 
GC 
GC + variable  multivariate n* 
Yes/no 
GC 
GC + variable  multivariate 
             
             
Hospitalization 
due to 
bleeding 
4892/ 
270556 
-965.1 
(-979.5, -950.8) 
<0.0001 
-207.1 
(-219.8, -194.3) 
<0.0001 
4655/ 
269070 
-4.63 
(-4.69, -4.56) 
<0.0001 
-1.25 
(-1.31, -1.97) 
<0.0001 
4249/ 
267192 
-2.59 
(-2.63, -2.54) 
<0.0001 
-0.94 
(-0.98, -0.90) 
<0.0001 
4655/ 
269068 
-1.88 
(-1.98, -1.78) 
<0.0001 
 
-0.91 
(-1.02, -0.80) 
<0.0001 
             
Hospitalization 
due to preterm 
4892/ 
270556 
-952.2 
(-966.8, -937.6) 
<0.0001 
-209.7 
(-222.6, -196.8) 
<0.0001 
4655/ 
269070 
-4.54 
(-4.61, -4.48) 
<0.0001 
-1.24 
(-1.30, -1.19) 
<0.0001 
4249/ 
26792 
-2.54 
(-2.59, -2.49) 
<0.0001 
-0.93 
(-0.99, -0.89) 
<0.0001 
4655/ 
269068 
-1.92 
(-2.02, -1.82) 
<0.0001 
-0.96 
(-1.07, -0.85) 
<0.0001 
             
Hospitalization 
due to other 
reasons 
4892/ 
270556 
-965.6 
(-979.9, -951.2) 
<0.0001 
-207.9 
(-220.6, -195.1) 
<0.0001 
4655/ 
269070 
-4.63 
(-4.69, -4.56) 
<0.0001 
-1.26 
(-1.31, -1.20) 
<0.0001 
4249/ 
267192 
-2.60 
(-2.64, -2.55) 
<0.0001 
-0.94 
(-1.00, -0.90) 
<0.0001 
4655/ 
269068 
-1.89 
(-1.99, -1.79) 
<0.0001 
-0.92 
(-1.03, -0.81) 
<0.0001 
             
Mode of 
delivery 
4892/ 
270556 
-949.6 
(-963.9, -935.2) 
<0.0001 
-202.4 
(-215.1, -189.6) 
<0.0001 
4655/ 
269070 
-4.51 
(-4.58, -4.45) 
<0.0001 
-1.24 
(-1.30, -1.18) 
<0.0001 
4249/ 
267192 
-2.64 
(-2.68, -2.59) 
<0.0001 
-0.94 
(-0.98, -0.90) 
<0.0001 
4655/ 
269068 
-1.92 
(-2.02, -1.82) 
<0.0001 
-0.87 
(-0.98, -0.77) 
<0.0001 
             
ICU after 
delivery 
(infant) 
4892/ 
270556 
-851.0 
(-865.5, -836.6) 
<0.0001 
-196.2 
(--209.0, -183.4) 
<0.0001 
4655/ 
269070 
-4.18 
(-4.24, -4.11) 
<0.0001 
-1.23 
(-1.29, -1.17) 
<0.0001 
4249/ 
267192 
-2.34 
(-2.38, -2.29) 
<0.0001 
-0.90 
(-0.94, -0.86) 
<0.0001 
4655/ 
269068 
-1.58 
(-1.68, -1.48) 
<0.0001 
-0.82 
(-0.92, -0.71) 
<0.0001 
             
Respiratory 
care (infant) 
4892/ 
270556 
-836.4 
(-851.0, -821.9) 
<0.0001 
-190.1 
(-202.9, -177.2) 
<0.0001 
4655/ 
269070 
-3.98 
(-4.04, -3.91) 
<0.0001 
-1.12 
(-1.18, -1.07) 
<0.0001 
4249/ 
267192 
-2.28 
(-2.33, -2.24) 
<0.0001 
-0.86 
(-0.90, -0.81) 
<0.0001 
4655/ 
269068 
-1.56 
(-1.67, -1.46) 
<0.0001 
-0.80 
(-0.90, -0.68) 
<0.0001 
             
Intubation 
(infant) 
4892/ 
270556 
-920.57 
(-935.0, -906.2) 
<0.0001 
-199.8 
(-212.6, -187.0) 
<0.0001 
4655/ 
269070 
-4.41 
(-4.47, -4.35) 
<0.0001 
-1.21 
(-1.27, -1.15) 
<0.0001 
4249/ 
267192 
-2.50 
(-2.54, -2.45) 
<0.0001 
-0.91 
(-0.95, -0.87) 
<0.0001 
4655/ 
269068 
-1.74 
(-1.84, -1.64) 
<0.0001 
-0.85 
(-0.96, -0.74) 
<0.0001 
             
Exchange 
transfusion(inf
ant) 
892/ 
270556 
-947.39 
(-961.8, -933.0) 
<0.0001 
-204.0 
(-216.8, -191.3) 
<0.0001 
4655/ 
269070 
-4.53 
(-4.60, -4.47) 
<0.0001 
-1.23 
(-1.28, -1.17) 
<0.0001 
4249/ 
267192 
-2.52 
(-2.57, -2.48) 
<0.0001 
-0.92 
(-0.96, -0.87) 
<0.0001 
4655/ 
269068 
-1.84 
(-1.94, -1.74) 
<0.0001 
-0.89 
(-1.00, -0.78) 
<0.0001 
             
Phototherapy(i
nfant) 
4892/ 
270556 
-905.8 
(-920.1, -891.5) 
<0.0001 
-208.3 
(-221.0, -195.5) 
<0.0001 
4655/ 
269070 
-4.39 
(-4.45, -4.32) 
<0.0001 
-1.26 
(-1.32, -1.20) 
<0.0001 
4249/ 
267192 
-2.44 
(-2.49, -2.40) 
<0.0001 
-0.94 
(-0.98, -0.90) 
<0.0001 
4655/ 
269068 
-1.76 
(-1.86, -1.66) 
<0.0001 
-0.91 
(-1.02, -0.80) 
<0.0001 
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 Birth weight (g) 
Estimates 
(95%CI) 
P-value 
Birth length (cm) 
Estimates 
(95%CI) 
P-value 
Head circumference(cm) 
Estimates 
(95%CI) 
P-value 
Ponderal index (cm) 
Estimates 
(95%CI) 
P-value 
New variable 
to control for 
n* 
Yes/no 
GC 
GC + variable  Multivariate* n* 
Yes/no 
GC 
GC + variable  Multivariate* n* 
Yes/no 
GC 
GC + variable  multivariate n* 
Yes/no 
GC 
GC + variable  multivariate 
Antibiotic 
therapy 
(infant) 
4892/ 
270556 
-896.12 
(-910.7, -881.6) 
<0.0001 
-203.9 
(-216.7, -191.0) 
<0.0001 
4655/ 
269070 
-4.36 
(-4.43, -4.30) 
<0.0001 
-1.26 
(-1.31, -1.20) 
<0.0001 
4249/ 
267192 
-2.43 
(-2.48, -2.39) 
<0.0001 
-0.90 
(-0.95, -0.86) 
<0.0001 
4655/ 
269068 
-1.62 
(-1.72, -1.51) 
<0.0001 
-0.79 
(-0.90, -0.68) 
<0.0001 
             
BP according 
to ICD 10 
codes 
4892/ 
270556 
-961.9 
(-976.2, -947.6) 
<0.0001 
-207.2 
(-220.0, -194.5) 
<0.0001 
4655/ 
269070 
-4.62 
(-4.69, -4.56) 
<0.0001 
-1.25 
(-1.31, -1.20) 
<0.0001 
4249/ 
267192 
-2.59 
(-2.64, -2.54) 
<0.0001 
-0.94 
(-0.98, -0.90) 
<0.0001 
4655/ 
269068 
-1.87 
(-1.97, -1.77) 
<0.0001 
-0.91 
(-1.02, -0.80) 
<0.0001 
             
             
Child with life 
threatening 
Malformations 
(available in 
preterm’s only) 
4892/ 
270556 
-959.7 
(-974.0, -945.3) 
<0.0001 
-206.6 
(-219.3, -193.8) 
<0.0001 
4655/ 
269070 
-4.59 
(-4.65, -4.52) 
<0.0001 
-1.24 
(-1.29, -1.18) 
<0.0001 
4249/ 
267192 
-2.65 
(-2.61, -2.52) 
<0.0001 
-0.93 
(-0.97, -0.88) 
<0.0001 
4655/ 
269068 
-1.89 
(-1.99, -1.79) 
<0.0001 
-0.92 
(-1.03, -0.81) 
<0.0001 
             
Child with 
ICD10 
malformations 
4892/ 
270556 
-967.7 
(-982.1, -953.4) 
<0.0001 
-207.2 
(-220.0, -194.5) 
<0.0001 
4655/ 
269070 
-4.7 
(-4.70, 4.57) 
<0.0001 
-1.25 
(-1.31,- 1.20) 
<0.0001 
4249/ 
267192 
-2.60 
(-2.64, -2.55) 
<0.0001 
-0.94 
(-0.98, -0.90) 
<0.0001 
4655/ 
269068 
-1.89 
(-1.99, -1.79) 
<0.0001 
-0.91 
(-1.02, -0.80) 
<0.0001 
             
Controlling for 
all of the 
above 
4892/ 
270556 
 -184.1 
(-197.1, -171.0) 
<0.0001 
4655/ 
269070 
 -1.09 
(-1.15, -1.04) 
<0.0001 
4249/ 
267192 
 -0.81 
(-0.85, -0.77) 
<0.0001 
4655/ 
269068 
 -0.72 
(-0.83, -0.61) 
<0.0001 
             
*Adjusted for: gestational weeks, sex, parity, maternal pre-pregnancy BMI, maternal smoking, maternal social adversity, 
pathological glucose test, and hospitalized for hypertension + new variable 
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Appendix 9 Mean differences (95% confidence intervals, CI) in birth size as predicted by the additive effects of social 
adversity and at least one risk allele (CCNL1/LEKR1- rs900400) stratified by sex 
 Mean difference  (95%CI) P-value 
 Birthweight (g) Birth length(cm) Head circumference(cm) Ponderal index(kg/m3) 
Exposure: n* Unadjusted Adjusted** n* Unadjusted Adjusted** n* Unadjusted Adjusted** n* Unadjusted Adjusted** 
MALES  ONLY:             
Neither adversity nor risk allele [ref] 737   733   724   733   
At least one risk allele only 942 -44.06               -66.8                 935 -0.005 -0.08 923 -0.06 -0.14 935 -0.32 -0.39 
  (-90.79, 2.67)   (-107.7, -25.8)  (-0.20, 0.19) (-0.24, 0.09)  (-0.20, 0.07) (-0.26, -0.01)  (-0.52, -0.11) (-0.60, -0.17) 
  0.07 0.001  0.96 0.39  0.35 0.03  0.003 0.0004 
Social adversity only 246 -100.6               -97.13               244 -0.38 -0.33 243 -0.22 -0.18 244 -0.21 -0.25 
  (-169.5, -31.8) (-159.0, -35.3)  (-0.66, -0.09) (-0.59, -0.08)  (-0.42, -0.03) (-0.37, 0.005)  (-0.51, 0.10) (-0.57, 0.07) 
  0.004 0.002  0.009 0.01  0.03 0.06  0.18 0.13 
Both adversity and at least one risk allele 333 -71.3  -85.9      332 -0.09 -0.11 327 -0.11 -0.13 332 -0.41 -0.50 
  (-133.6, -9.0) (-141.2, -30.6)  (-0.35, 0.16) (-0.33, 0.12)  (-0.29, 0.07) (-0.30, 0.04)  (-0.69, -0.14) (-0.78, -0.21) 
  0.03 0.002  0.47 0.37  0.23 0.14  0.003 0.0007 
P value for trend   0.0002   0.16   0.02   0.0002 
             
FEMALES ONLY:             
Neither adversity nor risk allele [ref] 809   807   793   807   
At least one risk allele only 931 -73.57               -86.9                 921 -0.10 -0.19 913 -0.17 -0.18 921 -0.35 -0.36 
  (-119.4, -27.7 ) (-126.3, -47.4)  (-0.29, 0.09) (-0.36, -0.02)  (-0.30, -0.05) (-0.30, -0.06)  (-0.57, -0.14) (-0.58, -0.14) 
  0.002 <0.0001  0.31 0.03  0.007 0.003  0.001 0.001 
Social adversity only 289 -107.2                 -53.7                  286 -0.28 -0.09 283 -0.26 -0.18 286 -0.37 -0.28 
  (-171.4, -43.1) (-110.5, 3.2)  (-0.55, -0.02) (-0.33, 0.15)  (-0.44, -0.09) (-0.35, -0.01)  (-0.67, -0.07) (-0.60, 0.03) 
  0.001 0.06  0.04 0.46  0.004 0.04  0.02 0.08 
Both adversity and at least one risk allele 333 -147.9              -149.5                       333 -0.53 -0.49 328 -0.30 -0.33 333 -0.38 -0.44 
  (-209.6, -86.3) (-203.4, -95.7)    (-0.79, -0.28) (-0.72, -0.27)  (-0.46, -0.13) (-0.49, -0.17)  (-0.67, -0.10) (-0.74, -0.15) 
  <0.0001 <0.0001  <0.0001 <0.0001  0.0006 <0.0001  0.009 0.004 
P value for trend   <0.0001   0.0002   <0.0001   0.003 
*n in the adjusted model, **controlling for gestational age, maternal smoking, maternal alcohol consumption,  parity, maternal pre-pregnancy BMI , sex,  gestational diabetes and hypertension 
during pregnancy 
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Appendix 10 Genotype frequency by birth size outcomes including means (±SD) 
 Birth weight (g)  Birth length(cm)  Head circumference (cm)  Ponderal index (kg/m3) 
 n(%) 
Mean 
(±SD) 
 n (%) 
Means 
(±SD) 
 n (%) 
Means 
(±SD) 
 n (%) 
Means 
(±SD) 
LEKR1/CCNL1 
rs900400 
           
CC  176    3657.05   174     51.03   172     35.31       174  27.54  
 (3.33) (477.45)  (3.32) (2.00)  (3.32) (1.37)  (3.32) (2.20) 
            
CT 1406   3599.78   1394   50.63   1369  35.20       1394  27.64  
 (26.60) (547.04)  (26.58) (2.29)  (26.44) (1.52)  (26.58) (2.37) 
            
TT 3703  3580.48   3677  50.54   3637  35.18       3677  27.65  
 (70.07) (513.01)  (70.11) (2.13)  (70.24) (1.44)  (70.11) (2.33) 
ADCY5  
rs9883204 
            
CC 3379  3580   3357  50.55   3321  35.17       3357  27.64  
 (69.92) (511.2)  (69.89) (2.12)  (70.03) (1.44)  (69.92) (2.34) 
            
CT 1289  3599.2   1281  50.67   1260  35.22       1281  27.59  
 (26.67) (544.1)  (26.67) (2.23)  (26.57) (1.50)  (26.68) (2.34) 
            
TT 165     3657.6   165      51.01   161     35.36       163  27.56  
 (3.41) (499.6)  (3.44) (2.13)  (3.40) (1.39)  (3.40) (2.12) 
            
Risk allele = C 
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Appendix 11 Test for interaction between the 
social adversity and rs900400 and rs9883204 
  rs900400  rs9883204 
 outcome P-value for 
interaction^ 
 P-value for 
interaction^ 
Social 
adversity 
    
 Birth weight 0.11  0.63 
 Birth length 0.43  0.78 
 Head 
circumference  
0.17  0.66 
 Ponderal index 0.25  0.36 
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Appendix 12 Distribution of additive variable in the population 
 n bw bl hc pi 
CCNL1  N(in multivariate analysis) 
rs900400      
Risk allele only 2088(40.20) 1873 1856 1836 1856 
Adversity only 625(12.03) 535 530 526 530 
Both adversity and at least one risk allele 758(14.59) 666 665 655 665 
Neither adversity nor risk allele [ref] 1723(33.18) 1546 1540 1517 1540 
      
ADCY5      
rs9883204      
Risk allele only 3415 624 614 609 614 
Adversity only 39 9 9 8 9 
Both adversity and at least one risk allele 1242 271 267 267 267 
Neither adversity nor risk allele [ref] 125 21 21 21 21 
      
HMGA2      
rs1042725      
Risk allele only 2680(54.59) 490 481 478 481 
Adversity only 338(6.89) 73 73 73 73 
Both adversity and at least one risk allele 961(19.58) 210 206 205 206 
Neither adversity nor risk allele [ref] 930(18.94) 171 168 166 168 
      
CDKAL1      
rs6931514      
Risk allele only 2342(44.31) 439 431 427 431 
Adversity only 536(10.14) 116 115 115 115 
Both adversity and at least one risk allele 845(15.99) 181 178 177 178 
Neither adversity nor risk allele [ref] 1562(29.56) 271 267 266 267 
      
5q11.2      
rs443284 [no association btw snp and bw]      
Risk allele only 1957(40.46) 367 359 356 359 
Adversity only 572(11.83) 130 129 129 129 
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Both adversity and at least one risk allele 702(14.51) 149 147 145 147 
Neither adversity nor risk allele [ref] 1606(33.20) 289 285 283 285 
      
LCORL      
rs724577 [no association btw snp and bw]      
Risk allele only 3209(65.92) 592 582 577 582 
Adversity only 136(2.79) 27 27 27 27 
Both adversity and at least one risk allele 1149(23.60) 255 251 250 251 
Neither adversity nor risk allele  374(7.68) 65 63 63 63 
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Appendix 13 Association of maternal social adversity during 
pregnancy on lipid profile of offspring at age 16 analysis 
excludes BMI and then examines the interaction 
Variable 
 Without BMI  Interaction adv*BMI 
N Estimate (95%CI)P value N p-value 
IDL [log] 946 2.57 (0.23, 4.96)0.03  <0.0001 
 2579    
Vldl_tg [log] 946 2.39 (-2.32, 7.32) 0.33  <0.0001 
 2576    
Apob[log] 874 1.51(-0.11, 3.15)0.07  <0.0001 
 2350    
Apoba [log] 874 2.08(0.25, 3.94)0.03  <0.0001 
 2350    
Cholestrol, mmol/L 942 0.03(-0.02, 0.09)0.27  <0.0001 
 2570    
HDL cholesterol, mmol/L 
942 
-0.01(-0.03, 0.01)0.32  <0.0001 
 2570    
LDL cholestrerol, mmol/L 942 0.06 (0.008, 0.11)0.02  <0.0001 
 2570    
Triglycerides, mmol/L [log] 942 2.52 (-0.52, 5.67) 0.11  <0.0001 
 2570    
*Controlling for sex, birth weight, gestational week, adolescent smoking, alcohol consumption .**Log results are percentage change 
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Appendix 14 Background characteristics of composite of social adversity  (Maternal age, maternal 
education, cohabitation) 
 Total  Total  Total  Total 
 Social adversity  
n(%) 
 Maternal age  
n(%) 
 Maternal education  
n(%) 
 cohabitation  
n(%) 
 Yes No  <20 >20  ≥11yrs ≥11yrs  Yes No 
Gestational age (gw)            
                   <34     24(0.9) 53(0.8)  1(0.3) 76(0.8)  48(0.8) 29(0.9)  73(0.8) 4(0.9) 
                    34-36  104(4.0) 165(2.5)  15(3.8) 257(2.8)  157(2.7) 115(3.5)  243(2.8) 29(6.2) 
                    37-39  1110(43.1) 2681(41.0)  169(42.6) 3633(39.8)  2356(40.5) 1446(43.6)  3640(42.0) 162(34.8) 
                   40-42  1329(51.6) 3624(55.5)  206(51.9) 4757(52.1)  3247(55.8) 1716(51.7)  4695(54.2) 268(57.6) 
                   43+     7(0.3) 9(0.1)  4(1.0) 12(0.1)  10(0.2) 6(0.2)  14(0.2) 2(0.4) 
                    Missing 0 0  2(0.5) 3(0.03)  0 5(0.2)  5(0.1) 0 
            
Birth weight (g)            
                <1500  5(0.2) 14(0.2)  0 19(0.2)  13(0.2) 6(0.2)  18(0.2) 1(0.2) 
                1500-2499  66(2.6) 141(1.6)  8(2.0) 203(2.3)  129(2.2) 82(2.5)  194(2.2) 17(3.7) 
                2500-2999  283(11.0) 480(5.3)  53(13.4) 715(8.2)  438(7.5) 330(10.0)  68(8.1) 700(14.6) 
                3000-3999  1750(68.0) 4506(49.5)  295(74.3) 5978(68.4)  4024(69.2) 2249(67.8)  5961(68.8) 312(67.1) 
               ≥4000  470(18.3) 1391(15.3)  41(10.3) 1823(20.9)  1214(20.9) 650(19.6)  1797(20.7) 67(14.4) 
                    Missing   0 0  0 0  0 0  0 0 
            
Head circumference (cm)           
                     ≤33  104(4.0) 164(2.5)  18(4.5) 254(2.9)  153(2.6) 119(3.6)  245(2.8) 27(5.8) 
                     33-33.9 253(9.8) 493(7.6)  47(11.8) 703(8.1)  454(7.8) 296(8.9)  690(8.0) 60(12.9) 
                     34-34.9  506(19.7) 1200(18.3)  107(27.0) 1603(18.4)  1104(19.0) 606(18.3)  1599(18.4) 111(23.9) 
                     35-35.9 668(26.0) 1803(27.6)  108(27.0) 2367(27.1)  1588(27.3) 887(26.7)  2357(27.2) 118(25.4) 
                     36-36.9 603(23.4) 1608(24.6)  68(17.1) 2148(24.6)  1402(24.1) 814(24.5)  2131(24.6) 85(18.3) 
                     37-37.9              0 0  0 0  0 0  0 0 
                     ≥38 104(4.04) 260(3.9)  10(2.5) 354(4.1)  239(4.1) 125(3.8)  351(4.1) 13(2.8) 
                    Missing  336(13.1) 1004(15.4)  39(9.8) 1309(15.0)  878(15.1) 470(14.2)  1297(15.0) 51(11.0) 
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 Total  Total  Total  Total 
 Social adversity  
n(%) 
 Maternal age  
n(%) 
 Maternal education  
n(%) 
 cohabitation  
n(%) 
 Yes No  <20 >20  ≥11yrs ≥11yrs  Yes No 
 
Birth length(cm)            
<47 n(%) 109(4.2) 208(3.2)  17(4.3) 305(3.5)  185(3.2) 137(4.1)  298(3.4) 24(5.2) 
47-48.9 336(13.1) 631(9.7)  64(16.1) 905(10.4)  568(9.8) 401(12.1)  894(10.3) 75(16.1) 
49-52.9 1744(67.8) 4513(69.1)  272(68.5) 6001(68.7)  4035(69.4) 2238(67.5)  5968(68.8) 305(65.6) 
53-55.9 352(13.7) 1085(16.6)  39(9.8) 1403(16.1)  940(16.2) 502(15.1)  1389(16.0) 53(11.4) 
≥56 15(0.6) 42(0.6)  1(0.3) 56(0.6)  43(0.7) 14(0.4)  53(0.6) 4(0.9) 
Missing 18(0.7) 53(0.8)  4(1.0) 68(0.8)  47(0.8) 25(0.8)  68(0.8) 4(0.9) 
            
Smoking            
             Non-smoker 1650(35.5) 5422(16.5)  213(53.7) 6859(78.5)  4775(82.1) 2297(69.3)  6842(78.9) 230(49.5) 
             Smoker 913(64.1) 1080(83.1)  175(44.1) 1819(20.8)  1038(17.8) 956(28.8)  1766(20.4) 228(49.0) 
             Missing 11(0.4) 30(0.5)  9(0.1) 60(0.7)  5(0.1) 64(1.9)  62(0.7) 7(1.5) 
            
Alcohol consumption           
              Non-drinker 2149(83.5) 5473(83.8)  317(79.9) 7305(83.6)  4963(85.3) 2659(80.2)  7297(84.2) 325(69.9) 
              Drinker 337(13.1) 732(11.2)  57(14.4) 1012(11.6)  779(13.4) 290(8.7)  961(11.1) 108(23.2) 
              Missing 88(3.4) 327(5.0)  23(5.8) 421(4.8)  76(1.3) 368(11.1)  412(4.8) 32(6.9) 
            
Parity            
Nulli-para 932(36.2) 2154(33.0)  350(88.2) 2736(31.3)  2135(36.7) 951(28.7)  2744(31.7) 342(73.6) 
Multi-para 1637(63.6) 4369(66.9)  41(10.3) 5966(68.3)  3674(63.2) 2333(70.3)  5886(67.9) 121(26.0) 
missing 5(0.2) 9(0.1)  6(1.5) 36(0.4)  9(021) 33(1.0)  40(0.5) 2(0.4) 
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Appendix 15 Examination of the association of social adversity and possible confounders of birth size 
 Gestational age Maternal age BMI Smoking Alcohol consumption parity 
 n β (95%CI) n β (95%CI) n β (95%CI) No Yes OR(95%CI) No Yes OR(95%CI) n β (95%CI) 
BOYS               
Social adv               
0 3492  3495  3413  2812 649  2889 398  3475  
1 
1097 -0.09(-0.19, 0.01) 
P= 0.81 
1099 -0.21(-0.58, 0.15) 
P=0.25 
1073 -0.49(0.25, 0.72) 
P=<0.0001 
735 357 25.11(1.81,2.45) 
P=<0.0001 
942 123 0.95(0.76, 1.18) 
P=0.63 
1095 0.29(0.17, 0.41) 
P=<0.0001 
≥2 
90 -0.03(-0.35, 0.29) 
P=0.85 
90 -10.13(-11.25, -9.01) 
P=<0.0001 
86 -1.11(-1.85, -0.38) 
P= 0.003 
50 40 3.47(2.27, 5.30) 
P=<0.0001 
74 16 1.57(0.91, 2.72) 
P=0.11 
90 -1.24(-1.61, -0.87) 
<0.0001 
               
Social adv               
No 3492  3495  3413  2812 649  2889 398  3475  
Yes 
1187 -0.09(-0.19, 0.01) 
P=0.09 
1189 -0.96(-1.33, -0.60) 
P=<0.0001 
1159 0.37(0.14, 0.59) 
P=0.002 
785 397 2.19(1.89, 2.54) 
P=<0.0001 
1016 139 0.99(0.81,1.22) 
P=0.95 
1185 0.18(0.06, 0.29) 
P=0.003 
               
GIRLS               
Social adv               
0 3314  3314  3228  2751 539  2754 396  3301  
1 
1056 -0.12(-0.23, -0.02) 
P=0.03 
1056 0.008(-0.36, 0.38) 
P=0.97 
1031 0.74(0.49, 0.98) 
P=<0.0001 
682 370 2.77(2.37,3.24) 
P=<0.0001 
896 123 0.95(0.77,1.19) 
P=0.67 
1051 0.37(0.24,0.50) 
P=<0.0001 
≥2 
81 -0.14(-0.48, 0.21) 
P=0.43 
81 -9.93(-11.11,-8.75) 
P=<0.0001 
75 -0.22(-1.02,0.57) 
P=0.58 
42 39 4.74(3.04,7.40) 
<0.0001 
67 13 1.35(0.74,2.47) 
P=0.33 
81 -1.15(-1.56,-0.75) 
P=<0.0001 
               
Social adv               
No 3314  3314  3228  2751 539  2754 396  3301  
Yes 
1137 -0.12(-0.23, -0.02) 
P=0.02 
1137 -0.70(-1.07, -0.32) 
P=0.0002 
1106 0.68(0.44,0.91) 
P=<0.0001 
724 409 2.88(2.48,3.36) 
P=<0.0001 
963 136 0.98(0.80,1.21) 
P=0.87 
1132 0.26(0.13,0.39) 
P=<0.0001 
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Appendix 16 Multivariate analysis* of lipid profile at 16 years of offspring of mothers with social adversity during 
pregnancy [controlling for adolescent smoking and alcohol consumption only] and stratified by BMI 
Variable 
 BMI<16  BMI16-18.5  BMI 18.5-25  BMI 25-30  BMI >30 
N 
Estimate or percentage 
change 
95%CI 
N 
Estimate or percentage 
change 
95%CI 
N 
Estimate or percentage 
change 
95%CI 
N 
Estimate or 
percentage 
change 
95%CI 
N 
Estimate or 
percentage 
change 
95%CI 
IDL [log] 6 
15.74 
(-15.29, 58.12)  
0.33 
138 
1.99 
(-3.22, 7.48) 
0.46 683 
1.43 
(-1.18, 4.11) 
0.29 82 
5.36 
(-3.29, 14.78) 
0.23 35 
6.08 
(-10.34, 25.52) 
0.48 
 20  446  1822  222  59  
Vldl_tg [log] 6 
71.58 
(-19.58, 266.06) 
0.15 
138 
-3.27 
(-14.11,8.94) 
0.58 683 
2.65 
(-2.18, 8.31) 
0.34 82 
2.79 
(-12.53, 
20.79) 
0.74 35 
-5.83 
(-31.43, 29.31) 
0.71 
 20  444  1821  222  59  
Apob[log] 5 
4.76 
(-18.35, 34.42) 
0.69 
122 
-0.08 
(-3.55, 3.51) 
0.96 632 
0.76 
(-1.06, 2.62) 
0.42 
79 
5.39 
(-0.62, 11.77) 
0.08 34 
2.21 
(-9.02, 14.84) 
0.71 
 17  392  1657  219  56  
Apoba [log] 5 
1.07  
(-23.30, 33.18) 
122 
1.79 
(-2.31, 6.09) 632 
1.07 
(-1.00, 3.12) 79 
3.97 
(-2.13, 10.45) 34 
2.95 
(-8.65, 16.02) 
229 
 
Variable 
 BMI<16  BMI16-18.5  BMI 18.5-25  BMI 25-30  BMI >30 
N 
Estimate or percentage 
change 
95%CI 
N 
Estimate or percentage 
change 
95%CI 
N 
Estimate or percentage 
change 
95%CI 
N 
Estimate or 
percentage 
change 
95%CI 
N 
Estimate or 
percentage 
change 
95%CI 
0.93 0.40 0.32 0.21 0.63 
 17  392  1657  219  56  
Cholestrol, mmol/L 7 
0.25 
(-0.51, 1.02) 
0.49 
142 
-0.07 
(-0.20, 0.06) 
0.29 673 
0.01 
(-0.05, 0.07) 
0.76 82 
-0.001 
(-0.19, 0.18) 
0.99 35 
0.19 
(-0.21, 0.58) 
0.35 
 19  445  1815  219  62  
HDL cholesterol, mmol/L 7 
0.08 
(-0.28, 0.44) 
0.65 
142 
-0.04 
(-0.010, 0.007) 
0.09 673 
-0.001 
(-0.03, 0.03) 
0.92 82 
0.03 
(-0.03, 0.09) 
0.34 35 
-0.04 
(-0.15, 0.08) 
0.50 
 19  445  1815  219  62  
LDL cholestrerol, mmol/L 7 
0.05 
(-0.50, 0.60) 
0.84 
142 
0.02 
(-0.09, 0.12) 
0.78 673 
0.02 
(-0.04, 0.08) 
0.43 82 
0.20 
(0.01, 0.40) 
0.04 35 
0.28 
(-0.09, 0.65) 
0.14 
 19  445  1815  219  62  
Triglycerides, mmol/L 
[log] 
7 
15.60 
(-16.95, 60.92) 
0.36 
142 
-0.24 
(-7.26, 7.32) 
0.95 673 
2.32 
(-1.13, 5.89) 
0.19 82 
2.99 
(-7.92, 15.21) 
0.61 35 
-1.83 
(-21.24, 22.37) 
0.87 
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Variable 
 BMI<16  BMI16-18.5  BMI 18.5-25  BMI 25-30  BMI >30 
N 
Estimate or percentage 
change 
95%CI 
N 
Estimate or percentage 
change 
95%CI 
N 
Estimate or percentage 
change 
95%CI 
N 
Estimate or 
percentage 
change 
95%CI 
N 
Estimate or 
percentage 
change 
95%CI 
 19  445  1815  219  62  
           
*Controlling for sex, birth weight, gestational week, adolescent smoking, alcohol consumption . 
**Log results are percentage change. 
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Appendix 17 The univariable association analyses between maternal characteristics, birth outcomes and social 
stress in the whole NFBC1986 Cohort (Chi-square tests for global heterogeneity) 
 
                                      Social Stress 
 Social adversity n(%)* Neighbourhood social disparity n(%) 
 Yes No Yes No 
Maternal Characteristics     
Smoking     
Non-smoker 1650(64.1) 5422(83.0) 1351(68.2) 5715(80) 
Smoker 913(35.5) 1080(16.5) 576(29.1) 1418(19.8) 
Missing 11(0.4) 30(0.5) 54(2.7) 15(0.2) 
p value <0.0001 <0.0001 
    
Alcohol consumption    
Non-drinker 2149(83.5) 5473(83.8) 1532(77.3) 6084(85.1) 
Drinker 337(13.1) 732(11.2) 272(13.7) 797(11.2) 
Missing 88(3.4) 327(5.0) 177(8.9) 267(3.7) 
p value 0.02 <0.0001 
     
Parity     
Nulliparaous 932(36.2) 2154(33.0) 882(44.5) 2204(30.8) 
Multiparous 1637(63.6) 4369(66.9) 1066(53.8) 4935(69.0) 
missing 5(0.2) 9(0.1) 33(1.7) 9(0.1) 
p value 0.003 <0.0001 
     
BMI     
Low (≤18.5) 285(11.1) 590(9.0) 277(14) 625(8.7) 
Normal(>18.5, ≤  25) 1780(69.2) 4938(75.6) 1412(71.3) 5304(74.2) 
Overweight (>25, ≤30) 382(14.8) 791(12.1) 139(7.02) 647(9.1) 
Obese(>30) 127(4.9) 213(3.3) 41(2.1) 206(2.9) 
Missing 0 0 112(5.7) 366(5.1) 
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                                      Social Stress 
 Social adversity n(%)* Neighbourhood social disparity n(%) 
 Yes No Yes No 
p value <0.0001 <0.0001 
   
Hypertensive disorder     
Gestational hypertension 89(3.5) 183(2.8) 116(3.0) 146(3.0) 
Pre-eclampsia 61(2.6) 121(1.9) 85(2.2) 91(1.9) 
Chronic hypertension 68(2.6) 143(2.2) 66(1.7) 127(2.7) 
Superimposed pre-eclampsia 33(1.3) 55(0.8) 29(0.8) 48(1.0) 
Proteinurea 327(12.7) 753(11.5) 456(11.8) 559(11.7) 
Normotensive 1932(75.1) 5179(79.3) 3050(79.0)) 3692(77.6) 
Missing 64(2.5) 98(1.5) 59(1.5) 97(2.0) 
p value 0.005 0.04 
     
Gestational Diabetes     
Pre-pregnancy diabetes mellitus 5(0.2) 19(0.3) 9(0.2) 14(0.3) 
Abnormal OGTT 49(1.9) 88(1.4) 62(1.6) 70(1.5) 
OGTT not performed despite 
indicated 
589(22.9) 1316(20.2) 697(18.1) 1147(24.1) 
No OGTT neither indications 1418(55.1) 3942(60.4) 2417(62.6) 2815(59.1) 
OGTT normal 307(11.9) 773(11.8) 526(13.6) 524(11.0) 
Missing 206(8.0) 394(6.0) 150(3.9) 190(4.0) 
p value 0.0005 <0.0001 
     
Birth Outcomes    
Gestational age (gw)    
<34 24(0.9) 53(0.8) 21(1.1) 56(0.8) 
34-36 104(4.0) 165(2.5) 69(3.5) 203(2.8) 
37-39 1110(43.1) 2681(41.0) 799(40.3) 3001(42) 
40-42 1329(51.6) 3624(55.5) 1084(54.7) 3875(54.2) 
43+ 7(0.3) 9(0.1) 3(0.2) 13(0.2) 
Missing 29(0.3) 5(0.1) 5 0 
p value 0.0001 0.32 
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                                      Social Stress 
 Social adversity n(%)* Neighbourhood social disparity n(%) 
 Yes No Yes No 
Birthweight (g)     
<1500 5(0.2) 14(0.2) 5(0.3) 14(0.2) 
1500-2499 66(2.6) 141(2.6) 55(2.8) 156(2.2) 
2500-2999 283(11.0) 480(7.4) 196(9.9) 571(8) 
3000-3999 1750(68.0) 4506(69) 1359(68.6) 4910(68.7) 
≥4000 470(18.3) 1391(21.3) 366(18.5) 1497(20.9) 
Missing 0 0 0 0 
p value <0.0001 0.008 
    
Head circumference (cm)    
≤33 104(4.0) 164(2.5) 83(4.2) 189(2.6) 
33-33.9 253(9.8) 493(7.6) 214(10.8) 533(7.5) 
34-34.9 506(19.7) 1200(18.4) 411(20.8) 1299(18.2) 
35-35.9 668(26.0) 1803(27.6) 523(26.4) 1951(27.3) 
36-36.9 603(23.4) 1608(24.6) 412(20.8) 1803(25.22) 
37-37.9 290(11.3) 871(13.3) 229(11.6) 938(13.1) 
≥38 104(4.04) 260(3.9) 67(3.4) 296(4.4) 
Missing 46(1.8) 133(2.0) 42(2.1) 139(1.9) 
p value <0.0001 0.0005 
    
Birth length(cm)      
<47 109(4.2) 208(3.2) 93(4.7) 229(3.2) 
47-48.9 336(13.1) 631(9.7) 243(12.3) 726(10.2) 
49-52.9 1744(67.8) 4513(69.1) 1333(67.3) 4936 (69.1) 
53-55.9 352(13.7) 1085(16.6) 287(14.5) 1154(16.1) 
≥56 15(0.6) 42(0.6) 10(0.5) 46(0.6) 
Missing 18(0.7) 53(0.8) 15(0.8) 57(0.8) 
p value <0.0001 0.0005 
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Appendix 18 Characteristics of metabolic phenotypes including blood pressure  
(mean, minimum and maximum) in adoloscents in the NFBC1986  
Variable 
Mean 
(min-max) 
IDL mmol/L 
0.17 
(0.03-0.78) 
VLDL mmol/L 
0.41 
(0.01-3.76) 
Apolipoprotien B g/L 
0.56 
(0.26-1.20) 
Triglycerides mmol/L 
0.83 
(0.13-4.90) 
Apolipoprotien A-I g/L 
1.47 
(0.90- 2.20) 
HDL mmol/L 
1.41 
(0.16-2.61) 
LDL mmol/L 
2.25 
(0.4-5.8) 
Glucose mmol/L 
5.18 
(2.2-26.0) 
Systolic BP mmHg 
115.41 
(70-165.3) 
Diastolic BP mmHg 
67.72 
(43-118.7) 
The lipid and lipoprotein values are comparable with those published earlier from another Finnish study by  
Niinikoski H, Pahkala K, Ala-Korpela M, Viikari J, Rönnemaa T, Lagström H, Jokinen E, Jula A, Savolainen MJ,  
Simell O, Raitakari OT.Pediatrics. 2012 Mar;129(3):e704-13. doi: 10.1542/peds.2011-1503. Epub 2012 Feb 13. 
 
